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Abstract 
 
Photochemical internalisation (PCI) is a method for enhancing delivery of drugs such as 
cytotoxins to their intracellular target sites of action through the use of low dose 
photodynamic therapy (PDT). One of the main applications of PCI is local treatment of 
solid cancerous tumours. The use of three-dimensional (3D) tissue culture cancer models 
can provide more physiologically relevant information compared to standard monolayer 
culture owing to the present of an extracellular matrix. The aim of this study was to 
examine the effect of PDT and PCI in 3D compressed collagen cancer constructs of breast 
and ovarian cancer. The use of plastically compressed collagen confers near 
physiological densities of collagen unlike standard hydrogels. 
 
In the first set of PCI studies, a disulfonated porphyrin (TPPS2a) was used as the 
photosensitiser together with a cytotoxic macromolecule, a ribosome inactivating protein 
(saporin) to investigate the efficacy of the treatment in spheroid and non-spheroid 
compressed collagen 3D constructs of breast and ovarian cancer versus conventional 2D 
culture. Three human cell lines were investigated, a breast cancer cell line (MCF-7) and 
two ovarian cancer cell lines (SKOV3 and HEY). Using a range of assays including optical 
imaging, the treatment resulted in significant and synergistic reduction in viability of cells 
in the 2D and non-spheroid constructs of all 3 cell lines when measured at 48 or 96 hours 
post-illumination. In a further set of experiments, PCI-induced enhancement in cytotoxicity 
was observed when Dactinomycin was used as the cytotoxic agent. This is the first time 
that PCI with Dactinomycin has been investigated. In the larger spheroid constructs of 
ovarian cancer cells, PCI was still effective but required higher saporin and 
photosensitiser doses compared to 2D and non-spheroid cultures. PCI treatment was 
observed to induce death principally by apoptosis in the non-spheroid constructs of 
ovarian cancer compared to the mostly necrotic cell death caused by PDT. At low oxygen 
levels (1%) both PDT and PCI were significantly less effective in the constructs compared 
to 2D models. Using the 3D tumouroid model, where a central cancer mass is surrounded 
by the collagen matrix populated by fibroblasts to simulate the stroma, PCI was found to 
be able to both kill ovarian cancer cells within the cancer mass and inhibit their migration 
to the stroma. 
 
In conclusion, the use of 3D cancer models provides a useful means to assess the efficacy 
of PCI for the minimally invasive treatment of breast and ovarian cancer prior to in vivo 
studies and could help reduce the number of animals used in animal experimentation. 
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Impact statement 
 
The use of three-dimensional (3D) cancer constructs provides a model system for 
researchers which is reproducible and easy to create. Such a model allows different 
densities and components to be used with the construct and match the purpose of the 
research better. For future studies within academia such constructs could be used to 
develop very complex cancer constructs to study cancer behaviour and the effects of 
various anti-cancer treatments including those which are involve nanoparticles. Outside 
of academia this model can contribute towards reducing the use of animal models for 
cancer related studies which in turn could also reduce animal suffering. Furthermore, the 
cancer models can be developed using tissue samples from the patient to simulate the 
clinical tumour so that the response of the cancer to different therapeutics can be tested 
quickly. This allows the use of personalised cancer treatment instead of subjecting the 
patient to different treatments, with significant benefits to the quality of the patient’s life. 
Immunological factors can also be incorporated into the model to test for any side effects 
or allergic reactions that may occur as a result of using the therapeutics so that the 
probability of such side-effects being experienced by patients can be minimised. 
 
Photochemical internalisation is designed to be a minimally invasive technique that is 
localised and does not induce the photoxicity observed with PDT. This therefore means 
that the treatment will cause minimal damage to healthy tissues in other parts of the body 
of the patient and will cause fewer side effects as very small doses of the drugs are 
required for use. Within academia, this treatment provides the potential for researching 
the delivery of various therapeutics to their sites of action not only for cancer treatment 
but also for the treatment of other non-oncological conditions. 
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Chapter 1  
 
1. Background and Introduction 
 
1.1 Introduction to breast and ovaries 
This thesis addresses a minimally invasive modality with potential applications for the 
treatment of breast and ovarian cancers. To introduce the thesis, the development of 
breast and ovarian cancer is summarised together with the current treatment options. The 
breast is an organ which in females has the special function of producing milk for lactation. 
This organ is located on top of the pectoral muscle which covers the ribcage. The epithelial 
parts of the breast tissue include lobules where milk is produced which are connected to 
ducts that lead out of the nipples. A majority of breast cancers develop from cells that form 
the lobules as well as the terminal ducts. The lobules and ducts are also found throughout 
the fibrous and adipose tissues which contribute majorly to the anatomy of the breast. 
Furthermore, the breast tissue is surrounded by a thin layer of connective tissue known 
as fascia. The deep layer of this connective tissue sits just on top of pectoral muscle and 
the superficial layer of it is located below the skin (1). 
Blood is supplied to the breast mainly from the internal mammary artery which is found 
underneath the main breast tissue. This blood supply is responsible for providing nutrients 
and oxygen to the breast tissue. The lymphatic vessels however run in the opposite 
direction of the blood supply draining into the lymph nodes. Breast cancers spread to 
lymph nodes through these lymphatic vessels which mostly flow to the axillary lymph 
nodes in the underarm while a few of the lymphatic vessels drain to internal mammary 
lymph nodes which sit deep in the breast. Breast tumours normally first encounter the 
sentinel lymph node which is the initial lymph node in the series of lymph nodes upon 
being drained through the lymphatic vessels. Surgeon may sometimes remove this lymph 
node in order to check for metastases in breast cancer patients (1, 2). Women can also 
develop breast cysts which are non-cancerous fluid filled sacs (3). 
The ovaries are a pair of organs in females that are responsible for producing eggs as 
well as maintaining the health of the female reproductive system. These organs also 
secrete two hormones (oestrogen and progesterone) which are crucial for the normal 
development of the reproductive system and fertility (4).  
 
In terms of anatomy the ovaries are oval in shape (approximately 3-5 cm) and sit on 
opposite ends of the pelvic wall and are therefore located on either side of uterus. The 
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ovaries are connected to the very narrow fallopian tubes (also called uterine tubes or 
oviducts) via a tissue called the fimbria and extend from the ovaries to the uterus (5, 6).  
The fimbria is a finger-like projections of the infundibulum which is the funnel shaped 
peripheral end of the fallopian tube. The fimbriated end of the fallopian tube is not covered 
by peritoneum, which allows the communication between the fallopian tube and the 
peritoneal (pelvic) cavity. The currents created in the peritoneal fluid from the beating of 
the fimbriae, help carry oocytes into the fallopian tube lumen where they may undergo 
fertilisation in a region within the fallopian tube called the ampulla. The anatomy of breast 
and ovary has been presented in Figure 1. 
The type of diseases and disorders that are normally associated with the ovaries include: 
• Osteoporosis which is normally linked with menopause along with other symptoms 
such as mood swings and hot flushes. Oestrogen is important for protecting bone 
strength and therefore the drop in oestrogen levels reduces bone density (7). 
 
• Ovarian cancer which has symptoms that typically do not become apparent until 
the disease has reached a late and developed stage (8).  
 
• Ovarian Cysts which are fluid filled sacs and can occur in women of all ages with 
those of child-bearing age being more susceptible to this problem. In term of size 
the cysts can grow up to 10 cm. usually cysts above 5 cm in diameter are removed 
surgically to prevent them from twisting the ovary that they are affecting and 
disrupting the blood supply to the ovary (9). 
 
• Polycystic Ovarian Syndrome (PCOS) which is a result of hormonal imbalance 
and owes most of its symptoms to increased production of androgens such as 
testosterone. Patients with PCOS suffer from problems such as infertility, irregular 
menstruation, acne, as well as increased hair growth on the face and body. Other 
PCOS related issues include obesity, insulin resistance and type 2 diabetes. It is 
possible for patients to overcome most of the symptoms of PCOS by losing weight 
(10). 
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Figure 1: Anatomy of female breast and ovaries.  A. Anatomy of the female breast. B. Anatomy 
of the ovaries. 
A 
B 
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1.2 Breast and Ovarian cancer  
 
Breast cancer 
According to the World Health Organisation, breast cancer is the most common cancer 
affecting females and affects more than 1.5 million women annually resulting in the 
highest number of cancer related mortalities amongst women (11). It was reported that in 
2015, 570,000 women died from breast cancer which accounted for almost 15% of all the 
cancer deaths among women (11). Although breast cancer rates are greater in women in 
more developed countries, an increase in such rates is seen in nearly every region around 
the world (11).  
 
Almost 54,900 new cases of breast cancer are diagnosed in the UK annually with the 
most aggressive breast cancers occurring in the upper outer quadrant of the breast (12). 
It is thought that 1 in 8 females and 1 in 870 males will become diagnosed with breast 
cancer in their lifetime (13). In 2012 approximately 1.7 million women were diagnosed 
with breast cancer with UK having the sixth highest incidence rate in Europe (14). The 
diagnosis of new breast carcinoma in situ in UK is about 7,700 cases annually with 30 
new cases found in men and 7,900 new cases diagnosed in women in 2015 alone. A 
majority of the in situ breast carcinoma cases are intraductal (15). 
 
With breast cancer being the 4th most frequent cause of cancer death in UK, the total 
number of deaths from this disease total 11,400 per year. Around 522,000 women died 
of breast cancer worldwide in 2012 and the UK had the 14th highest mortality rate in 
Europe (15). Statistics from 2010-2011 found that about 65% of women in England and 
Wales who are diagnosed with breast cancer survive this disease for 20 years or more. 
However, the five-year survival rate from breast cancer in women in England, Wales and 
Scotland is below the European average (16). 
 
Breast cancer is mainly diagnosed through screening with a majority of cases being 
diagnosed at an early stage. Symptoms of breast cancer include, development of a lump 
or thickened tissue on either breast, a change in breast size or shape, discharge with 
blood stains released from the nipples, development of lump or swelling in the armpits, 
occurrence of dimples on the skin of the breast and/or rash on or surrounding the nipple 
and change in nipple appearance (17).  
 
Ovarian cancer 
Almost 7400 new cases of ovarian cancer are diagnosed in UK every year, making this 
disease the 6th most common type in females in the UK (18). A CRUK 2014 report found 
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that nearly 6 out of 10 cancers were diagnosed at a later stage in England and Northern 
Ireland. Approximately 239,000 females were diagnosed with ovarian cancer worldwide 
in 2012 with UK being the 9th country in Europe to experience the highest number of 
incidents (18). Furthermore, ovarian cancer is the 6th most frequent cause of cancer death 
in UK females making the UK mortality rate from this disease the 16th highest in Europe. 
Approximately 152,000 women around the world died from ovarian cancer in 2012 (18). 
If diagnosed at the earliest stage, it gives 9 out of 10 women with the disease a chance 
survival for 5 years or more, however less than 5 out of 100 women diagnosed with 
ovarian cancer at the latest stage will experience such survival rate. The 5-year survival 
rate for ovarian cancer in the UK is below the European average (16).  
 
Ovarian cancer is diagnosed using CA125 (biomarker of ovarian cancer cells) blood test 
and ultrasound (18). Symptoms of ovarian cancer include: constant feeling of 
bloatedness, swelling in the tummy, feeling of discomfort in the abdomen or pelvic area, 
loss of appetite and the urge to urinate more often (19). 
 
1.3 Risk factors of breast and ovarian cancer 
 
Factors that increase the chances of contracting breast and ovarian cancer include being 
overweight, having a family history of either cancer, inheriting mutated BRCA1 or BRCA2 
genes, variations in levels of sex hormones such as oestrogen and testosterone and 
progesterone with changes in levels of the first two hormones mentioned increasing the 
risk for breast cancer and exposure to radiation. Age is also another factor influencing the 
risk of breast and ovarian cancer contraction with women over 50 being more at risk (19). 
Interestingly, while the use of contraceptive pills slightly increases the risk of breast 
cancer, it decreases the risk for ovarian cancer. Furthermore, women who have previously 
had breast cancer are at higher risk of getting both another breast cancer and/or ovarian 
cancer compared to the general population. Drinking alcohol also puts the risk for breast 
cancer at an increase (20). 
 
1.4 Treatments available for breast and ovarian cancer 
 
Current treatments for breast and ovarian cancer include surgery, radiotherapy, 
chemotherapy, hormonal therapy and HER2 targeted therapy. 
 
Surgery: 
For breast cancer, surgery involves the removal of the tumour as well as its surrounding 
tissue. This procedure can also be used for examining the axillary lymph nodes for the 
spread of cancer. There are two types of procedures: Lumpectomy which involves the 
subtraction of the tumour and a small, margin of the healthy tissue surrounding the tumour 
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and Mastectomy which involves the removal of the whole breast. For cancers treated 
with lumpectomy if the cancer is invasive then radiation therapy may be applied to the 
rest of the breast tissue (17). 
 
For ovarian cancer however the 3 mostly applied surgeries include Unilateral salpingo-
oophorectomy which is the surgical resection of one ovary in addition to one fallopian 
tube, Bilateral salpingo-oophorectomy which is the surgical removal of both ovaries as 
well as both fallopian tubes and Total hysterectomy which involves the removal of the 
uterus. Chemotherapy may also be recommended after ovarian cancer surgery (21). 
 
Radiation therapy: 
Radiation therapy or radiotherapy uses high power X-rays or other particles to destruct 
cancer cells. This treatment may be given after surgery to destroy the remaining tumour 
cells as “adjuvant radiation therapy” or prior to surgery as “neoadjuvant radiation therapy” 
to shrink the size of a large tumour to make it easier to surgically remove (17, 22). 
 
Side effects of such therapy include fatigue, changes in the skin of the treated area (e.g 
redness, discoloration/hyperpigmentation, pain and burning sensation as well as 
blistering and peeling), nausea, vomiting and diarrhoea. Vaginal irritation may also occur 
in patients with ovarian cancer (17, 22). 
 
Chemotherapy: 
Chemotherapy uses drugs to kill cancer cells by stopping the cancer cells from growing 
and dividing. As with radiation therapy, chemotherapy may be given either before surgery 
to reduce the size of large tumours to make their removal easier (neoadjuvant 
chemotherapy) or be given after surgery to minimise the likelihood of recurrence (adjuvant 
chemotherapy) (17, 22).  
 
Side effects of this treatment can vary depending on the drugs used and doses given but 
normally include tiredness, chance of infection, nausea and vomiting, alopecia, loss of 
appetite as well as diarrhoea (23).  
 
Hormonal therapy: 
Hormonal therapy or endocrine therapy involves effectively targeting tumours that test 
positive for oestrogen and progesterone receptors (known as ER positive and PR positive) 
(24). These types of tumours depend on hormones to aid their growth thus blocking the 
release of such hormones to help cancer growth and recurrence when used on its ownw 
or in combination with adjuvant or neoadjuvant chemotherapy (24).  
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Therefore, like chemotherapy and radiation therapy, hormonal therapy can be applied 
before surgery again for the purpose of shrinking tumour size for easier removal 
(neoadjuvant hormonal therapy) or after surgery to decrease the risk of cancer recurrence 
(adjuvant hormonal therapy) (24, 25). 
 
Side effects of hormonal therapy include pain in muscles and joints, hot flushes, vaginal 
dryness, an increase in risk of developing osteoporosis and bone fractures as well as high 
cholesterol levels (25). 
 
The following sections introduce other energy-based therapies that can potentially be 
applied to breast and ovarian cancer as with radiotherapy with potentially fewer side-
effects. 
 
1.5 Photodynamic therapy (PDT) 
Photodynamic therapy (PDT) is a minimally invasive treatment used for different types of 
cancer as well as non-malignant lesions (26, 27). PDT requires molecular oxygen and is 
carried out through the administration of a photosensitiser, which is then activated by light 
of specific wavelength (e.g blue, red or near infrared (NIR) light) thus resulting in the 
production of cytotoxic reactive oxygen species (ROS). This treatment method has been 
clinically approved for treating numerous forms of tumours for example prostate (28),head 
and neck, skin and oesophagus (29). PDT has also been employed to treat non-
cancerous conditions such as age-related macular degeneration, atherosclerosis and 
bacterial infections (30).  
This treatment holds advantages for both the patient and the clinician as it greatly reduces 
the requirement for major surgery, shortens recovery periods, stimulates good healing 
and maintains integrity and function of organs with posing very little risk of local and 
systemic treatment-related morbidity as well as side-effects (31-34). Moreover, PDT can 
be applied repeatedly and even used after various treatments such as surgery, 
chemotherapy and radiotherapy without inducing any immunosuppressive or 
myelosuppressive effects (27, 35). Generally red or NIR light is used for PDT since tissue 
is relatively more transparent in this wavelength range beyond strong haemoglobin 
absorption. Very superficial treatment can however be achieved using blue light excitation 
instead. Although the light delivery can be targeted to the lesion, the degree of selectivity 
in tumour uptake of the photosensitiser following intravenous administration is generally 
insufficient to result in tumour-selective treatment. However, the good healing of normal 
 25 
tissue adjacent to the tumour does offer an important therapeutic benefit in contrast to 
radiotherapy where normal tissue damage is a major side-effect. 
1.6 Mechanism of action of PDT and mode of cell death 
The mechanism of action of PDT and the mode of cell death it induces depend on several 
factors e.g genotype of cells, PDT dosimetry (e.g. light intensity) and the localisation of 
the photosensitiser (36, 37). As a majority of photosensitisers do not tend to accumulate 
within the nuclei (38), PDT is not prone to cause DNA related damage, mutations or 
carcinogenesis (37). Photosensitisers, that predominantly localise within the 
mitochondria, induce apoptosis (39),whilst photosensitisers that localise within the plasma 
membrane mainly stimulate necrosis upon exposure to light (40). Overall the mode of cell 
death triggered shifts from apoptotic to necrotic as the intensity of the damage caused to 
the cell increases which results in swift cell lysis instead of an orderly programmed type 
of cell death (41). Photodamage may also lead to a cytoprotective response termed 
autophagy (42). Figure 2 has been specifically produced for this thesis and shows the 
possible cell death pathways activated upon treatment with PDT. 
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In terms of electronic configuration, photosensitisers possess a stable singlet state (ie no 
net electronic spin) in their lowest energy level (43). By absorbing a photon of light of a 
certain wavelength, the photosensitiser molecules are raised to an excited state which is 
also a singlet state  but short-lived (44) (45). The photosensitiser may then return to 
ground state via internal conversion where the energy is lost as heat or through the 
emission of a photon as fluorescence which can be used for photodetection purposes in 
a clinical setting (46). However in order for a therapeutic photodynamic effect to be 
produced the photosensitiser must undergo conversion to the triplet state via a change in 
electronic spin, a process known as intersystem crossing (31). This process can be rapid 
for aromatic photosensitising dyes with comparable or higher efficiencies than 
fluorescence. Typically, the probability (or quantum yield) of conversion to the triplet state 
will be > 0.5 for many photosensitisers. 
 
In this case if a sufficient supply of oxygen is available, the triplet excited photosensitiser 
can either undergo a type I or type II reaction (47) since the triplet state is relatively long-
lived. In a Type I reaction the sensitiser reacts with a substrate in a direct manner through 
proton or electron transfer to produce radicals, which then interact with oxygen molecules 
to form oxygenated products or reactive oxygen species (ROS)  that are damaging to the 
Figure 2: Mode of cell death induced by PDT depending on the localisation of the 
photosensitiser within the cell. (A) Shows a healthy cell with normal functioning organelles. (B) 
Necrotic cell death leads to the destruction and rupturing of the cell membrane resulting in 
non-functional organelles. Apoptosis (C) however, causes shrinkage of the organelles leading 
to the breakage of the cell into numerous apoptotic bodies, although the organelles are still 
functioning. 
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integrity of the cell membrane (48). In a type II reaction on the other hand the energy of 
the sensitiser is directly transferred to the oxygen molecules to generate the singlet 
oxygen species, which is believed to be one of the most potent reactive oxygen species 
in PDT (49). 
 
Singlet oxygen is extremely reactive and short –lived with the ability to diffuse 
approximately 0.01-0.02µm in its short lifetime (50). This therefore means that the reaction 
occurs within a limited distance and volume resulting in a cytotoxic response being 
created in a localised manner (50).  
 
1.7 Photosensitisers used in PDT 
 
Ideally a photosensitiser should display chemical, photophysical as well as biological 
characteristics, which allow it to be uptaken by a tumour, undergo fast clearance and have 
a large absorption peak at wavelengths of light above of 630nm (50).  
 
First generation photosensitisers: 
First generation photosensitisers are known to include haematoporphyrin derivatives 
(HpD) as well as Photofrin (49).  HpD has shown to localise within the tumours and 
produce a good tumouricidal response upon activation by red light. Porfimer sodium 
(Photofrin) which is a chemically purified portion of the active component found in HpD 
was the first photosensitiser to obtain approval for treating recurring superficial papillary 
bladder cancers using PDT (50) at concentration of 2 mg/kg (51). Porfimer sodium has 
numerous absorption peaks with the weakest being found at 630nm (52). Despite the 
display of the weak absorption peak, the light of wavelength 630nm is commonly used in 
clinical applications for the activation porfimer sodium since lights of a shorter wavelength 
preclude deep tissue penetration (53). This also means that only light doses ranging from 
100-200 J/cm2 are required for the purpose of tumour treatment (54).  Although Photofrin 
is the most commonly clinically used first generation photosensitier, apart from the 
relatively short absorption wavelength, its potential has been undermined by a further 
disadvantage such as long-term photosensitivity of the skin (55), which lasts for a period 
of 4-12 weeks (50). 
 
Second-generation photosensitisers: 
Several second generation photosensitiers have been created to overcome issues related 
to side effects e.g skin photosensitisation and inadequate tissue penetration that are 
normally associated with first generation photosensitisers (37) but they must also be as 
effective in treating tumours as Photofrin (50). In comparison with the first generation 
molecules, the second-generation photosensitisers are generally more chemically pure, 
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capable of absorbing light of longer wavelengths and result in considerably less 
photosensitisation of the skin after treatment (50). Compounds such as benzoporphyrin 
derivative and temoporfin (mTHPC) are referred to as second generation photosensitisers 
and have a stronger ability to produce singlet oxygen (48). 
 
An alternative approach is to use 5-aminolavulinic acid (ALA) which is an approved agent 
used for treating cutaneous lesions in combination with red or blue light. This compound 
does not have any photosensitising properties per se but it is a natural precursor of haem 
(56), which is generated by the conversion of protoporphyrin IX (Pp IX), an effective 
photosensitiser,  into haem with the aid of ferrochelatase (57). Since most tumours have 
a lower level of ferrochelatase activity compared to normal tissue, administering ALA 
results in a significantly increased amount of PpIX in the tumour cells (57). PpIX  has an 
absorption spectrum  close to that of porfimer sodium (50)  and can therefore be activated 
by red light of wavelengths near 630nm (58). 
 
The advantages of PDT with ALA over porfimer sodium PDT are the rapid clearance of 
PpIX which leads to reduced photosensitivity (normally 1-2 days) (59) (50), its topical and 
oral applications in the case of treating skin cancer and oral cavity/ digestive tract cancer 
respectively as well as its ability to attain better tumour selectivity (60) (61). One 
disadvantage of using ALA however, is that this compound possesses a highly hydrophilic 
nature and thus cannot penetrate through the cells easily (62). This issue has been 
resolved through the development of a number of alkyl ester derivatives of ALA that have 
the ability to enter the cells more efficiently (63). 
 
One of the second-generation photosensitisers that has been approved for use in head 
and neck cancers in 2001 is mTHPC (tempoporfin, Foscan) (64). This photosensitiser has 
a higher potency than ALA (50), or porfimer sodium (65) and only requires light dose of 
20 J/cm2 for treating tumours (66). Moreover mTHPC absorbs light at 652nm (67) (68). In 
comparison to the 630nm absorption peak of both porfimer sodium and ALA which allows 
it to penetrate deeper into the tissue (50).  
 
The development of new photosensitisers has been a subject of intense interest (69). This 
has involved development of photosensitising drugs that are more tumour specific, can 
undergo activation with light of a longer wavelength and result in an overall shorter period 
of photosensitivity and is still ongoing (70). Other photosensitisers that have been tested 
in clinical trials are tin ethyl etiopurpurin (SnET2) (71), mono-L-aspartyl chlorin e6 (Npe6) 
(72), benzoporphyrin derivative (BPD) (73), and lutetium texaphyrin (Lu-Tex) (74). These 
compounds have absorption peaks at higher wavelengths of 660 nm (75), 664 nm (72), 
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690nm (54) and 732nm respectively and cause very mild and brief skin photosensitivity 
(50). 
 
In recent years the term of ‘third-generation’ photosensitiser has become more widely 
used, where the photosensitiser can be targeted to the cancer in order to improve 
treatment selectivity. The use of targeted nanoparticles for PDT has been a particularly 
active area.  
 
1.8 The use of nanoparticles in PDT 
Due to limitations related to the use of current photosensitisers such as poor bioavailability 
(eg poor water solubility), nanoparticles have been employed to aid the improvement of 
PDT (76)(77). Photosensitisers can be modified by for example being incorporated into 
delivery systems such as liposomes, polymer nanoparticles, micelles, gold nanoparticles 
and ceramic nanoparticles (78). Nanoparticles used for the improvement of PDT efficacy 
can be categorised in accordance to their functional roles and whether they are actively 
or passively targeted (79).  
The utilisation of targeted nanoparticles has the benefit of improved selectivity by 
delivering the photosensitiser to the tumour site thus resulting in very minimal harm to the 
normal tissues.  Nanoparticles can be “actively” targeted to the cancer site using surface-
conjugated ligands that bind to overexpressed receptors or antigens on the target tissue. 
The tumour targeting properties of nanoparticles can also be improved through the 
enhanced permeability and retention (EPR) effect that can enhance selective uptake and 
retention with respect to normal adjacent tissue, a process called “passive” targeting 
selectivity. In this case, the targeting of photosensitisers can be made possible via 
encapsulation or conjugation to nanocarriers (80). These nanoparticles are sub-classified 
depending on whether their composition is biodegradable or non-biodegradable.  
Non-biodegradable nanoparticle-based photosensitisers include for example 
upconversion nanoparticles, quantum dots and self-lighting nanoparticles where the 
nanoparticle material has intrinsic photosensitising properties (78).  
In the following section some examples of new types of nanoparticles for PDT are 
reviewed. Since nanoparticle uptake normally takes place via endocytosis this subject is 
relevant to the theme of this thesis. 
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Fullerenes and Carbon nanotubes (CNTs) 
Fullerenes (C60) consist of 60 carbon atoms arranged in a highly stable spheroidal 
structure with a diameter of about 2 nm which absorb wavelengths within the visible light 
spectrum. They also have high triplet yields and an ability to produce to ROS when 
illuminated (81). The poor solubility of fullerenes in aqueous solutions places these 
nanoparticles at a disadvantage when considering their use in biological systems. 
However, such issue may be overcome via methods such as encapsulation in particular 
carriers, such as undergoing suspension with the aid of co-solvents, introducing 
hydrophilic attachments or reducing the molecules to water soluble anions (82). One 
major drawback of fullerenes is that their highest absorption lies in the ultraviolet and blue 
regions preventing them from penetrating deep into the tissue (83). Therefore, although 
treatment of cancer using PDT with fullerenes has been demonstrated in vivo, it is crucial 
to develop fullerenes, which can absorb red or in fact near-infrared light, in order to be 
used successfully for clinical applications with PDT. 
Carbon nanotubes (CNTs) are also composed of a lattice of carbon atoms like fullerenes 
but with a rolled structure in form of a tube (84). CNTs can be categorised into either 
single-walled nanotubes (SWNTs) or multi-walled nanotubes (MWNTs). Due to the high 
surface area of the nanotubes, drugs, peptide and nuclei acid molecules can be merged 
into their walls as well as tips allowing the mammalian cell membrane to be crossed 
through endocytosis or enabling cancer specific receptors on the surface of cells to be 
recognised (85). SWNTs are also known as useful fluorescence probe quenchers (86). 
However, due to limited knowledge regarding the pharmacological and toxicological 
properties of CNTs, they are not yet being utilised in PDT studies clinically. 
Quantum dots (QDs)  
Quantum dots (QDs) are nanocrystals typically a few nm in diameter that possess 
properties such as high fluorescence quantum yields, and photostability (87). Compared 
to most fluorophores, these nanoparticles have bigger absorption coefficients in addition 
to size-tunable light emission and greater signal brightness (35). Through specific surface 
coating modifications, water-soluble and targeted QDs can be developed. Cadmium 
selenide (CdSe) is the most commonly used material in semiconductor QDs. To reduce 
their cytotoxicity, Cadmium free QDs have been developed through replacing the 
cadmium either with nontoxic metals or those with lower toxicity e.g Indium (In) (88, 89). 
Yaghini et al. (2016) recently showed the potential of Indium-based QDs as a better 
alternative to blue dyes for sentinel lymph node mapping in breast cancer patients using 
animal models (90). The conjugation of QDs with photosensitisers (QDs-PS) can 
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significantly enhance their photosensiting properties (91).  
Upconversion nanoparticles 
Upconversion nanoparticles (UCNPs) are a new generation of fluorophores, which can 
be activated by near infrared (NIR) radiation through a non-linear optical mechanism  (92). 
The principal material used in the making of UCPs is NaYF4 (93). A type of UCP, NaYF4 
nanocrystal with mesoporous silica-loaded zinc phthalocyanine (ZnPc) coating has 
demonstrated the ability to change NIR light into visible light after becoming excited by a 
NIR laser. This allows further activation of the photosensitiser resulting in the release of 
1O2  and ultimately killing cancer cells. Apart from being resistant to photobleaching, other 
advantages of UCPs include deeper tissue penetration due to excitation by NIR light, 
which makes them desirable for use in PDT. Furthermore, the discovery of self-lighting 
PDT through the utilisation of scintillation luminescent nanoparticle-attached 
photosensitisers has allowed the enhancement of PDT efficacy without the requirement 
of an external light source (94).  
1.9 Role of nanoparticles as photosensitiser carriers in PDT 
Two of the drawbacks of most clinically approved photosensitisers are their poor 
bioavailability as well as their unfavourable biodistribution (95). This can be resolved by 
the enhanced permeability and retention (EPR) effect, which results from the irregular 
tumour neovasculature which is more permeable than normal tissue microvasculature, 
and the poorer tumour lymphatic drainage that in combination aids both the diffusion and 
retention processes of photosensitiser carriers within tumours. The EPR effect can be 
taken advantage of by nanoparticles that function as photosensitiser carriers to improve 
aspects such as cellular uptake, biodistribution, bioavailability and pharmacokinetics of 
the photosensitisers systemically. Biodegradable nanoparticles consist of polymers that 
experience enzymatic hydrolysis within biological environments hence liberating the 
photosensitisers (96). Nonbiodegradable nanoparticles such as silica are also effective 
for PDT. In such cases the detachment of photosensitisers from the nanoparticles carriers 
is not necessarily essential since free oxygen diffusion in and out of the nanoparticles  
enables generation and release of singlet oxygen (77). These two different classes are 
now summarised in more detail. 
Biodegradable nanoparticles  
Biodegradable polymer-based nanoparticles have displayed an enormous potential as 
photosensitiser carriers owing to their ability to control drug release, their versatile 
properties in material manufacturing processes and their great drug loading capabilities. 
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The polymers can be adapted in terms of chemical composition and architecture to suit, 
various photosensitisers with different hydrophobicity degrees, molecular weights, pH and 
charges (97). Degradation can be stimulated by the lower tumour pH or enzymatically 
based on higher tumour expression of the particular enzymes. Surface modifications of 
nanoparticles can further trigger active targeting to specific sites of actions. The delivery 
of photosensitisers can be carried out via micelles, liposomes, dendrimers and 
nanoparticles (98). Nanoparticles are generally composed of natural or synthetic 
polymers. Even though synthetic polymers are more desirable for utilisation in drug 
delivery systems, because of their capacity to adjust their mechanical properties as well 
as degradation kinetics to fit the purpose of different applications, the use of natural 
polymers such as chitosan has attracted more attention due to their availability, lower 
costs and potential of being chemically modified (99). Despite the developments made in 
drug delivery using synthetic biodegradable polymers, natural polymers still continue to 
be an area of interest in research. 
Non-biodegradable nanoparticles 
Non-biodegradable nanoparticles function differently in PDT due to their lack of 
degradability and uncontrollable drug release. Such nanoparticles are not destroyable by 
treatment processes and are therefore appropriate for repeatable use if activated 
adequately. Nonbiodegradable nanoparticles hold several advantages in comparison to 
biodegradable polymeric nanoparticles. These advantages include: 1) the easy 
management of the particle sizes, shapes, porosities and monodispersibilities of these 
nanoparticles; 2) the stability of the nanoparticles towards environmental fluctuations; 3) 
their resistance to microbial attacks and 4) continuous diffusion of oxygen in and out of 
the particles due to the adjustable pore sizes (99). The majority of non-biodegradable 
nanoparticles comprise of silica or metallic material. Owing to their unique properties, 
metallic nanoparticles have been a subject of great research in order to explore their 
potentially applicable uses in biochemistry as chemical and biological sensors, in 
nanoelectronics and nanostructured magnetism as systems as well as in medicine as 
means of drug delivery. In contrast to most silica-based nanoparticles, metallic 
nanoparticles have to be conjugated with the photosensitisers on their surfaces (100). 
Gold nanoparticles are an example of metallic nanoparticles that have been intensely 
investigated because of their inert chemical properties as well as their ability to induce 
minimal acute cytotoxicity (101). 
1.10 Light sources used in PDT 
 
An extensive range of laser and non-laser sources of light can be used in photodynamic 
therapy (102). Wide spectrum light sources e.g arc lamps that are cost effective and 
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simple to use can be used to activate photosensitisers (103, 104).The disadvantages of 
using these lamps include the difficulty behind coupling them to light delivery fibres without 
having to reduce their optical power, calculating the amount of the efficient dose of light 
delivered, the limitation of power output to 1W maximum and the requirement of filters to 
eliminate UV radiation as well as infrared emission which can result in heating (50). 
 
The discovery of lasers with the ability to emit focused beams of light with the exact 
essential wavelengths proved to be a significant discovery for PDT (105) (106). The 
additional advancements in the semiconductor diode technology led to the development 
of more cost-effective systems with high power output, which have the advantage of being 
compact (107) as well as portable (108). A majority of these systems consist of an internal 
unit for dosimetric calculations alongside built-in treatment programs that makes them 
easier to use (109)(104). The one limitation of these laser diodes is their ability to provide 
one single output wavelength (50). Light emitting diodes (LEDs) may be used clinically 
(110) as they are small as well as less costly compared to above-mentioned light sources 
and can offer a maximum power output of 150 mW/cm2 at wavelengths ranging from 350-
1100 nm (45). 
 
Optical fiber technology has become an important means of delivering light to the 
treatment site to activate the photosensitiser in recent years (111). Optical fibers have the 
capacity to illuminate at different localisations owing to their ability to convey light to the 
target site more accurately with a homogenous distribution (112). In the case of treating 
superficial cancers, optic fibres with a lens on their tips are used to distribute the light 
across the targeted area (104). For hollow organs e.g bladder and esophagus, illumination 
is normally carried out using cylindrical diffusers coupled with inflated balloons to aid the 
provision of uniform light distribution (113)(114)(115). Also black coating a side of the 
balloon can protect healthy tissue areas by offering shielding (50). 
 
1.11 Clinical trials of PDT in cancer patients 
 
PDT can be applied clinically as a monotherapy or after surgery, chemotherapy and 
radiotherapy and has been tested in different trials worldwide and received approval for 
treatment of several solid cancers, eg prostate, head and neck. The numerous trials 
include treating advanced head and neck cancer, gastrointestinal cancers (oesophagus, 
stomach, pancreas), pulmonary cancers and ovarian cancer as well as pre-cancerous 
lesions such as actinic keratoses to prevent its progression to squamous cell carcinoma 
(28, 71, 116-118).  
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PDT has also been tested in several trials in patients with breast cancer including one 
study by Li et al. (2011) which coupled PDT with immunotherapy to treat patients with 
metastatic breast cancer (stage 3 or 4). Out of all patients in this study, one showed a 
complete response, four demonstrated partial responses, two maintained the disease in 
stable state and two patients showed disease progression. Furthermore, no serious side 
effects or deaths as a result of this treatment were observed (27, 119). In another clinical 
trial study which used Photofrin PDT for the treatment of ovarian cancer in 13 patients, it 
was found that 2 out of 13 patients did not experience recurrence (118).  
 
Hahn et al. (2006) carried out a phase II trial study on the effect of PDT on 33 patients 
with ovarian cancer using photofrin as a photosensitiser. The results showed an overall 
survival of 20 months; however, the treatment was not found to lead to significant 
complete responses or long term tumour control in patients (120). 
 
Banerjee et al. (2017) on the other hand carried out a phase I/IIa trial study on the effect 
of verteporfin (BPD)- PDT on 11 patients with primary breast cancer. In all patients plateau 
with no diameter increase in the area of necrosis was achieved with increasing light dose. 
Although the light doses used ranged from 20J- 50J, no information was provided about 
the minimum light dose that was required for the treatment as the trial is still ongoing 
(121). 
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1.12 Photochemical internalisation (PCI) 
 
Although chemotherapy is a commonly used treatment for many metastatic cancers, it is 
accompanied by side effects as well as likelihood of developing multidrug resistance 
(122). Improved drug delivery and circumvention of the development of drug resistant are 
therefore key challenges that need to be overcome to improve treatment response. One 
factor that degrades the efficacy of immunotoxic and biologic agents is that owing to their 
size they are generally taken up via endocytosis.  Since most therapeutic macromolecules 
target intracellular components, endocytic uptake presents a barrier against successful 
intracellular targeting (123) since the agents are not able to reach their target efficiently 
via diffusion through the cytosol. Entrapment within endosomes and subsequently 
lysosomes also renders these agents susceptible to degradation by proteolytic enzymes 
which further limits their efficacy and bioavailability. In some cases even for small 
molecules the poor bioavailability due to endocytic uptake can also be attributed to low 
water solubility and/or reduced penetration through cell membrane (124).  
 
Photochemical Internalisation (PCI) is a modification of Photodynamic therapy (PDT) 
which aids the cytosolic delivery of therapeutic macromolecules and certain small drugs, 
which are prone to endo-lysosomal entrapment and degradation to their cytosolic sites of 
action using low-dose PDT (125-128). Like PDT, PCI is spatially selective since the 
cytosolic release is triggered by light delivered at the target site and not elsewhere in the 
body. This is achieved through the utilisation of an amphiphilic photosensitiser which 
localises in the membrane of the endolysosomal vesicle whilst the bioactive agent resides 
inside the vesicle and causes disruption of the endosomal membrane via the production 
of reactive oxygen species upon activation by light of a specific wavelength thus releasing 
the macromolecules into the cytosol (129, 130). Figure 3 demonstrates the mechanism of 
uptake of the photosensitiser and bioactive agent and the destruction of the cancer cell 
through PCI. 
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There are also other types of cytosolic drug delivery systems such as endo/lysosomal pH-
responsive drug release systems, redox-responsive drug release systems and lysosomal 
enzyme-responsive drug release systems (131). However, compared to PCI such 
systems cannot control the timing of the drug release as well as possible toxicity caused 
by the delivery system and unlike PCI are not spatially selective. 
 
1.13 Different mechanisms of Endocytosis 
 
There are various mechanisms by which endocytosis occurs. The main pathways include 
clathrin-mediated endocytosis, caveolin-mediated endocytosis and clathrin- and caveolin-
independent endocytosis. In clathrin-mediated endocytosis, the cell surface receptors 
become bound to appropriate macromolecular ligands and accumulate within specific 
regions of the plasma membrane called coated pits containing clathrin. The pits then pinch 
off forming coated vesicles. Once in the cell, the internalised macromolecules are trapped 
within endo/lysosomal vesicles and eventually undergo degradation by lysosomal 
enzymes. Caveolae-	 dependent endocytosis however is a clathrin-independent 
endocytosis process and involves the formation of bulb shaped plasma membrane 
ROS
Endosome
Photosensitiser
Cytotoxic agent
Light
BA C
Intracellular 
target
Figure 3: Mechanism of Photochemical Internalisation (PCI) of a cytotoxic agent: Endocytic 
uptake of photosensitiser (red) and chemotherapeutic drug (green) by cancer cells and the 
release of endocytosed drug into the cytosol through PCI. (A) Uptake of photosensitiser and 
chemotherapeutic drug by the cancer cell via endocytosis and their localisation within 
endosomes and subsequently lysosomes. (B) Localisation of photosensitiser in the 
membrane of the endosome post washing and the light-induced generation of ROS in the 
membrane of the endosome containing the chemotherapeutic drugs. (C) Photo-induced 
rupture of the endo/lysosomal membrane after prolonged irradiation via interaction of ROS 
with the membrane, leading to the escape of the chemotherapeutic drugs into the cytosol 
where they can be delivered to their target sites of action to exert their effects. 
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invaginations known as caveolae. In this type of endocytosis, the caveolae pinch off the 
plasma membrane and whilst some of the caveolae try to fuse back with the plasma 
membrane most reach early endosome and are then recycled back to the plasma 
membrane (132, 133). 
 
1.14 Photosensitisers used in PCI 
 
In order to be suitable for use in PCI, photosensitisers are required to localise within the 
membranes of the endosomes or lysosomes. To assist with this mechanism, carboxylic 
groups can be incorporated into the photosensitisers, however these groups also allow 
the photosensitiser to penetrate through the cell membrane. Therefore, by replacing these 
groups with sulfonate groups which remain negatively charged at physiological pH, the 
photosensitisers can be taken up by adsorptive endocytosis and do not penetrate through 
cell membrane or undergo protonation in the acidic environment of the lysosomes (134). 
 
AlPCS2a (aluminium phthalocyanine) has been utilised in many in vitro and in vivo PCI 
studies due to its advantages such as having a stable azaporphyrin macrocycle which 
allows better absorption of light in the far red region (670nm) as well as the two adjacently 
substituted sulfonate groups that contribute to the amphiphilicity of the sensitiser (135, 
136). 
 
Another sulfonated chlorin based sensitiser, disulfonated tetraphenyl chlorin (TPCS2a- 
AmphinexÒ) was developed as an alternative to AlPCS2a as it can be more reliably 
synthesised in bulk with relatively few regioisomers.  Furthermore, TPCS2a has an 
enhanced photobleaching rate which is beneficial for the patient as it reduces skin toxicity 
thus providing TPCS2a with the optimal photobiological and photophysical features 
required for PCI. Meso-tetra-phenyl porphyrin disulfonate (TPPS2a) is the porphyrin 
equivalent of TPCS2a and is readily available from several commercial sources. TPPS2a 
is often used for pre-clinical level studies and was the main photosensitiser used in this 
thesis. Its structure is shown in Figure 4A. 
 
Martinez et al. (2017) used TPCS2a and TPPS2a to carryout PDT and PCI studies on 2D 
and 3D hydrogel models of prostate cancer and not only observed a more superior effect 
with PCI than PDT in 2D cultures but also found a morphological change in the 3D cultures 
(137). 
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1.15 Chemotherapeutic drugs used in PCI 
 
Examples of macromolecular drugs that have been approved for clinical use include 
CD33-targeted immunoconjugate (Mylotarg), HER2-targeted antibody (Herceptin), 
(EGFR)- targeted antibody (Cetuximab), IL-2 modified diphteria toxin fusion protein 
(Ontak) (138).The most commonly used chemotherapeutic agents which have been used 
experimentally for PCI include saporin, bleomycin, gelonin (137-139), but to date only 
bleomycin has been used in clinical trials of PCI. One common chemotherapeutic to be 
used experimentally is Doxorubicin, whose structure is shown in Figure 4. Since this drug 
is a weak base owing to the presence of the amino group it is susceptible to protonation 
within acidic lysosomes thus resulting in its entrapment since the ionise form is less likely 
to pass through the lysosomal membranes into the cytosol. 
 
Saporin: also known as Saporin-S6 is a natural toxin derived from a plant and acts as 
Type 1 ribosome-inactivating protein (RIP). RIPs function by removing the A4324 adenine 
residue, in the rat ribosome which then interferes with the interaction between the 
ribosome and elongation factor 2, which irreversibly damages the ribosome and results in 
the inhibition of protein synthesis (140). As saporin has a high molecular weight (30 kDa) 
(141), it is prone to endocytic uptake and subsequent endolysosomal degradation and 
therefore has limited efficacy when applied alone. The structure of saporin is illustrated in 
Figure 4B. 
 
Bleomycin: is a glycopeptide antibiotic which acts by causing a break in the double strand 
of DNA therefore imitating the effects of ionising radiation. Although the exact 
mechanism by which bleomycin functions is still not fully understood, there has been a 
suggestion that this drug form complexes with iron ions thus forming a pseudoenzyme 
which can generate hydroxide and superoxide radicals that can cause breaks in DNA 
strands. However, the benefits of bleomycin can be limited by its toxic effects in the 
lung leading to fibrosis (142). 
 
 
Gelonin: like saporin is also a natural ribosome-inactivating protein derived from a plant. 
Gelonin therefore functions by removing the base A4324 in 28S rRNA and preventing the 
association of elongation factor-1 and -2 with the 60 s ribosomal subunit, thus resulting in 
cell death. Due to its large molecular weight (29 kDa), gelonin is not able to cross the 
plasma membrane and exert its therapeutic effect when applied alone and therefore 
displays very limited toxicity under such circumstances (143, 144).  
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Dactinomycin: is a clinically approved agent which acts as an anti-tumour antibiotic and 
functions through DNA intercalation as well as inhibition of RNA and protein synthesis. 
This agent has not been tested for PCI before and based on its high molecular weight 
(approximately 1255 Da), it should be taken up partly via endocytosis like bleomycin which 
has a molecular weight of approximately 1400 Da. Furthermore, as Dactinomycin is 
fluorescent unlike bleomycin, therefore fluorescence imaging can be carried out to show 
endolysosomal localisation of this drug.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
Figure 4: Structure of photosensitiser and chemotherapeutic agents used in PCI. A. Structure of 
TPPS2a (145). B. Structure of saporin  (140). C. Structure of Doxorubicin (146) . 
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1.16 Three- dimensional (3D) in vitro cell culture models  
 
Whilst various non- mammalian in vivo models such as fruit fly, zebra fish, amphibians 
and chicken embryos have also shown potential for use in PDT studies, the development 
of in-vitro three-dimensional (3D) cancer models has attracted considerable interest as it 
has provides a way of recapitulating key aspects of a solid cancer tissue, including 
tumour-stromal cell interactions without the use of living species (147-149). 3D models 
have several advantages over simple two-dimensional (2D) cell culture e.g the 
enhancement of the expression of differentiated functions, improvement of cell or tissue 
organisation, anti-apoptotic signalling, multicellular resistance as well as expression of 
hypoxic conditions and limited drug penetration. Furthermore, the cellular and stromal 
characteristics of the 3D cultures can be manipulated to provide a more representative 
model for assessing the therapeutic response as an alternative to animal model testing 
(150-155).  
 
Various methods can be employed for the development of 3D culture models, for example 
multicellular aggregates, culturing cells on inserts or embedding cells in an artificial 
nanofibrous matrix or scaffold developed from natural or synthetic material (156). A 
summary of the different characteristics of various types of 3D models is presented below. 
 
 
Spheroids 
Spheroids (also called spheres, nodules or micronodules) are well-rounded 3D cancer 
models that are usually several hundred µm in diameter (157-159). These models can be 
developed either by growing cells in low adhesion conditions (e.g plates, hanging drop 
methods etc.) where they adopt a spherical shape through aggregation (160-162) or by 
embedding cells in a 3D matrix. The closely packed arrangement of cells in spheroids, 
which provides cell to cell contact as well as reduced rate of drug and oxygen diffusion 
through the models makes the spheroids comparable to in vivo tissues (163). Spheroid 
3D models can be used for the assessment of various specific 3D properties such as the 
development of invasive characteristics, changes in the dependence of cells on growth 
factors, increased luminal survival because of the stimulation of anti-apoptotic and pro-
proliferative signals and the capability to avoid growth arrest because of these pro-
proliferative signals (147) (164). Spheroids have also been widely used for a variety of 
photosensitiser-PDT studies. 
 
Cell derived matrices (CDMs) 
 
CDMs are normally produced by culturing cells that excrete ECM proteins on pre-coated 
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scaffold surfaces or as a monolayer (2D), or multicellular aggregates (3D) to allow enough 
ECM to be deposited. Once adequate ECM has been deposited, the cellular component 
is removed from the ECM using decellularisation processing. Such processing is crucial 
for minimising the risk of encountering adverse immunological responses (165). Cells that 
are cultured on CDMs have shown to have similar morphologies to those observed in vivo 
as they are able to form specified 3D matrix adhesions, which are also found within in vivo 
models (166). 
 
Microfluidic devices 
 
The microfluidic technology also called Lab-on-a-chip (LOC) (145) allows the 
development of 3D cell cultures and cell-based assays in complex microenvironments 
whilst providing the capability for the environment to be controlled, reproduced and 
optimised (146). There are several key features possessed by this type of technology: 
1) it exhibits micro-scale dimensions which have great compatibility to the microstructures 
found in the microenvironments of in vivo cancer models; 2) It allows small quantities of 
samples to be used which keeps reagent consumption low therefore reducing the costs 
of bioanalysis as well as drug discovery and development; 3) Some of the substrates used 
in microfluidic devices enable high O2 diffusion which has an important impact on cell 
proliferation and 4) numerous features such as cell culture and sampling, control of fluids, 
cell capturing, cell lysis and detection can be integrated on one single microfluidic device 
(147, 148). The various types of microfluidic devices that have been used in studies 
involving 3D cell cultures include glass/silicon-based, polymer-based together with paper-
based platforms, which have been given their names based on the substrates used in the 
production of the micro-device (146). 
 
Scaffolds 
 
3D scaffolds consist of a nano-fibrous matrix which allow the creation of an environment 
that supports the proliferation, growth and migration of cancer cells thus providing the 
opportunity for such aspects to be investigated (150). In comparison to spheroids, 
scaffolds hold several advantages particularly the capability of mimicking tumour 
heterogeneity as well as the control of the 3D dimensions. Furthermore, it is possible to 
control the extent of migration, proliferation and aggregation of the cells through the 
surface properties as well as the composition, configuration and the porosity of the 
scaffolds (150, 151). Such properties also make scaffolds suitable candidates for 
nanocarrier delivery studies as shown by Lopez et al. (2016) who focused on the diffusion 
properties of liposomes and micelles in a 3D collagen scaffold model (152). Scaffolds can 
be categorised into natural or synthetic scaffolds depending on the materials incorporated 
into them (153). 
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Natural scaffolds are mainly hydrogels that consist of mostly water (167) and natural 
components such as collagen type 1, Matrigel (a gelatinous complex protein mixture), 
agarose, elastin, laminin and hyaluronic acid (164) (168). Although the large volume of 
excess fluid with these models makes them mechanically, the hydrogel models allow the 
movement and proliferation of cells within a biological environment (169). However the 
low density of these models does not represent the density observed in the environment 
surrounding tumour cells in vivo (169). This problem can partially be resolved by the 
remodelling of the hydrogel to assist cell-matrix interaction studies and an increase in 
matrix density due to contraction (170).  
 
The development of the plastic compression technology has led to production of better 
biomimetic scaffolds with increased cell and collagen density due to removal of interstitial 
fluid from the hydrogel model (171). The collagen density in these compressed hydrogels 
(c. 10% wt/wt) is similar to physiological values. The collagen stiffness and density in 
these scaffolds not only affects rate of cell growth as well as morphologies (172), but also 
enables the hypoxic core that is normally observed in vivo to be imitated in vitro as a result 
of the reduced oxygen diffusion through the denser matrix (169). Figure 5 demonstrates 
the stages involved in the formation of the compressed 3D model. Recent studies with 
compressed collagen hydrogels have used ‘tumouroid’ models consisting of a cancer 
mass surrounded by a multi-cellular stroma to investigate the uptake of nanoparticles as 
well as their use in enhancing drug delivery (173) (155). The construction of tumouroids 
was originally demonstrated by Nyga et al. (2013), who used plastic compression of 
collagen type I to create a colorectal tumouroid construct (174). 
 
Synthetic scaffolds can also be developed from polymers such as polyactide (PLA), 
polyglycolide (PGA) and co-polymers (PLGA) (175). Such polymers are biodegradable 
and can be molded into a variety of structures such as mesh, fibers and sponge (176). In 
terms of mechanical structure, synthetic scaffolds are stronger than natural scaffolds and 
are able to specifically replicate biomolecular structures observed in vivo (177). However, 
one disadvantage associated with these polymers is the weaker cell adhesions therefore 
surface modifications are needed to overcome this issue (169).  
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Figure 5: Fabrication of tumouroid constructs.A: The original method of creating simple and complex 
3D compressed collagen cancer models  (174).  B: PDT in 3D compressed cancer constructs and 
the construction of compressed 3D cancer models (i) PDT using photosensitiser in 3D compressed 
collagen construct consisting of cancer cells surrounded by a matrix (eg type 1 rat tail collagen) 
illustrated with sequential procedures  (80); Step 1: seeding of cancer cells in the collagen scaffold; 
Step 2, addition of a photosensitiser for cell uptake followed by washing; Step 3: the irradiation of 
the 3D model with light of a specific wavelength and generation of ROS. Step 4; the dead cancer 
cells in the collagen scaffold. (ii)  Novel method of constructing  compressed 3D collagen cancer 
models with higher collagen density for therapeutic studies illustrated sequentially. Step 1, the 
formation of collagen/cell mix before undergoing plastic compression using an insertable absorber 
to extract fluid from the hydrogel; Step 2 gradual absorption of the interstitial fluid from the 
collagen/cell mix by the absorber and the slow compression of the model; Step 3 the creation of the 
thinner (typically 200 µm depth) compressed 3D collagen cancer model following the absorption of 
the fluid from the model resulting in a ten-fold higher collagen density. 
 44 
1.17 In vitro and in vivo studies of PDT       
 
PDT has been used in many in vitro studies and in vivo studies to examine the 
effectiveness of various photosensitisers for treating different types of cancer. Some of 
the in vitro PDT studies have included the use of nanoparticles to improve the efficacy of 
the treatment (178).    
 
There are numerous studies and reviews of PDT using conventional 2D models but in 
recent years the development and employment of 3D models for cancer studies including 
PDT has specifically provided many benefits for PDT-related investigations since their 
use allowed the uptake, localisation and efficacy of the drugs to be studied in more 
physiologically realistic models.  In the following section, the types of 3D models being 
used are summarised. This section is later followed by a section that summarises PDT 
studies carried out using 3D models to date. A summary of the PDT studies which have 
involved the use of 3D models is provided in Table 1. 
 
The studies summarised in table 1 have mainly used spheroid models for their 
experiments. Spheroids also known as spheres, nodules and micronodules are spheroidal 
3D cancer models that can be several hundred μm in diameter. Till et al. (2016) employed 
the 3D spheroid model from human colorectal carcinoma cell line (HCT-116) and human 
squamous cell carcinoma cell line (FaDu) to investigate PDT efficacy of free pheophorbide 
photosensitiser (Pheo) compared to the use of encapsulated photosensitiser in 
crosslinked polymeric micellar self-assemblies and their uncrosslinked micellar 
counterparts (161). However, in another study Hung et al. (2016) used the ovarian cancer 
spheroid model from OVCAR5 cells to examine whether the dark toxicity of 5-ethylamino-
9- diethylaminobenzo[a] phenothiazinium chloride (EtNBS) can be reduced through its 
encapsulation in PLGA nanoparticle (179). The same cell line was also used in two other 
studies by Evans et al. (2011), and Rizvi et al. (2013) to form ovarian cancer spheroids 
(180, 181). Like Hung et al., the study by Evans et al.  also used EtNBS as a 
photosensitiser but in this case to study the effect of this photosensitiser on the hypoxic 
cell populations situated within the 3D spheroids. Rizvi et al. (2013) however, focused on 
the effect of Benzoporphyrin Derivative (BPD)-PDT on the ovarian cancer spheroids.
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Photosensitiser Nanoparticle Description of 3D cancer model Cancer cell line Ref.
  
Methylene blue - Spheres on (poly 2- hydroxyethyl 
methacrylate) (polyHEMA) coated microwells 
in a microfluidic device 
Human breast carcinoma (T47D) (182) 
Benzoporphyrin Derivative (BPD)  - Micronodules on Matrigel matrix Human ovarian carcinoma (OVCAR5) (183) 
5-ethylamino-9-diethylaminobenzo[a] 
phenothiazinium chloride (EtNBS) 
- Nodules on growth factor reduced (GFR) 
Matrigel matrix 
Human ovarian carcinoma (OVCAR5) (180) 
BPD in DMSO - Micronodules on Matrigel matrix Human ovarian carcinoma (OVCAR5) (184) 
BPD - Micronodules on Matrigel matrix Human ovarian carcinoma (OVCAR5) (181) 
5-Aminolevulinic acid (5-ALA) - Nodules on Matrigel matrix Human epidermal carcinoma  (A431) (45) 
BPD, mono-N-aspartyl derivative of 
chlorin e6 (MACE) 
- Mammary architecture and micro-
environment engineering (MAME) of breast 
cancer- Spheroids formed on glass cover 
slips coated with reconstituted basement 
membrane 
Human breast carcinoma (SUM149, 
MDA-MB-231, Hs578T) 
(185) 
Tetraphenyl disulfonated porphyrin 
(TPPS2a ), Disulfonated tetraphenyl 
chlorin (TPCS2a ) 
 
- Single cells seeded in hydrogel (collagen) 
scaffold 
Human prostate adenocarcinoma  (PC3) (137) 
Tetraphenyl disulfonated porphyrin 
(TPPS2a ), Disulfonated tetraphenyl 
chlorin (TPCS2a ) 
- Single cells seeded in hydrogel (collagen) 
scaffold 
Human head and neck squamous cell 
carcinoma (PCI30) 
(186) 
mTHPC 
 
- Single cells seeded in hydrogel (collagen) 
scaffold 
Human breast carcinoma (MCF-7) (187) 
BPD 
 
- Nodules on Matrigel Human ovarian carcinoma (OVCAR5) (188) 
 
Hypericin 
 
- Spheroid on agarose coating Human bladder carcinoma (RT-112) (189) 
 
Ruthenium(II) polypyridyl complexes 
(Ru1- Ru3) 
- Spheroid on agarose coating 
 
Human cervical carcinoma (HeLa) (190) 
 
Ruthenium(II) polypyridyl complexes 
(RuL1- RuL4) 
 
- Spheroid on agarose coating Human cervical carcinoma (HeLa) (191) 
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         Table 1: Summary of PDT studies in 3D in vitro cancer models with or without nanoformulated photosensitisers
Fluorinated ruthenium(II) complexes 
(Ru1- Ru5) 
- Spheroid using liquid overlay method Human cervical carcinoma (HeLa) (192) 
5- Aminolaevulinic acid (5-ALA) 
induced PPIX 
Gold 
nanoparticle 
(AuNPs) 
Nodules on microfluidic device Human breast carcinoma (MCF-7) (193)  
Pheophorbide A (Pheo) Micelles (poly 
ethyleneoxide-b-
3-caprolactone)  
Spheroid on ultra- low attachment well plates Human colorectal carcinoma (HCT-116), 
Human squamous cell carcinoma (FaDu)   
(161)  
m-tetrahydroxyphenylchlorin 
(mTHPC)  
Lipidots Spheroid using hanging drop method Human tongue squamous cell carcinoma  
(CAL-33) 
(162) 
 
EtNBS Poly(lactic-co-
glycolic acid) 
(PLGA) 
Spheroid on Matrigel Human ovarian carcinoma (OvCAR) (179) 
Cis-Bis(2, 2'-
bipyridine)dichlororuthenium(II) 
hydrate  
SWCNTs Spheroid using liquid overlay method 
 
Human cervical carcinoma (HeLa)  
(194) 
Chlorin e6 (Ce6) Reduced 
Graphene Oxide 
(rGO) 
Spheroid Human brain carcinoma (U87) (195) 
m-THPC Liposome 
(FoslipTM and 
FospegTM) 
Spheroid using liquid overlay method Human cervical carcinoma (HeLa) (196) 
Zinc Phthalocyanine (ZnPc) Liposome Spheroid on agarose coating Human cervix adenocarcinoma (HeLa 
cells) and Mouse Mus musculus colon 
carcinoma (CT26) 
(197) 
Photofrin 
 
Liposome Spheroid using spinner flasks on a stir-plate    Human bladder carcinoma (MGHU3)  
 
(198) 
 
Indocyanine green PLGA/lipid Spheroid on agarose coating Mouse breast carcinoma (4T1) (199) 
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1.18 Pre-clinical and clinical studies of PCI 
 
PCI has been studied pre-clinically in vitro (137)(186) and in vivo (137). The majority of 
studies have either been in 2D monolayer culture or using experimental tumour models 
in mice which are now briefly summarised in the following sections.  For example, an in 
vitro and in vivo PCI study of colorectal adenocarcinoma and murine colon carcinoma 
models by Berg et al. (2005) found that TPPS2a and bleomycin significantly enhanced 
cytotoxicity by three times compared to bleomycin alone in vitro. The in vivo studies 
showed that photochemical internalisation of bleomycin led to delay in tumour regrowth. 
Furthermore 60% of the animals were found to be tumour free 200 days post PCI 
treatment, however in the case of PDT treated animals only 10% were found to be tumour 
free after the same period. None of the animals were found to be tumour free after 
treatment with bleomycin alone (139).  
  
PCI using bleomycin combined with AlPcS2a lead to a significant delay in tumour growth 
in comparison to control groups which had not undergone PCI (139). In a different study, 
Arentsen et al. (2014) demonstrated enhanced cell killing in monolayer and multicellular 
spheroid cultures of bladder and brain cancer also using bleomycin PCI (200). 
 
A clinical study using PCI in patients with local recurrent, advanced, or metastatic 
cutaneous or subcutaneous malignancies has also been conducted recently using 
Amphinex as photosensitiser and bleomycin as chemotherapeutic drug and the treatment 
was found to be safe and tolerable (201). 
 
1.19 Advantages of PCI over PDT 
 
Although both PDT and PCI share some common features, PCI offers several potential 
advantages over PDT. PCI relies on the use of sub-lethal PDT to trigger cytosolic release 
of agents entrapped within endolysosomes. Firstly, the lower dose of photosensitiser 
required for PCI could reduce skin photosensitivity that is normally associated with PDT. 
Secondly, compared to PDT, PCI may lessen and delay the damage caused to endothelial 
cells, that in turn leads to vascular shutdown, perhaps due to lower PCI light fluence used 
(202-204). Consequently oxygenation of the tumour required for production of singlet 
oxygen may be less affected by PCI thus resulting in greater eradication of the tumour 
(203). Another advantage of PCI is that the photosensitisers used for this treatment, e.g 
TPPS2a, are not substrates for efflux via ABCG2 transporters which mediate cellular 
multidrug resistance whilst many of the second generation photosensitisers used in PDT 
have shown to be subject to efflux by ABCG2 (127, 205-208).  
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Lou et al. (2006) found that PCI was able to overcome doxorubicin resistance in MCF-
7/ADR cells and render them nearly as sensitive to the drug as for the MCF-7 cells. Weak-
base drugs like doxorubicin are thought to be susceptible to entrapment in endocytic 
vesicles of multiple drug resistant cells which exhibit increased acidification of the vesicles 
as well as increased cytosolic pH (209). Bostad et al. (2013) on the other hand used PCI 
to target CD133-positive colon cells (WiDr) using an immunotoxin consisting of mAb 
CD133/1 bound to ribosome inactivating plant toxin saporin (anti-CD133/1-sap). They 
found that TPCS2a-PCI of anti-CD133/1-sap increased the effect of the immunotoxin. 
Furthermore, the WiDr cells were found to be resistant to PDT, whereas the use of PCI 
helped bypass this resistance (210). 
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1.20 Aims of the thesis 
Due to the benefits that 3D cancer models offer over other simpler in vitro systems and 
based on the potential compressed collagen 3D models have in mimicking in vivo models, 
the aim of this thesis was to investigate and evaluate the potential of PDT and PCI in 
different 3D compressed collagen models of breast and ovarian cancer.  
In this work experiments were conducted in vitro using monolayer and 3D constructs to 
serve as templates that could provide guidance for further in vivo studies that may be 
undertaken in the future. The outcomes from the aims set during this project have been 
presented in different sections within this thesis. 
The main hypothesis was that Photochemical Internalisation (PCI) is an efficient means 
of enhancing the cytotoxicity of a macromolecular toxin when applied to cancer cells 
grown in a 3D model and could present an improvement in therapeutic efficacy compared 
to PDT. 
Three cancer cell lines were selected for this project. These cell lines included breast 
cancer cell line (MCF-7) and ovarian cancer cell lines (HEY and SKOV3). MCF-7 cells are 
luminal A breast carcinoma cells which are oestrogen receptor positive (ER+) and human 
epidermal growth factor receptor 2 negative (HER2-) whilst the ovarian cancer cell lines 
form papillary cystadenocarcinomas and clear cell adenocarcinomas, respectively. The 
fact that all cancer cell lines used in this study develop in epithelial tissues, makes them 
suitable for treatment with PDT and PCI.  
 
Drugs used in this study included the photosensitiser meso-tetraphenyl porphine 
disulfonate (TPPS2a) and chemotherapeutic drugs Saporin and Dactinomycin. TPPS2a, 
has two sulfonate groups substituted on adjacent phenyl rings of the porphyrin macrocycle 
which reside at the aqueous-lipid interface with the hydrophobic portion of the macrocycle 
inserted into the lipid bilayer. Saporin and Dactinomycin both have high molecular weights 
over 1000 Da and are therefore relatively large molecules which makes them prone to 
endolysosomal degradation and therefore suitable for delivery via PCI. Also, due to the 
fluorescence of dactinomycin, it can be used to show endolysosomal localisation via 
fluorescence imaging. 
The primary objective was to examine the efficacy of PDT and PCI in treating monolayer 
as well as non-spheroid and spheroid constructs of breast and ovarian cancer cells using 
TPPS2a as a photosensitiser and saporin as the chemotherapeutic agent. The uptake of 
the photosensitiser as well as change in oxygen consumption with the growth of ovarian 
cancer cells in 3D were also investigated using fluorescence staining and microscopy. 
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The effects of pre-incubating the cells with the drugs prior to seeding as well as applying 
the treatments without chasing and the modes of cell death stimulated after each 
treatment were additionally studied using cytotoxicity assays and fluorescence imaging. 
The second objective of this project was to test Dactinomycin also known as Actinomycin 
D as a chemotherapeutic drug in PCI studies in non-spheroid 3D ovarian cancer 
constructs using viability assays and to confirm the mechanism by which dactinomycin is 
uptaken by the cells. 
The final objective of this project was to study the effect of PDT and PCI (using saporin 
as toxin) in complex tumouroid constructs of ovarian cancer which also included a stroma 
with stromal cell consisting of fibroblasts and endothelial cells. Since tumours in vivo are 
more complex than the simple models created in vitro. Embedding the original cancer 
mass in a bigger compressed collagen construct consisting of stromal cells allows the 
growing cancer cells to invade the stromal environment unlike the spheroid constructs 
where the cells could only grow within the simple cancer mass model. In this part of the 
study the invasion of stroma by cancer cells and the effect of PDT/PCI on the cancer cells 
in the original cancer mass and those that had invaded the stroma as well as stromal cells 
were examined. The regrowth of cancer cells after PDT treatment was also examined. 
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Chapter 2 
 
2. Methods and Materials 
 
2.1 Cell culture 
 
Human breast (MCF-7) and ovarian (SKOV3 and HEY) carcinoma cell lines (American 
Type Culture Collection, ATCC, U.S.) were cultured in Dulbecco's modified Eagle's 
medium (DMEM/F-12, low glucose, Sigma Aldrich, UK) using aseptic techniques. Human 
dermal fibroblasts (HDFs) and Human umbilical vein endothelial cells (HUVECS) (both 
used as cell lines by previous researchers in our group and were available at Division of 
Surgery and interventional Sciences, UCL) were cultured in high glucose DMEM (Gibco, 
by Life Technologies, Thermo Fisher Scientific, UK) and endothelial cell growth medium 
(PromoCell, UK) respectively using aseptic techniques. All cell culture mediums again 
consisted of 10% heat inactivated fetal bovine serum (FBS, Gibco by Life Technologies, 
Thermo Fisher Scientific, UK) and 1% penicillin (5000 units/mL) and streptomycin (5000 µg/mL) solution (Gibco by Life Technologies, Thermo Fisher Scientific, UK). 
 MCF-7 cells are luminal A breast carcinoma cells which are oestrogen receptor positive 
(ER+) and human epidermal growth factor receptor 2 negative (HER2-) whilst the ovarian 
cancer cell lines form clear cell adenocarcinomas and papillary cystadenocarcinomas, 
respectively. 
 
2.2 Alamar blue cytotoxicity assay 
 
The cell viability in the 2D monolayer cultures and 3D cancer models were measured 
using the Alamar Blue reagent (Invitrogen, Thermo Fisher Scientific, UK). Alamar blue 
reagent functions through its active component “resazurin” changing colour from blue to 
pink upon becoming reduced by the metabolic activity of viable cells. The working solution 
of this assay was made by the addition of the dye to fresh culture media with the dye 
making up 10% of the overall solution. The models were incubated with the Alamar blue 
solution for 4 hours and the solutions were transferred from each well into a corresponding 
well in a black well plate (TPP, Sigma Aldrich, UK) for measurements. The fluorescence 
intensities were measured at wavelengths of (#Ex/Em 530nm /620nm) using Fluoroskan 
ascent FL plate reader (Thermo Labsystems, UK). Treatment-free monolayer cultures and 
3D models were also used as controls. The MTT assay based on absorbance was used 
solely for measuring viability in 2D cultures.  
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2.3 MTT cytotoxicity assay 
 
The MTT assay was used to measure cell viability in the monolayer cultures. This assay 
functions through the reduction of the tetrazolium dye by NAD(P)H dependent 
oxireductase enzymes in viable cells. The MTT reagent (Thiazolyl Blue Tetrazolium 
Bromide, Sigma Aldrich, UK) was dissolved in cell culture media at concentration 1mg/mL 
and filtered before being applied to monolayer cultures, which underwent incubation for 2 
hours. The MTT solution was then removed and DMSO (Sigma Aldrich, UK) was added 
to the well plates to dissolve the crystals formed. Absorbance was measured at 562nm 
using absorbance plate reader (BioTek, ELx800, U.S.). 
 
2.4 Total DNA cytotoxicity assay 
 
In preparation for the Total DNA assay which measures the amount of intact DNA in the 
samples, media from SKOV3 monolayer cultures were removed from the wells and the 
cells were washed with PBS at the end of the PCI experiment. The PBS was then removed 
and replaced with 100µL of distilled water per well. The cells were lysed following 3 freeze 
thaw cycles where each cycle involved placing the well plates in -80 C and then at room 
temperature for 30-45 minutes each. A serial dilution (concentrations 0-10 µg/mL) used 
for generating a standard curve were prepared in duplicates from the cell thymus DNA 
provided in the total DNA kit (Sigma Aldrich, UK) and 100µL each were added to well in 
a black well plate. Once the cell lysis process was complete, 100µL of the SKOV3 cell 
lysates were added to each well plate in a black well plate. (Hoescht 33298) fluorescent 
dye solution was prepared at (1:100) dilution with assay buffer. 100µL of Fluorescent dye 
solution was then added to each well containing the SKOV3 cell DNA and the standard 
DNA resulting in 200µL volume per well and were mixed well. The Fluorescence levels 
were measured using an excitation wavelength of 360nm and an emission wavelength of 
460nm in a Fluorescence microplate reader (Fluorosckan Ascent FL, Thermo Fisher 
Scientific, UK). 
 
2.5 Fabrication of simple non- spheroid and spheroid 3D cancer constructs 
The 3D in vitro compressed spheroid and non-spheroid cancer constructs were created 
following the protocol from RAFT 3D culture systems (Lonza, Slough, UK) (211) (212). 
The compressed 3D culture system contains a cell-embedded Type 1 collagen matrix that 
has been subjected to plastic compression through the use of fluid absorbers producing 
3D constructs with a thickness of c. 200 µm (collagen density, 9.6%) in wells of a 96 well 
plate (212).  
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The hydrogels were prepared from a mixture containing 10% 10x medium essential 
medium (MEM) (used as colour/ pH indicator) (Gibco by life technologies, Thermo Fisher 
Scientific, UK), 80% Rat Tail Collagen Type I (First Link UK Ltd. Custom Bio-Reagents) 
before undergoing neutralisation using neutralising solution made from 1.65 M NaOH and 
840 mM HEPES buffer solution (Gibco by Life Technologies, Thermo Fisher Scientific, 
UK). The cells were seeded separately into each collagen mix at concentrations of 75,000 
cells (determined after a cell density gradient experiment) for non-spheroidal models and 
50,000 cells for spheroidal constructs at volumes of 240µL per well in 96 well plate (TPP, 
Sigma Aldrich, UK). The constructs were incubated at 37℃ for 15 minutes to set before 
being subjected to plastic compression using absorbers (Lonza, UK) at room temperature 
for a further 15 minutes. After the removal of the absorbers, Fresh media was added to 
each construct before incubation at 37℃. The cell culture media of the constructs were 
changed daily.  
2.6 Cell seeding and imaging of spheroid formation 
 
The response of larger spheroids, consisting of multicellular aggregates of SKOV3 and 
HEY cells that grew over a period of 7 days prior to treatment were investigated. As part 
of the pilot study, cell morphology and spheroid formation at different time points (days 3, 
5 and 7) after the initial seeding and compression were investigated using fluorescently 
labelled Phalloidin to visualise filamentous actin, and the Hoechst 33258 dye to observe 
the cell nuclei. The constructs were fixed with Formalin (10%) and washed with PBS. They 
were then permeabilised with 1% BSA and 0.3% Triton X solution and stained with 
Phalloidin (2.5% in BSA /Triton-X solution) for 90 minutes before washing with PBS (3x) 
and further staining with Hoechst 33258 (%Ex/Em 352/461 nm), 2	µg/mL in PBS for 10 
minutes. Alexa Fluor 488 labelled Phalloidin ( %Ex/Em 495/518 nm, Molecular Probes, Life 
Technologies) and Hoechst 33258 (%Ex/Em 352/461 nm, Sigma-Aldrich) were imaged using 
an EVOS fluorescence inverted microscope (EVOS FL color, Life Technologies, Thermo 
Fisher Scientific, UK). The cellular aggregate sizes were measured using image analysis 
by delineating the boundary and the area was computed by the software. Approximately 
20-30 aggregates were measured per construct. The same imaging technique using 
Phalloidin/ Hoechst 33258 was used in therapeutic studies of spheroids that followed later. 
Image analysis of the fluorescence images was carried out using the open source ImageJ 
software (NIH, US). In general, the HEY cells formed a higher population of larger 
spheroids compared to SKOV3 cells. Although irregular in shape they approximate to a 
circular shape, with the approximate diameters being estimated using the cross-sectional 
area. The small (approximately < 50 µm in diameter) and medium (100-150 µm) 
aggregates predominated (over 50% of total sampled) in the SKOV3 constructs whereas 
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the medium and large (approximately >150 µm) predominated in the HEY constructs. 
 
2.7 Fabrication of Tumouroid constructs 
The tumouroid construct was created using a compressed cancer mass, which was 
sandwiched between two layers of collagen containing stromal cells (fibroblasts and 
endothelial cells). 
The cancer masses were developed following the same protocol described in section 2.5 
using 50,000 cells/construct seeding density. The artificial stroma was then created also 
following the same steps as above to prepare the hydrogels with HDFs and HUVECS 
seeded at densities of 25,000 and 50,000 cells respectively (densities-based protocol by 
Magdeldin et al. (2017)) (212) and volumes of other components as instructed by Lonza. 
First half of the total volume per well (650µL) of the stromal cell/collagen mix was added 
to each well on a 24 well plate (Corning, Costar) and allowed to set slightly at room 
temperature for 5 minutes. The cancer constructs were then removed from the 96 well 
plate and each placed on top of a slightly set stroma hydrogel in the 24 well plate before 
being topped with an additional 650µL of the stroma cell/collagen mix (totaling 1.3 mL per 
well) and incubated at 37℃ for 15 minutes to set well. Once set well the tumouroid 
hydrogels undergo compression using absorbers (Lonza, UK). Upon removal of the 
absorbers, 200µL of each media (600µL in total) appropriate to the individual cell lines 
included in the tumouroid construct was added per well. Based on previous experiments 
on mature 3D constructs, the tumouroids constructs were incubated at 37℃	for 7 days to 
allow the HEY cells to grow forming spheroid like structures and metastasise prior to 
undergoing treatment. The cell culture media of the constructs was changed on daily 
basis. Figure 6 shows partially compressed 3D tumouroid collagen hydrogels. The fully 
compressed 3D tumouroid collagen constructs are shown in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Partially compressed 3D tumouroid collagen hydrogels. The compressed cancer mass 
embedded between the two layers of hydrogels containing stromal (fibroblasts and endothelial) 
cells. 
Compressed 
cancer mass 
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2.8 In vitro PDT/PCI phototoxicity studies in 2D monolayer cultures 
 
PDT and PCI treatments were carried out in 2D monolayer cell culture for the purpose of 
comparing the results to the 3D constructs. HEY, SKOV3 and MCF-7 cells were seeded 
as well as cultured at a density of (5000 cells/ well) in 96 well plates for 24 hours. 
Concentrated stock solutions of the photosensitiser, TPPS2a (Frontier Scientific Inc. U.S.), 
were prepared in dimethyl sulfoxide (DMSO). TPPS2a absorbs across the visible spectrum 
with its longest wavelength peak at 650 nm but strongest absorption peak at c. 420 nm 
(Soret band) and emits red fluorescence (600-720 nm). Initial screening studies were 
carried out with each cell line to determine appropriate concentrations of the TPPS2a and 
the cytotoxic agent, saporin (Sigma Aldrich). Cells were incubated with TPPS2a 0.4µg/mL 
(HEY) and 0.3µg/mL (SKOV3 and MCF-7) alone respectively (for PDT only), Saporin 
(Sigma Aldrich, UK) only (concentrations ranging from 10nM-20nM) or Dactinomycin 
(1nM) (Sigma Aldrich, UK) and co-incubation of TPPS2a and saporin or TPPS2a and 
Dactinomycin (for PCI) with all drugs being dissolved in media before addition. Similar drug 
doses have been used in previous studies in the lab. Figure 8 demonstrates a time- line 
showing the steps involved in the PDT/PCI treatment of cultures. 
 
Compressed 
cancer mass 
Figure 7: Compressed 3D tumouroid constructs. The construct consists of a compressed cancer 
mass created in a 96 well plate which is sandwiched between two layers of compressed collagen 
constructs containing stromal cells in a 24 well plate. 
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The cells were then incubated for 20 hours before being exposed to drug removal, 
thorough washing with phosphate-buffered saline (PBS, PH 7.4, Sigma Aldrich, UK) and 
fresh media replacement (to prevent the occurrence of strong PDT effect exerted by 
photosensitiser residing in the extracellular membrane). Incubation was repeated for a 
further 4 hours and then the cells treated with light irradiation using blue lamp (Lumisource, 
7mW/cm2, PCI Biotech, Norway) (shown in Figure 9) with peak emission at 423 nm for 
periods of 3 minutes, 5 minutes and 7 minutes. The cells were again incubated for either 
a further 48 or 96 hours at 37℃ before being subjected to termination of the experiment 
using the Alamar blue or MTT assay. 
Figure 8: Time- line showing the process of carrying out PDT/PCI experiment in a non- spheroid 
3D construct. The process was carried out for cultures that were seeded as monolayer cultures. 
For the spheroid and tumouroid constructs, the constructs were incubated for 7 days before the 
addition of drugs. As the time-line shows in this figure, the samples were incubated for 48 hours 
post illumination however, in some cases, the experiments were terminated 96 hours post 
illumination. 
 57 
 
 
 
2.9 In vitro PDT/PCI phototoxicity studies in 3D cancer constructs 
 
The non-spheroid 3D constructs of SKOV3, HEY and MCF-7 cells were seeded at 
densities of 75,000 cells/well. Cell densities of 50,000 cells/well were used for spheroid 
constructs of SKOV3 and HEY cells as well as tumouroid constructs of HEY cells. The 
non-spheroid cultures were treated following the same protocol, which was used for 2D 
monolayer cell cultures for all three cell lines with the concentrations of the drugs used in 
the non-spheroid constructs also remaining the same as those used in the 2D monolayer 
cultures as the pilot studies indicated that the same concentrations of the drugs were 
appropriate.   Saporin (40nM) was also used for treating SKOV3 and MCF-7 non- spheroid 
constructs. For the spheroid and tumouroid cancer models however the addition of drugs 
for either PDT or PCI was carried out on day 7 (ie 7 days post initial seeding) and the rest 
of the experiment continued until day 10 (termination point). Pilot studies showed that the 
concentrations of TPPS2a used for HEY and SKOV3 cells in the spheroid constructs and 
the HEY tumouroid constructs also varied from the ones used for both 2D and non-
spheroid cultures. Such concentrations were 0.5µg/mL (HEY cells) and 0.7µg/mL (SKOV3 
cells). Saporin concentrations ranging 20-40 nM were used for spheroid constructs and 
20nM for tumouroid constructs. In the tumouroid constructs concentrations of TPPS2a used 
for the PDT experiments were 0.5µg/mL and 1µg/mL although for the PCI experiments the 
concentration 0.5µg/mL was determined to be appropriate based on previous experiments 
with spheroid cancer constructs, which indicated that such concentration caused sub-
Figure 9: Blue lamp (Lumisource, 7mW/cm2, PCI Biotech) used for the irradiation of the 
constructs. The constructs were illuminated for less than 10 minutes for each experiment. 
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lethal PDT effect. While the non-spheroid and spheroid constructs underwent light 
illuminations of 3, 5 and 7 minutes using blue lamp (Lumisource, 7mW/cm2, PCI Biotech, 
Norway) the tumouroid constructs were illuminated for 3 minutes (PCI experiment) and 5 
minutes (PDT experiment). The non-spheroid, spheroid and tumouroid constructs were 
incubated at 37℃	for a further 48 hours post illumination before the termination of the 
experiment. Upon termination of the experiments, the cell viabilities in the non-spheroid 
and spheroid constructs were measured using Alamar blue assay and fluorescence plate 
reader (Fluoroskan, Ascent FL, Thermo Fisher Scientific, UK) and images were obtained 
with Live-dead imaging assay (non-spheroid and spheroid) and Phalloidin/ Hoechst 33258 
staining (spheroid) using EVOS fluorescence microscope (EVOS FL color, Life 
Technologies, Thermo Fisher Scientific, UK). The tumouroid constructs were stained with 
Cytokeratin 7 (Alexa Fluor 488) %Ex/Em: 490/525 conjugated antibody (Abcam, UK) (for HEY 
cells), Anti- Vimentin (Alexa Fluor 405)	%Ex/Em: 401/421 conjugated antibody (Abcam, UK) 
(for HDFs) and Anti-CD31 (PerCP-eFluor 710) %Ex/Em: 482/709 conjugated antibody 
(eBioscience, Thermo Fisher Scientific, UK) and imaged using Olympus fluorescence 
microscope (Olympus BX63).  
 
For studying the effect of PDT/PCI on invasion of stroma by cancer cells in tumouroid 
constructs, 8 measurements were taken from the original cancer mass of each construct 
to the longest distance invaded (starting clockwise and covering all the angles around the 
original cancer mass).  
 
2.10 In vitro PDT/PCI phototoxicity studies in 3D fibroblast constructs 
 
The effect of PDT/PCI on the stroma environment of the tumouroid construct was studied 
separately. HDF and HUVEC cells were seeded in compressed collagen construct in 24 
well plate and densities of 25,000 and 50,000 cells/construct respectively.  The constructs 
were incubated at 37℃	for 7 days before being incubated with either TPPS2a (0.5µg/mL) 
for (PDT) or TPPS2a (0.5µg/mL) and saporin (20nM) for (PCI) for 20 hours. The constructs 
were then washed with PBS and incubated with fresh media at 37℃ for a further 4 hours 
before undergoing 3 minutes of irradiation with blue lamp (Lumisource, 475nm, 7mW/cm2, 
PCI Biotech, Norway). 48 hours post illumination, the fibroblast cells were stained with 
Anti- Vimentin (Alexa Fluor 405)	%Ex/Em: 401/421 conjugated antibody (Abcam, UK) and 
imaged using Olympus fluorescence microscope (Olympus BX63) (shown in Figure 10). 
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2.11 Tumouroid re-growth studies 
The tumouroid constructs were treated with PDT using TPPS2a (0.5µg/mL) and 3 minutes 
illumination period 7 days post-seeding. The constructs were then incubated at 37℃ for a 
further 7 days prior to termination of the experiment. Upon termination of the experiment 
the constructs were stained with Cytokeratin 7 (Alexa Fluor 488) conjugated antibody and 
imaged using Olympus fluorescence microscope. 
2.12 In vitro PCI phototoxicity studies in monolayer and 3D cancer cultures in hypoxic 
conditions 
Monolayer and non-spheroid cultures of SKOV3 cells were seeded at densities of 5,000 
cells/well and 75,000 cells/construct respectively and incubated at 37℃ in normoxic 
conditions (20% oxygenation) for 24 hours. The constructs were then incubated in the 
same conditions with TPPS2a (0.3	µg/mL) only, saporin (40 nM) only or combination of 
saporin and TPPS2a for 20 hours before undergoing washing with PBS. Afterwards the 
constructs were incubated for a further 4 hours with fresh medium without drug or 
photosensitiser in a hypoxia incubator (Innova co-48, New BrunswickTM scientific, UK) 
(Figure 11) (1% oxygenation) prior to light exposure; the well plates were sealed just 
Figure 10: EVOS Fluorescence microscope (EVOS FL color, Life 
Technologies). 
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before light irradiation to prevent reoxygenation. The constructs were then exposed to 
blue light for 7 minutes, which under normoxia elicits a large reduction in viability. The 
experiment was terminated by measuring cell viability using Alamar blue assay 
(Invitrogen, Thermo Fisher Scientific, UK) and live-dead staining (Molecular Probes, 
Thermo Fisher Scientific, UK) and imaging. For the spheroid constructs the same process 
was repeated after 7 days of incubation (cell seeding density: 50,000 cell/ construct) at 
37℃ in normoxic conditions (to allow spheroids to form) using TPPS2a (0.7	µg/mL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.13 In vitro PCI phototoxicity studies in 3D cancer cultures pre-incubated with drugs 
 
The SKOV3 and MCF-7 cells were pre-incubated with either TPPS2a only (0.3 µg/mL), 
saporin (20nM) or both drugs 24 hours prior to seeding in 3D constructs. The constructs 
underwent light illumination using a blue lamp for 7 minutes (light source), 24 hours after 
seeding. Alamar blue assay (Invitrogen, Thermo Fisher Scientific, UK) 
(%Ex/Em	530nm/620nm) and live-dead assays (Thermo Fisher scientific, UK) were carried 
Figure 11: Hypoxia incubator (Innova co-48, New BrunswickTM Scientific). 
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out 48 hours post light illumination. The alarm blue measurements were obtained using 
fluorescence plate reader (Fluoroskan Ascent FL, Thermo Fisher Scientific, UK) and live-
dead images were obtained using fluorescence microscope (EVOS FL color, Life 
Technologies, Thermo Fisher Scientific, UK). 
 
2.14 PCI experiment without chasing in 2D and 3D cancer cultures 
 
The SKOV3 and MCF-7 monolayer and 3D cultures were seeded in a 96 well plate and 
incubated with TPPS2a only (0.3 µg/mL), saporin (20nM) or both drugs 24 hours after 
seeding. The drugs remained in the culture medium and the chasing step omitted, ie the 
drug removal and washing step. The cells underwent light illumination using the blue lamp 
for various periods, 24 hours after initial incubation with the drugs. The Alamar blue assay 
(Section 2.12) was carried out 48 hours post illumination with measurements being taken 
using a fluorescence plate reader (Fluoroskan Ascent FL, Thermo Fisher Scientific, UK). 
 
2.15 Temperature based mode of dactinomycin uptake by ovarian cancer cells in 
monolayer cultures 
 
This purpose of this experiment was to confirm the uptake of Dactinomycin via 
endocytosis. For this experiment SKOV3 cells were seeded in a 96 well plate and 
incubated with Dactinomycin (1nM) (Sigma Aldrich, UK) for 2 hours either at 4°C or 37°C, 
24 hours after seeding. The drug was removed at the end of the 2-hour incubation period 
and the cells were washed with PBS prior to being treated with fresh drug-free media.  
The cells were incubated at either 4°C or 37°C for a further two hours before the 
fluorescence levels were measured using a fluorescence plate (TECAN, infinite M200 
PRO, Switzerland) at (%Ex/Em 420/580nm). 
 
2.16 Live/dead staining for fluorescence imaging 
 
At set time points following treatment, the 3D constructs were stained for viability imaging 
using the Live-dead viability kit (Molecular Probes, Thermo Fisher Scientific, UK). 3D 
constructs were incubated with the Live-dead solution containing 0.05% of 4 mM Calcein-
AM (%Ex/Em 495/515 nm) and 0.2% of 2 mM Ethidium homodimer-1 (%Ex/Em 495/635 nm) at 
room temperature for 30 minutes before imaging with an inverted fluorescence microscope 
(EVOS FL color, Life Technologies, Thermo Fisher Scientific, UK).  
2.17 Immunostaining for fluorescence imaging 
Following the termination of the experiment, the tumouroids were stained using Anti-
Cytokeratin 7 (Alexa Fluor 488) %Ex/Em: 490/525 conjugated antibody (Abcam, UK) (for HEY 
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cells), Anti- Vimentin (Alexa Fluor 405)	%Ex/Em: 401/421 conjugated antibody (Abcam, UK) 
(for HDFs) and Anti-CD31 (PerCP-eFluor 710) %Ex/Em: 482/709 conjugated antibody 
(eBioscience, Thermo Fisher Scientific, UK) to image the constructs. Prior to the staining 
process, the tumouroids were fixed using Formalin (10%) (CellPath) solution for 10 
minutes before being washed with PBS. The cells in constructs were then permeabilised 
using 1% BSA and 0.3% triton X solution for 30 minutes before undergoing washing with 
PBS once again. The anti-cytokeratin 7 (Alexa Fluor 488) and anti-CD31 (PerCP-eFluor 
710) antibody conjugated solution was prepared with the immunostains being mixed in 
1% BSA and 0.3% triton X solution at ratios of 1/100 and 1/500 Respectively before being 
added to the tumouroid constructs and incubating at 4℃ overnight (20 hours). The stains 
were then removed, and the constructs were washed 3 times with PBS each time 
incubating at room temperature for 5 minutes. Finally, the anti-vimentin (Alexa Fluor 405) 
conjugated antibody stain was mixed in PBS at ratio of 1/200 before being added to the 
tumouroid constructs and incubating for 3 hours at room temperature. At the end of the 3 
hours, the constructs were washed with PBS and placed between a glass slide and cover 
slip in preparation for imaging. Images were taken with Olympus fluorescence microscope 
(Olympus BX63) using the pre-selected filter channels, FITC (for HEY cells), DAPI (for 
HDFs) and Cy7 (for HUVECS), and either 4x and 10x objectives. 
2.18 Imaging hypoxia levels in 3D constructs 
 
The reductions in oxygen levels within the cellular aggregates in the spheroid constructs 
as well as treated non-spheroid constructs of both cell lines were imaged using Image-iT 
Hypoxia reagent kit (488 nm excitation/ 610 nm peak emission, Molecular Probes by Life 
Technologies, Thermo Fisher Scientific, UK) according to the protocol supplied by the 
manufacturer. Two µL of 1 mM hypoxia reagent were added and mixed with 100	µL of cell 
culture medium in each well. Imaging of the well plates was carried out with an inverted 
fluorescence microscope (EVOS FL color, Life Technologies, Thermo Fisher Scientific, 
UK).   
 
The Image-iT Hypoxia Reagent is a fluorogenic compound which fluoresces in 
environments with low oxygen concentrations and therefore the emission intensity of this 
reagent correlates inversely to the oxygen partial pressure. Control constructs had cells 
incubated without the hypoxia reagent in normoxic conditions, and cells incubated with 
the hypoxia reagent in normoxic conditions. 
 
2.19 TPPS2a uptake and localisation 
 
To examine the uptake of TPPS2a within the SKOV3 and HEY cells in non-spheroid 
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constructs (75,000 cells/construct), the constructs were incubated with TPPS2a (1µg/mL), 
for 20 hours. Afterwards, the constructs were washed with PBS and incubated with fresh 
cell culture medium without photosensitiser for a further 4 hours before imaging. The 
constructs were imaged with a fluorescence microscope with quasi-confocal structured 
illumination capability (20x objective, Apotome.2, Carl Zeiss). The optical sectioning 
capability of this microscope enabled imaging within the 3D gels with retention of imaging 
resolution. Fluorescence from the photosensitiser was recorded within the range of 600-
700 nm using Alexa Fluor 647 channel. To determine the intracellular localisation of 
TPPS2a within non-spheroid constructs, separate constructs of both cell lines were 
prepared (10,000 cells/model). The constructs were incubated with TPPS2a (3	µg/mL) for 
20 hours before washing with PBS and incubating with fresh medium for 3.5 hours. The 
medium was then replaced with fresh medium containing LysoTracker Green (Molecular 
Probes, Thermo Fisher Scientific, UK) at 100 nM concentration for 30 minutes before 
microscope imaging. The constructs were washed 2 times with PBS and incubated with 
drug-free medium for imaging with Olympus fluorescence microscope (20x objective, 
Olympus BX63). The fluorescence from LysoTracker green and TPPS2a were recorded at 
520 nm and 650nm respectively. A lower number of cells were used in these constructs 
as it allowed the co-localisation of Lysotracker Green and TPPS2a to be observed more 
clearly. Confocal imaging was also used to look at the uptake of TPPS2a in 3D, however 
the system was not sensitive enough to provide any suitable results. 
 
2.20 Intracellular uptake of Dactinomycin in monolayer and 3D cultures 
 
Both cell lines were seeded on Petri dishes with a central glass cover slip base 
(Fluorodishes, WPI, UK) at density of 5000 cells/dish (monolayer cultures) and SKOV3 
cells were seeded at density of 10,000 cells/ construct (3D non-spheroid cultures) and 
incubated at 37℃ for 24 hours. The cells were then treated with Dactinomycin (Sigma- 
Aldrich, UK) at 50nM concentration for 4 hours at 37℃.	At the end of that incubation period 
the excess drug was removed from the dishes and the cells were washed with PBS before 
being incubated with fresh medium containing Lysotracker red (Molecular Probes, 
Thermo Fisher Scientific, UK) at 100 nM concentration for 30 minutes before microscope 
imaging. The constructs were washed with PBS and incubated with drug-free medium for 
imaging with Olympus fluorescence microscope (60x objective (2D) and 20x objective 
(3D), Olympus BX63). The fluorescence from LysoTracker red and Dactinomycin were 
recorded at 590 nm and 520nm respectively. 
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2.21 Mode of cell death (apoptosis/necrosis studies) 
 
Annexin V-FITC apoptosis detection kit (Abcam, UK) was used to confirm the initiation of 
necrosis and apoptosis in different treated 3D non-spheroid (SKOV3 and HEY cells) and 
spheroid (HEY cells) cancer constructs compared to non-treated control 3D cancer 
constructs. The cells were seeded at density of 75,000 cells (non-spheroid) and 50,000 
(spheroid) per compressed collagen construct and incubated for either 24 hours (non-
spheroid constructs) or 7 days (spheroid constructs) prior to treatment. The constructs 
were incubated with either TPPS2a only (0.3µg/mL for SKOV3 cells) (0.4µg/mL for HEY 
cells) (PDT) (for non-spheroid constructs) or (0.5µg/mL for HEY cells) (spheroid 
constructs), saporin only (20nM) or a combination of both drugs (PCI) and were 
illuminated 24 hours after initial incubation with the drugs (4 hours after drug removal, 
washing with PBS). Either 24 hours or 48 hours after being exposed to irradiation with 
blue lamp, 100µL of 1X Binding buffer was added to the models in each well before adding 
1µL of Annexin V-FITC, (%Ex/Em 488/525 nm) and 5µL of propidium iodide, (%Ex/Em 535/617 
nm) to the buffer solution in each of the wells. The models were then imaged using an 
EVOS fluorescence microscope (EVOS FL color, Life Technologies, Thermo Fisher 
Scientific, UK). 
 
2.22 Evaluation of synergistic effects 
 
To evaluate whether a synergistic interaction between the two separate therapies applied, 
we used the following equation to calculate the value of alpha (∝): 
 ∝	= 	 ,-./	0	,123434056,14785693546                                        equation 1 
                                                                                         
In the numerator of equation 1, the terms FPDT and Fcytotoxin designate the fractional viability 
for each separate therapy, PDT and the application of the cytotoxin, and the denominator 
is the fractional viability observed following the PCI combination treatment. If α > 1 then a 
synergistic effect is present whereas an antagonistic effect is denoted by α < 1. This 
analysis has been used previously by us and others to identify synergistic effects in PCI 
(130, 137, 213). 
To assess the efficacy of PCI (PCI efficacy) versus cytotoxin alone, we calculated the 
ratio of the viability without PCI (i.e. cytotoxin alone) divided by the viability measured after 
PCI. Likewise, to assess the PCI efficacy versus PDT alone, we calculated the ratio of the 
viability with PDT divided by the viability measured after PCI. 
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2.23 Data analysis 
 
Experiments were carried out in triplicate. Results were analysed using 2-way ANOVA 
with post-hoc analysis and values of P < 0.05 were considered to be statistically 
significant. Error bars from the mean show +/- standard deviation (SD). 
2.24 Image analysis 
The images used for finding the distance of which the cancer cells had invaded the stroma 
in tumouroid constructs were analysed using open source Image J software (NIH, US). 
An average from 8 measurements were taken from each tumouroid. 
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Chapter 3  
 
3. Photochemical internalisation in 3D constructs of 
breast and ovarian cancer using saporin as the 
chemotherapeutic drug 
 
In this chapter PDT/PCI experiments are described on 2D and 3D non- spheroid 
compressed collagen constructs of breast (MCF-7 cells) and ovarian cancer (SKOV3 and 
HEY cells) using TPPS2a as a photosensitiser and saporin as the chemotherapeutic agent. 
The compressed collagen constructs are approximately 200µm thick. The experiments on 
the monolayer cultures were initially carried out as pilot studies and for comparative 
purposes to the non-spheroid 3D constructs. The treatments were also repeated on 
spheroid 3D compressed collagen constructs of ovarian cancer (SKOV3 and HEY cells). 
In addition, the uptake of the photosensitiser by the SKOV3 and HEY cells (2D and 3D 
non-spheroid cultures) and the modes of cell death stimulated by each treatment (3D non-
spheroid and spheroid cultures) were investigated. Due to the important role oxygen 
availability plays in the effectiveness of both PDT and PCI, the dependence of the 
treatment efficacy on oxygen levels in non-spheroid and spheroid cultures was examined. 
The effects of pre-incubating the cells with the drugs prior to seeding (to study the effect 
of the collagen matrix on drug uptake and efficacy) as well as applying the treatments 
without chasing were also investigated. 
 
3.1 In vitro PDT/PCI phototoxicity studies in 2D monolayer cancer cultures 
 
 
PDT experiments were initially carried out using a range of TPPS2a concentrations to 
determine the concentration, which results in sub-lethal PDT effect and is therefore 
suitable for PCI experiments. In HEY cells, PDT using TPPS2a concentrations ranging 
from 0.2-0.6	µg/mL were first tested with the MTT assay (Figure 12): 0.4	µg/mL was found 
to cause a suitable sub-lethal  PDT effect (66% cell viability) required for PCI to work after 
treatment with the lowest illumination period used in our studies (3 minutes). The sublethal 
PDT effect would also be important for reducing side effects caused by PDT clinically. 
Since Alamar blue was the assay used in the PDT/PCI studies on the 3D constructs, this 
assay was also tested on some of the monolayer cultures for comparative purposes. 
When testing with Alamar Blue the sub-lethal concentration (0.4	µg/mL) identified by MTT 
was used as the lowest concentration in the range studied. The Alamar blue results 
(Figure 13) also showed that 0.4	µg/mL was the suitable TPPS2a concentration to use as 
it resulted in 82% viability in the HEY cells after 3 minutes of light illumination. Although 
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in the two assays a difference of 16% can be seen in the percentage viabilities achieved 
post PDT with TPPS2a 0.4	µg/mL, both assays reveal this to be the most appropriate 
concentration to use for PCI compared to the other concentrations of TPPS2a tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In SKOV3 monolayer cultures, from the MTT assay results (Figure 14) it was deduced by 
interpolation that 0.3	µg/mL should be the appropriate concentration of TPPS2a since 
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Figure 12: Viability of HEY cells post PDT treatment using different 
concentrations of TPPS2a (MTT assay). The samples were 
illuminated with blue lamp (420nm). MTT assay was used 
measurement of cell viability in this experiment. 
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Figure 13: Viability of HEY cells post PDT treatment using different 
concentrations of TPPS2a (Alamar blue assay). The samples were 
illuminated with blue lamp (420nm).  Alamar  Blue assay was used 
measurement of cell viability in this experiment. 
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0.2	µg/mL caused an inadequate PDT effect (88% cell viability) and 0.4	µg/mL caused a 
higher level of toxicity than required for PCI (57% cell viability). The Alamar Blue assay 
results also confirmed that 0.3	µg/mL was the most suitable concentration to use (Figure 
15). MTT assay was carried out initially with the maximum concentration of 
photosensitiser tested being 0.6 µg/mL. However, since 0.2 µg/mL caused a slightly lower 
cell kill then required and 0.4 µg/mL caused a slightly higher cell kill than required, 0.3 
µg/mL was also tested using the Alamar blue assay. Since the MTT results showed that 
0.6 µg/mL resulted in a significant reduction in percentage viability of SKOV3 cells, such 
concentration was not tested again with the Alamar blue assay. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Viability of SKOV3 cells post PDT treatment using 
different concentrations of TPPS2a (MTT assay). The samples 
were illuminated with blue lamp (420nm).  MTT assay was used 
measurement of cell viability in this experiment. 
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As the TPPS2a concentrations indicated to be appropriate for PCI studies in the SKOV3 
and HEY monolayer cultures by both MTT and Alamar blue the same, only the MTT assay 
was carried out on the MCF-7 cells. The MTT assay showed that TPPS2a at concentration 
of 0.3	µg/mL was suitable for PCI studies in MCF-7 cells (data not shown). 
 
Saporin concentrations used in the PCI studies in the monolayer cultures ranged from 
10nM- 20nM. MTT, Alamar blue or Total DNA studies were carried out either 48 hours or 
96 hours post illumination (termination point). According to MTT assay results in 
comparison to saporin only, viability reductions from 93% to 44% (3 minutes), 97% to 20% 
(5 minutes) and 95% to 17% (7 minutes) were seen in HEY cells using 10nM saporin 
(Figure 16A) with the PCI efficacies being (1.6 and 2.1) (3 minutes), (2.2 and 4.9) (5 
minutes) and (1.9 and 5.6) (7 minutes) compared to PDT and saporin only respectively. 
To evaluate the extent of synergistic interaction between PDT and saporin, calculation of 
the alpha values were found to be 1.5 (3 minutes), 2.2 (5 minutes) and 2 (7 minutes).  
The alpha value is the fractional viability for each separate therapy, PDT and the 
application of the cytotoxin, divided by the fractional viability observed following the PCI 
combination treatment. If α > 1 then a synergistic effect is present whereas an antagonistic 
effect is denoted by α < 1.  
 
With the same saporin concentration viability reductions from 91% to 42% (3 minutes), 
97% to 32% (5 minutes) and 98% to 27% (7 minutes) were achieved in SKOV3 cells 
(Figure 16B) with the efficacies being (1.7 and 2.2), (1.6 and 3.1) and (1.4 and 3.6) for 
020
4060
80100
120140
CNT 0.2 0.3 0.4
Vi
ab
ili
ty
	%
Concentration	of		TPPS2a		μg/mL	
Dark
3	minutesillumination
Figure 15: Viability of SKOV3 cells post PDT treatment using 
different concentrations of TPPS2a (Alamar blue assay). The 
samples were illuminated with blue lamp (420nm).  Alamar  Blue 
assay was used measurement of cell viability in this experiment. 
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each increasing illumination period compared to PDT and saporin only. In this experiment 
the alpha values were calculated to be 1.5 (3 minutes), 1.5 (5 minutes) and 1.4 (7 
minutes). In MCF-7 cells saporin (10nM) the viabilities dropped from 95% to 32% (3 
minutes), 95% to 17% (5 minutes) and 93% to 11 (7 minutes) compared to saporin only 
with the efficacies for each illumination period being (2.4 and 3), (1.7 and 5) and (2.4 and 
8.5) compared to PDT or saporin only respectively (Figure 16C). The alpha values for this 
concentration of saporin were 2.3 (3 minutes), 1.7 (5 minutes) and 2.2 (7 minutes), which 
are all greater than unity and demonstrate a synergistic effect. 
 
The increase of saporin concentration to 20nM showed that the viabilities dropped from 
95% to 20% (3 minutes), 93% to 16% (5 minutes) and 96% to 12% compared to saporin 
alone in HEY cells (Figure 17A) with the efficacies being (3.8 and 4.7), (3.2 and 5.9) and 
(2.9 and 8) for each illumination period compared to PDT and saporin only. The alpha 
values calculated after this experiment were 3.7, 3.0 and 2.8 for the HEY cells. For the 
same concentration of saporin, their SKOV3 counterparts on the other hand showed 
decreases from 93% to 22% (3 minutes), 83% to 15% (5 minutes) and 92% to 10% (7 
minutes) compared to saporin only (Figure 17B) with the efficacies being (2.9 and 4.2) (3 
minutes), (3 and 5.5) (5 minutes) and (3.3 and 9.6) (7 minutes) compared to PDT and 
saporin only. The alpha values were calculated to be 2.7, 2.5 and 3.0. Similar to the 
ovarian cancer cells using 20nM saporin caused a more increased cell killing in MCF-7 
cells with the viabilities being reduced from 93% to 25% (3 minutes), 89% to 10% (5 
minutes) and 96% to 6% (7 minutes) compared to saporin only with the efficacies for each 
increasing illumination period being (2.8 and 3.7), (2.5 and 8.9) and (2.8 and 16) 
compared to PDT or saporin only respectively (Figure 17C). The alpha values for this 
experiment were calculated to be 2.6 (3 minutes), 2.2 (5 minutes) and 2.7 (7 minutes). 
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Figure 16: Viability of HEY (A), SKOV3 (B) and MCF-7 (C) monolayer cultures post treatment with 
PDT, saporin only and PCI using saporin (10nM). The cells were treated with PDT (TPPS2a 0.4 :g/mL (HEY) or 0.3	:g/mL (SKOV3 and MCF-7)), Saporin only (10nM) and PCI. The samples were 
illuminated with blue lamp (420nm). MTT was carried out 48 hours after illumination. ***P<0.001, 
*P<0.05, ns: P>0.05. 
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After elongating the incubation period post illumination to 96 hours and using saporin 
(20nM), a further reduction in viability was observed with the viabilities dropping from 86% 
to 16% (3 minutes), 90% to 9% (5 minutes) and 94% to 4% (7 minutes) in HEY cells and 
from 91% to 19% (3 minutes), 97% to 6% (5 minutes) and 95% to 3% (7 minutes) in 
SKOV3 cells. 
 
The Alamar blue results however showed that 48 hours post illumination PCI using 10nM 
saporin and 3, 5 and 7 minutes light irradiation periods resulted in viability reductions of 
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Figure 17: Viability of HEY (A), SKOV3 (B) and MCF-7 (C) monolayer cultures post treatment 
with PDT, saporin only and PCI using saporin (20nM). The cells were treated with PDT (TPPS2a 
0.4 :g/mL (HEY) or 0.3	:g/mL(SKOV3 and MCF-7)), Saporin only (20nM) and PCI. The samples 
were illuminated with blue lamp (420nm).  MTT was carried out 48 hours after illumination. *** 
P<0.001. 
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from (92% to 38%), (98% to 18%) and (92% to 16%) in HEY 2D cultures respectively 
compared to using saporin alone. In comparison to using PDT and saporin (10nM) only, 
this meant a higher efficacy of almost (1.8 and 2.4), (2.2 and 5.3) and (1.7 and 5.9) fold 
for each illumination period respectively. For SKOV3 cells the same concentration of 
saporin and illumination periods led to roughly a decrease of viability from (94% to 44%), 
(94% to 24%) and (93% to 16%) compared to saporin only in the 2D cultures respectively. 
This again implied a (1.7 and 2.2), (1.5 and 4) and (1.5 and 5.8) fold higher efficacy in cell 
destruction compared to PDT or saporin alone respectively. Increasing the concentration 
of saporin to 20nM resulted in a more significant cell killing and PCI efficacies in both cell 
lines. In HEY cells, the cell viabilities reduced from 91% to 30% (3 minutes), 88% to 11% 
(5 minutes) and 92% to 6% (7 minutes) compared to saporin only. This meant that the 
PCI efficacies achieved in comparison to PDT and saporin alone for each ascending 
illumination period were (3.2 and 3.8), (3.5 and 7.7) and (5.5 and 16.9) respectively. In 
the SKOV3 cells, viabilities decreased from 91% to 27% (3 minutes), 92% to 18% (5 
minutes) and 92% to 8 % (7 minutes) compared to saporin alone.  For this cell line the 
PCI efficacies achieved for each increasing illumination period compared to PDT and 
saporin only were (2.9 and 3.4), (2.9 and 5.1) and (4.5 and 12.3) respectively. From the 
Alamar blue results obtained 48 hours post illumination, the alpha values calculated for 
each illumination period using 10nM saporin were 1.7, 2.1 and 1.5 (HEY cells) and 1.6, 
1.4 and 1.4 (SKOV3 cells). Using 20M saporin such values were found to be 2.8, 3.2 and 
4.6 (HEY cells) and 2.6, 2.7 and 3.9 (SKOV3 cells). 
 
Experiments with 20nM saporin and 96 hours incubation post illumination period 
demonstrated further cell killing in the monolayer cultures of both cell lines compared to 
their counterparts which were incubated for 48 hours post illumination. In HEY cells the 
viabilities reduced from 90% to 14% (3 minutes), 94% to 8% (5 minutes) and 87% to 3% 
(7 minutes) compared to saporin alone with the PCI efficacies for each illumination period 
being (4.6 and 6.5), (4.1 and 12.0) and (7.1 and 31.6) fold higher compared to PDT and 
saporin alone respectively. A similar decrease was observed in the SKOV3 cells with the 
viabilities reducing from 94% to 21% (3 minutes), 95% to 13% (5 minutes) and 94% to 4% 
(7 minutes) compared to saporin only with the PCI efficacies for each corresponding 
illumination period being (3.2 and 4.5), (3.1 and 7.3) and (9.0 and 23.0) compared to PDT 
and saporin only respectively. The synergistic alpha values calculated for this experiment 
per increasing illumination period were 4.1, 3.7 and 5.8 (HEY cells) and 3, 2.9 and 8.5 
(SKOV3 cells). Data obtained from PCI experiments on the monolayer SKOV3 and HEY 
cultures using Alamar blue assay are shown in Table 2. 
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Table 2: Summary of percentage viabilities ±	%SD and PCI efficacies in 2D monolayer cultures of SKOV3 and HEY cells. The values were calculated from data 
obtained via Alamar blue assay 
             2D  culture    
Cell line Incubatio
n period 
post light 
exposure 
(hour) 
Light 
Exposure 
period 
(minute) 
Saporin 
concentration 
(nM) 
 
 
 
PDT only 
(% mean 
viability ±	% SD)    
 
Saporin only 
(% mean 
viability ± % 
SD) 
 
PCI (% 
mean 
viability ± 
%SD)	 
PCI efficacy 
ratio vs. PDT 
PCI efficacy 
ratio vs. saporin 
only  
SKOV3 48 
 
3 
 
10 74. 3 ±3.8 94. 5 ±3.7 43.7±5.4 1.7 2.2 
HEY 48 3 
 
10  68.8±6.9 92. 1 ±7.5 38. 1 ±5.8 1.8 2.4 
SKOV3 48 5 10 35. 8 ±6.4 94. 5 ±7.0 23.6±4.7 1.5 4.0 
HEY 48 5 10 39.8±6.9 97.6±1.0 18. 5 ±5.2 2.2 5.3 
SKOV3 48 7 10 23.7±5.0 93.4±2.9 16. 0 ±2.6 1.5 5.8 
HEY 48 7 10 25.8±5.4 91.9±4.2 15.5±2.4 1.7 5.9 
SKOV3 48 3 20 76. 3 ±7.6 90.7±7.0 26.7±1.9 2.9 3.4 
HEY 48 3 20 75. 3 ±6.4 91. 3 ±4.5 23.9±1.8 3.2 3.8 
SKOV3 48 5 20 52. 4 ±8.1 91.6±7.9 18. 0 ±8.3 2.9 5.1 
HEY 48 5 20 40. 1 ±3.5 88. 1 ±5.0 11. 4 ±2.9 3.5 7.7 
SKOV3 48 7 20 33.7±8.6 92. 3 ±5.1 7.5±3.2 4.5 12.3 
HEY 48 7 20 30. 3 ±2.2 92. 2 ±4.8 5. 5 ±2.3 5.5 16.9 
SKOV3 96 3 20 65.7±5.1 93.9±9.1 20.7±2.5 3.2 4.5 
HEY 96 3 20 63. 5 ±5.2 89.5±4.6 13.8±6.3 4.6 6.5 
SKOV3 96 5 20 40. 2 ±6.4 94.9±6.8 13.1±3.1 3.1 7.3 
HEY 96 5 20 31.6±6.3 93. 3 ±6.1 7.8±4.4 4.1 12.0 
SKOV3 96 7 20 36.4±6.5 93.9±6.8 4. 1 ±0.9 9.0 23.0 
HEY 96 7 20 19. 5 ±3.8 87. 4 ±9.8 2.8±0.6 7.1 31.6 
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The Total DNA assay was also carried out on SKOV3 cells after PCI treatment both 48 
and 96 hours post illumination using saporin (20nM) as an alternative method of 
measuring viability of cells by quantifying the amount of undamaged DNA after each 
treatment condition. In terms of achieving a lower percentage viability and PCI effect after 
treatment with PCI compared to PDT or Saporin only, the results were consistent with the 
MTT and Alamar blue results (Figure 18). However, the viabilities measured after PCI 
using this assay were higher than those measured by MTT and Alamar blue. 
Measurements taken 48 hours post illumination showed the viabilities decreased from 
95% to 40% (3 minutes), 93% to 28% (5 minutes) and 99% to 23% (7 minutes) after PCI 
compared to using saporin only. Results obtained 96 hours post illumination showed 
further reduction in percentage viability compared to the shorter incubation period (48 
hours) with the viabilities being 32% (3 minutes), 21% (5 minutes) and 16% (7 minutes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Viability of SKOV3 monolayer cultures post treatment with PDT, saporin only and PCI 
(Total DNA assay). Cells were treated with PDT (0.3	"g/ml), Saporin only (20nM) and PCI. The 
samples were illuminated with blue lamp (420nm). Total DNA assay was carried out either 48 
hours (A) or 96 hours (B) after illumination. **P<0.01, *P<0.05, ns: P>0.05. 
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3.2 PCI experiment without chasing in monolayer cancer cultures 
PCI experimental protocols generally employ a ‘chasing’ period so as to minimise the cell 
membrane content of the photosensitiser which can induce a strong PDT effect and mask 
the PCI effect. In this experiment the four-hour chasing period step was omitted and the 
efficacy was tested on one ovarian cancer cell line (SKOV3) and breast cancer cell line 
(MCF-7), ie the drugs were not removed, and the cells were not washed with PBS. The 
results showed a significant reduction in cell viability after both PDT and PCI post all 
illumination periods. In SKOV3 cells the viabilities after PDT and PCI were 18% vs. 9% (3 
minutes), 7% vs. 6% (5 minutes) and 5% vs. 4% (7 minutes) respectively (Figure 19A). A 
similar effect was observed in MCF-7 cells with the viabilities being 22% vs. 10% (3 
minutes), 6% vs. 5% (5 minutes) and 5% vs. 4% (7 minutes) when comparing PDT results 
to PCI (Figure 19B). As discussed later, these results confirm that chasing is required to 
reduce the PDT effect with respect to the PCI effect on cell viability. Such reduction in 
PDT effect can help to reduce side effects caused by PDT such as phototoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Viability of SKOV3 (A) and MCF-7 (B) cells post treatment with PDT, saporin 
only and PCI (without chasing). Cells were treated with PDT (0.3	"g/mL), Saporin only 
(20nM) and PCI without undergoing chasing. The samples were illuminated with blue 
lamp (420nm).  MTT was carried out 48 hours after illumination.  
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3.3 In vitro PDT/PCI phototoxicity studies in early 3D cancer cultures 
 
The Alamar blue assay was used for quantitative measurements of viability in the three 
cell lines. The preliminary PDT experiments on the 3D constructs indicated that TPPS2a 
concentrations 0.3 µg/mL (SKOV3 and MCF-7 cells) and 0.4 µg/mL (HEY cells) were 
suitable for carrying out PCI experiments. 
The reductions in viability were lower in the 3D cultures compared to the monolayer 
cultures using similar drug and light doses. Using saporin 10nM, in HEY cells declines 
from (96% to 48%), (94% to 29%) and (97% to 22%) were achieved compared to saporin 
only for each irradiation period with the PCI efficacies being (1.5 and 2), (1.6 and 3.3) and 
(1.7 and 4.5) folds higher compared to PDT alone and saporin alone respectively for each 
time point, thus revealing a less major difference to the PDT. The 3D models of SKOV3 
cells similarly showed reasonable drops in cell viability rates from (93% to 58%), (91% to 
41%) and (92% to 29%) for each illumination period when TPPS2a and saporin were 
combined in comparison to using saporin alone. PCI also showed to be (1.3 and 1.6), (1.4 
and 2.2) and (1.7 and 3.2) higher compared to using PDT and saporin alone respectively. 
Using this concentration of saporin the alpha values were calculated to be 1.2 (3 minutes), 
1.3 (5 minutes) and 1.6 (7 minutes) in SKOV3 cells and 1.5, 1.5 and 1.6 in HEY cells 
following the same illumination period order. The results of this experiment in MCF-7 cells 
showed decreases from 96% to 60% (3 minutes), 96% to 60% (5 minutes) and 97% to 
28% (7 minutes) in viability of cells compared to saporin only with the efficacies being (1.3 
and 1.6), (1.3 and 2.1) and (1.7 and 3.5) compared to PDT and saporin only respectively. 
The alpha values calculated after the treatment of this cell line were 1.2, 1.3 and 1.6 after 
each illumination period. 
Increasing the saporin concentration to 20nM produced a good PCI effect across all 
irradiation periods. The SKOV3 3D cultures the PCI treatments revealed cell viability 
decreases of from (96% to 40%) (3 minutes), (92% to 20%) (5 minutes) and (93% to 11%) 
(7 minutes) compared to saporin only. The PCI efficacies versus PDT alone and saporin 
alone after each irradiation period were respectively (2 and 2), (2.8 and 4.5) and (4.3 and 
8.4) fold higher. The HEY 3D cultures similarly showed a good pattern of increasing cell 
destruction rate with PCI treatment and prolonging irradiation periods. Again, compared 
to saporin only, the cell viabilities in these cultures were lowered from (98% to 29%), (96% 
to 23%) and (97% to 12%) for each of the presented irradiation periods respectively. The 
PCI efficacies of these models versus PDT alone and saporin alone after each irradiation 
period were (2.8 and 3.4), (1.9 and 4.2) and (3.1 and 8) fold higher respectively. The alpha 
values for SKOV3 cells were 1.9, 2.5 and 4.1, and 2.7, 1.8 and 3.0 for the HEY cells. In 
MCF-7 cells the viabilities dropped from 98% to 34% (3 minutes), 94% to 13% (5 minutes) 
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and 91% to 11% (7 minutes) compared to saporin only with the efficacies being (2.2 and 
2.9) (3 minutes), (5.2 and 7.2) (5 minutes) and (5.0 an 8.3) (7 minutes). The alpha values 
were calculated to be 2.2, 4.8 and 4.6. Figures 20, 21 and 22 show Live-dead images of 
HEY, SKOV3 and MCF-7 cell compressed collagen constructs obtained after PCI with 
saporin (20nM). 
In a further experiment, the 3D cultures for all three cell lines treated with saporin 20nM 
were subjected to an extended incubation period of 96 hours post illumination prior to 
termination. The treatment not only elicited a good PCI effect in both cultures of both cell 
lines but also resulted in a further increased cytotoxic activity compared to cultures, which 
had been exposed to the same concentration of saporin but a shorter incubation post 
illumination period. In comparison to treatment with saporin only, the percentage cell 
viability rates were reduced to 18% (from 99%), 12% (from 98%) and 7% (from 90%) per 
ascending illumination period in 3D models of HEY cells and to 27% (from 98%), 17% 
(from 99%) and 6% (from 99%) in their SKOV3 cell counter parts. The alpha values 
calculated for each increasing illumination period were 3.7, 3.0 and 3.2 in HEY cells and 
2.4, 3 and 7.4 in SKOV3 cells. The MCF-7 similarly showed significant drops in viability 
compared to using saporin only (99% to 32%), (95% to 10%) and (94% to 7%) after each 
increasing illumination period. The alpha values calculated for the MCF-7 cells after this 
experiment were 2.1, 5.1 and 6.3. The percentage viabilities of all three cell lines following 
the experiments discussed in this section and the PCI efficacies are summarised in Table 
3. Table 4 shows a summary of synergistic alpha values calculated for each cell line in 
the non-spheroid cultures. Figure 23 also displays the results of the experiments using 
graphs. 
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Figure 20: Live-Dead images of HEY 3D non-spheroid cultures. The cultures were treated 
with PDT (B, F, J and N), Saporin only (20nM) (C, G, K and O) and PCI (D, H, L and P) 
treatment using different light conditions. The samples were illuminated with blue lamp 
(420nm).  The assay was carried out 48 hours post illumination. 3D constructs were 
incubated with the Live/dead solution containing Calcein-AM to stain live cells (green) and 
Ethidium homodimer-1 to stain dead cells (red). The scale bar presented in each image is 
400"$. 
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Figure 21: Live- Dead images of SKOV3 3D non-spheroid cultures. The cultures were 
treated with PDT (B, F, J and N), Saporin only (20nM) (C, G, K and O) and PCI (D, H, L 
and P) treatment using different light conditions. The samples were illuminated with blue 
lamp (420nm). The assay was carried out 48 hours post illumination. 3D constructs were 
incubated with the Live/dead solution containing Calcein-AM to stain live cells (green) and 
Ethidium homodimer-1 to stain dead cells (red). The scale bar presented in each image is 
400"$. 
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Figure 22: Live- Dead images of MCF-7 3D non- spheroid cultures. The cultures were 
treated with PDT (B, F, J and N), Saporin only (20nM) (C, G, K and O) and PCI (D, H, L 
and P) treatment using different light conditions. The samples were illuminated with blue 
lamp (420nm). The assay was carried out 48 hours post illumination. 3D constructs were 
incubated with the Live/dead solution containing Calcein-AM to stain live cells (green) and 
Ethidium homodimer-1 to stain dead cells (red). The scale bar presented in each image is 
400"$. 
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                    Table 3: Summary of percentage viabilities ±	%SD and PCI efficacies in 3D non-spheroid cultures of SKOV3, HEY and MCF-7 cells    
             3D culture    
Cell line Incubation 
period post 
light exposure 
(hour) 
Light 
exposure 
period 
(minute) 
Saporin 
concentration 
(nM) 
PDT only 
(% mean 
viability   ±	%SD) 
Saporin only 
(% mean 
viability ±	%SD) 
PCI (% mean 
viability  ± %SD) PCI efficacy vs. PDT PCI efficacy vs. saporin only  
SKOV3 48 
 
3 
 
10 76.9±7.8 92.9±6.3 58. 0 ±7.9 1.3 1.6 
HEY 48 3 
 
10 73.9±7.4 
 
95.8±4.6 47.8±1.7 1.5 2.0 
MCF-7  48 3 10 77.9±4.8 95.7±4.3 60.0±5.8 1.3 1.6 
SKOV3 48 5 10 57.9±6.6 91. 4 ±5.8 40.7±7.0 1.4 2.2 
HEY 48 5 10 46. 3 ±4.6 94. 3 ±4.5 28.9±4.5 1.6 3.3 
MCF-7 48 5 10 60.4±5.3 96.4±4.7 45.3±5.5 1.3 2.1 
SKOV3 48 7 10 49. 0 ±3.8 92. 4 ±7.8 28.8±5.8 1.7 3.2 
HEY 48 7 10 36.6±5.5 97. 2 ±5.1 21.6±4.0 1.7 4.5 
MCF-7 48 7 10 47.2±4.4 96.5±6.0 27.5±1.4 1.7 3.5 
SKOV3 48 3 20 80.7±5.0 96. 4 ±2.9 39.6±5.7 2.0 2.4 
HEY 48 3 20 80.7±5.9 98. 4 ±6.9 29. 1 ±3.6 2.8 3.4 
MCF-7 48 3 20 75.9±7.1 98.3±7.5 34.4±6.8 2.2 2.9 
SKOV3 48 5 20 57.5±4.9 92. 1 ±4.2 20. 5 ±6.8 2.8 4.5 
HEY 48 5 20 43.5±5.7 96. 2 ±5.4 23. 0 ±3.4 1.9 4.2 
MCF-7 48 5 20 67.0±1.1 93.7±6.5 13.4±1.3 5.2 7.2 
SKOV3 48 7 20 47. 5 ±5.8 93. 0 ±5.1 11. 1 ±2.3 4.3 8.4 
HEY 48 7 20 37. 3 ±3.3 96.7±5.3 12. 1 ±0.9 3.1 8.0 
MCF-7 48 7 20 55.4±3.6 91.2±1.5 10.5±1.8 5.0 8.3 
SKOV3 96 3 20 69. 3 ±2.5 97.6±1.7 27. 5 ±1.4 2.5 3.5 
HEY 96 3 20 67. 4 ±2.0 99. 4 ±3.7 18. 4 ±1.6 3.7 5.4 
MCF-7 96 3 20 67.5±2.0 99.1±1.8 32.1±1.0 2.1 3.1 
SKOV3 96 5 20 51.6±2.8 98.6±1.5 17. 1 ±1.8 3.0 5.8 
HEY 96 5 20 37. 4 ±1.8 98. 2 ±6.5 11.7±3.0 3.2 8.4 
MCF-7 96 5 20 53.8±2.3 95.0±2.9 9.8±4.2 5.5 9.7 
SKOV3 96 7 20 45. 0 ±1.2 99. 3 ±2.6 6. 3 ±1.8 7.2 15.9 
HEY 96 7 20 25. 1 ±3.6 89.6±7.7 7. 1 ±0.4 3.6 12.7 
MCF-7 96 7 20 47.4±4.2 93.9±1.4 6.8±1.3 7.0 13.8 
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  Table 4: Summary of synergistic alpha values for non- spheroid cultures of SKOV3, HEY and 
MCF-7 cells
                       
3D Cultures 
 
Cell line Incubation 
period post 
light 
exposure 
(hour) 
Light 
exposure 
period 
(minute) 
Saporin 
concentration 
(nM) 
Alpha 
values 
SKOV3 48 
 
3 
 
10 1.2 
HEY 48 3 
 
10 1.5 
MCF-7  48 3 10 1.2 
SKOV3 48 5 10 1.3 
HEY 48 5 10 1.5 
MCF-7 48 5 10 1.3 
SKOV3 48 7 10 1.6 
HEY 48 7 10 1.6 
MCF-7 48 7 10 1.6 
SKOV3 48 3 20 1.9 
HEY 48 3 20 2.7 
MCF-7 48 3 20 2.2 
SKOV3 48 5 20 2.5 
HEY 48 5 20 1.8 
MCF-7 48 5 20 4.8 
SKOV3 48 7 20 4.1 
HEY 48 7 20 3.0 
MCF-7 48 7 20 4.6 
SKOV3 96 3 20 2.4 
HEY 96 3 20 3.7 
MCF-7 96 3 20 2.1 
SKOV3 96 5 20 3.0 
HEY 96 5 20 3.0 
MCF-7 96 5 20 5.1 
SKOV3 96 7 20 7.4 
HEY 96 7 20 3.2 
MCF-7 96 7 20 6.3 
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Figure 23: Percentage viability of HEY (A, D, G), SKOV3 (B, E, H) and MCF-7 (C, F, I) cells in non-spheroid 3D compressed collagen 
constructs after treatment with PDT, saporin only and PCI. Constructs for graphs (A, B and C) were treated with 10 nM saporin, (D, E and 
F) with 20 nM saporin and assay at 48 hours incubation post illumination; (G, H and I) with 20 nM saporin and assay at 96 hours incubation 
post illumination. The samples were illuminated with blue lamp (420nm). *p<0.05, **p<0.01 and ***p<0.001. The p values show the 
significance difference between PDT and PCI.  
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In a different experiment 3D non-spheroid constructs of SKOV3 and MCF-7 cells were 
subjected to PCI treatment using 40nM saporin (Table 5). This led to a further reduction 
in percentage viability of cells. The cell kill obtained post treatment with 40nM saporin and 
7 minutes light illumination (48 hours incubation post illumination) was similar to that 
observed using the same illumination period and 20nM saporin in both cell lines (96 hours 
incubation post illumination) (Table 6). The Live-Dead images from this experiment have 
been presented in Figure 24. 
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Table 5: Summary of percentage viabilities ±	%SD and PCI efficacies in 3D non-spheroid cultures of SKOV3 and MCF-7 cells after treatment with saporin (40nM) 
 
 
 
 
 
 
 
Table 6: Comparison of percentage viabilities of SKOV3 and MCF-7 cells in 3D non- spheroid cultures after PCI treatment using 20nM saporin (96 hours incubation 
post illumination) vs. 40nM saporin (48 hours incubation post illumination). The constructs were illuminated for 7 minutes 
Cell line Incubation 
period post 
light 
exposure 
(hour) 
Light 
exposure 
period 
(minute) 
Saporin 
concentration 
(nM) 
PDT only 
(% mean 
viability   ±	%SD) 
Saporin 
only (% 
mean 
viability ±	%SD) 
PCI (% 
mean 
viability  ± %SD) 
PCI 
efficacy 
vs. PDT 
PCI efficacy 
vs. saporin 
only  
SKOV3 48 3 40 78.2 ± 1.9 84.3 ± 3.4 37.7 ± 
2.4 
2.1 2.2 
MCF-7 48 3 40 73.1 ± 1.1 83.2 ± 3.6 32.8 ± 
4.4 
2.2 2.5 
SKOV3 48 5 40 57.8 ± 4.2 84.6 ± 2.2 15.8 ± 
2.3 
3.6 5.3 
MCF-7 48 5 40 58.0 ± 1.6 81.0 ± 1.6 11.3 ± 
2.6 
5.1 7.1 
SKOV3 48 7 40 51.8 ± 2.7 84.5 ± 2.6 7.3 ± 
2.8 
7.1 11.5 
MCF-7 48 7 40 54.2 ± 2.2 85.8 ± 1.0 8.3 ± 
1.3 
7.3 11.7 
Cell line Incubation 
period post 
light 
exposure 
(hour) 
Light 
exposure 
period 
(minute) 
Saporin 
concentration 
(nM) 
PCI (% mean 
viability  ± %SD) 
SKOV3 48 7 40 7.3 ± 2.8 
MCF-7 48 7 40 8.3 ± 1.3 
SKOV3 96 7 20 6.9 ± 2.1 
MCF-7 96 7 20 8.0 ± 0.9 
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CNT PDT Saporin only PCI 
 Figure 24: Live dead images of HEY 3D cultures post PDT, saporin only 
and PCI treatment using saporin (40nM). Constructs (B and F) underwent 
PDT treatment, (C and G) underwent saporin only (40nM) treatment and (D 
and H) underwent PCI treatment using 5 minutes light illumination period. 
The samples were illuminated with blue lamp (420nm). The scale bar 
presented in each image is 400!". 
A B C D 
E F G H 
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3.4 Localisation of TPPS2a in 2D and 3D cultures of SKOV3 and HEY cells 
In 2D cultures, 24 hours after seeding, the cells were treated with TPPS2a (1µg/mL) for 20 
hours. The same incubation protocol was used as for the therapeutic PCI studies so after 
20 hours the cells were washed with PBS and incubated with fresh drug free media for a 
further 4 hours before fluorescence microscopic imaging with Olympus fluorescence 
microscope (Olympus BX63) (60x magnification) using CY5 channel. Figure 25 shows the 
uptake of TPPS2a in SKOV3 (A and B) and HEY (C and D) monolayer cultures. As shown 
in the images higher fluorescence can be detected in cultures treated with TPPS2a (B and 
D) compared to the control cultures (A and C).  
In the 3D cultures the cells were treated with TPPS2a (1µg/mL) for 20 hours to investigate 
cellular uptake of TPPS2a by SKOV3 and HEY cells in the constructs.  The medium 
containing TPPS2a was then removed and the constructs were washed with PBS before 
being incubated with fresh photosensitiser-free medium for an additional 4 hours and 
imaged using a fluorescence microscope with quasi-confocal capability (20x objective, 
Apotome.2, Carl Zeiss). As shown in Figure 25, in comparison to the control 3D construct 
(A and C), bright fluorescence signals of the TPPS2a were observed in both SKOV3 and 
HEY constructs incubated with TPPS2a, which indicated the intracellular uptake of the 
photosensitiser in the 3D constructs (Figure 26 B and D). Such results indicate that in the 
treated 3D constructs the TPPS2a was taken up by the cells instead of becoming bound in 
the collagen matrix. The both control collagen constructs for SKOV3 (A) and HEY (C) cells 
without photosensitiser showed negligible autofluorescence levels. The images at the side 
of the central show the cross-sectional pattern of fluorescence as a function of depth. 
 
In a further experiment undertaken to confirm cellular uptake of TPPS2a in the 3D cultures, 
constructs containing a lower cell density of cells (10,000 cells/construct) were treated 
with TPPS2a (3	µg/mL) and additionally stained with LysoTracker Green (100nM) prior to 
imaging (Figure 27). Co-staining the cells with Lysotracker Green provided further 
evidence for intracellular uptake of TPPS2a in the 3D constructs. Confocal imaging was 
also attempted to obtain higher resolution, but the intensities were too weak. This is partly 
because the detectors used for confocal microscopy (photomultipliers) are less sensitive 
than the CCD cameras used to acquire the images shown here. Another compounding 
factor is that porphyrins are not efficient fluorophores compared to fluorescein for 
example. 
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Figure 25: Uptake of TPPS2a by monolayer cultures of SKOV3 (A-B) and HEY (C-D) cells. A and 
C: control cultures treated with drug free media, B and D: cultures treated with TPPS2a (1!&/mL). 
Images were taken with Olympus BX63 (60x magnification). Scale bar presented is 10!". 
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Figure 26: Intracellular uptake of TPPS2a in SKOV3 and HEY non-spheroid 3D compressed 
collagen cultures. (A): control SKOV3 cell constructs, (B): intracellular uptake of TPPS2a in SKOV3 
non-spheroid 3D compressed collage constructs, (C): control HEY cell constructs, D: intracellular 
uptake of TPPS2a in HEY non-spheroid 3D compressed collagen construct.  Images (B and D) 
were obtained through stacking with fluorescence microscope (20x objective, Apotome.2, Carl 
Zeiss). The photosensitiser fluorescence was measured between 600-700 nm using Alexa Fluor 
647 channel. The scale bar presented in each image is 50	!". t: top; b: bottom. 
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Figure 27: Intracellular localisation of TPPS2a in 3D compressed collagen non-spheroid constructs 
of SKOV3 (A-C) and HEY (D-F) cells. The constructs contained cell density of 10,000 
cells/construct. The constructs were treated with TPPS2a (3!g/mL) and Lysotracker green (100nM) 
and imaged using a fluorescence microscope (20x objective, Olympus BX63). A and D show the 
localisation of TPPS2a and B and E show the localisation of Lysotracker green stain within the small 
cellular aggregates. The co-localisation of both TPPS2a and Lysotracker green is shown in C and 
F. The scale bar presented in each image is 50!". 
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3.5 In vitro PCI phototoxicity studies in 3D cancer cultures pre-incubated with drugs 
 
Pre-incubation of SKOV3 and MCF-7 cells with TPPS2a and saporin (20nM) 24 hours prior 
to seeding in 3D demonstrated a very low reduction in percentage viability of PCI treated 
cells even after 7 minutes of light illumination compared to the control constructs (81% 
and 70% viability in SKOV3 and MCF-7 cells respectively). Figure 28 shows live dead 
images of constructs pre-incubated with drugs of interest prior to seeding and PCI 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
MCF-7 
SKOV3 
CNT PCI 
Figure 28: Live- Dead images of MCF-7 and SKOV3 
cell 3D non- spheroid constructs pre-incubated with 
drugs prior to seeding. MCF-7 (A-B) and SKOV3 (C-
D) cell 3D constructs were pre-incubated with TPPS2a 
and Saporin prior to seeding and PCI treatment (B 
and D) compared to control constructs (A and C). The 
samples were illuminated with blue lamp (420nm). 
The scale bar presented in each image is 400	!". 
A B 
C D 
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3.6 PCI experiment without chasing in 3D cancer cultures 
 
PDT and PCI experiments without removal of drugs and washing with PBS (ie ‘chasing’) 
resulted in 7% vs. 8% viability (PDT) and 1.8% vs. 2.2% viability (PCI) in SKOV3 (Figure 
29A) and MCF-7 (Figure 29B) cells respectively after 7 minutes light illumination. A higher 
cell kill was therefore achieved after both PDT and combined treatment without chasing 
compared to with chasing, however no PCI effect was observed. 
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Figure 29: PDT and PCI without chasing in SKOV3 (A) and MCF-7 (B) cell 3D non- spheroid 
cancer constructs. The samples were illuminated with blue lamp (420nm).  Alamar blue was 
carried out 48 hours post illumination. 
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3.7 In vitro PDT/PCI phototoxicity studies in mature 3D spheroid cancer cultures 
The PCI experiments were repeated on spheroid 3D compressed constructs of SKOV3 
and HEY cell lines since they are better representatives of a tumour model in terms of 
physiological properties. The compact structures formed by the cancer cells can affect 
drug uptake and their hypoxic cores can influence PDT/PCI efficacy. Furthermore, cancer 
cells can develop resistance towards treatments when they form aggregates.   
The ‘mature’ constructs of this study developed after several days incubation enabling the 
cells to proliferate and develop into spheroids prior to undergoing treatment. The SKOV3 
and HEY cells developed into sizable and measurable near spheroidal cellular aggregates 
by day 7. The aggregate sizes of 100 spheroids per cell line were measured and 
categorised into small, medium and large as shown in Figure 30 and Table 7. The HEY 
cells generally formed larger aggregates compared to SKOV3 cells. While the SKOV3 
cells mainly formed small and medium aggregates, the HEY cells mostly formed medium 
and large aggregates. Phalloidin/ Hoechst staining was used to visualise the structure of 
the spheroids formed as well as their destruction after treatment. The green fluorescent 
Alexa fluor 488 dye of Phalloidin binds to filamentous actin in cells with high affinity thus 
allowing the cytoskeletal structure of the cells and spheroids to be explored. The Hoechst 
dye concurrently stains the nuclei which together with Phalloidin provides a clear image 
of the spheroids to be recognised. 
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Table 7: The sizes of SKOV3 and HEY cell spheroids based on the area (µm2) and diameter (µm). 
The diameter sizes presented have been calculated as mean diameters based on measurements 
taken from the two longest cross sections in every spheroid. The measurements were taken using 
Image J software. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earlier PDT experiments indicated that the concentrations of TPPS2a, which were able to 
induce sub-lethal PDT effects, were 0.5	µg/mL in HEY cells and 0.7	µg/mL in SKOV3 cells 
(data not shown). The spheroid constructs of the SKOV3 cells demonstrated no PCI effect 
using saporin 20nM, however upon increasing the concentration of saporin to 40nM, the 
    Aggregate  
type  
   
 Small  Medium  Large  
 Area (µm2) 
(1000>5000
) 
 
Diamete
r (µm)  
(40>100) 
Area (µm2) 
(5000>12,000
) 
Diameter 
(µm) 
(100>160
) 
Area 
(µm2) 
(1200
0 and 
above) 
Diamete
r (µm)  
(160 and 
above) 
SKOV3 1871- 4931 45-99 5000- 11723 100-159 12166
- 
13714 
166-171 
HEY 3457- 4737 64-77 5309-11985 100-159 12666
-
82931 
162-412 
Figure 30: Examples of small (A) and large (B) 
spheroids of SKOV3 cells formed 7 days after 
seeding. The cytoskeletal structure of the cells in the 
aggregates was stained with Alexa Fluor 488 
Phalloidin (Green) and the nucleus of cells was 
stained with Hoechst dye (Blue). The scale bar 
presented in each image is 60µm. 
A B 
 96 
viabilities showed significant reductions from (97% to 41%), (91% to 39%) and (92% to 
31%) compared to saporin only therapy for each irradiation period as well as a slight PCI 
effect after 3 minutes of light irradiation with the PCI efficacy being (1.7 and 2.4) fold 
higher than PDT or saporin alone respectively.  
The spheroid constructs of the HEY cells on the other hand displayed reasonable PCI 
effects using 20nM saporin with the % percentage viabilities dropping from (98% to 30%), 
(97% to 24%) and (97% to 19%) compared to saporin only treatment and the PCI 
efficacies being (2.5 and 3.3), (1.9 and 4.1) and (2 and 5.2) fold higher than using PDT or 
saporin alone for each irradiation period respectively (Figure 31). 
Phalloidin/Hoechst (Figures 32 and 33) and live-dead (Figure 34) staining provide visual 
results that support the data obtained from Alamar blue assay. 
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Figure 31: Percentage viability of HEY (A) and SKOV3 (B) cells spheroid 3D compressed collagen 
constructs after treatment with PDT, saporin only and PCI. Constructs for the SKOV3 cells were 
treated with TPPS2a  (0.7 μg/ml) and 40nM saporin, and for the HEY cells with TPPS2a  (0.5 
μg/ml) and 20nM saporin. The samples were illuminated with blue lamp (420nm). The constructs 
were incubated for 48 hours post illumination before terminating the experiment using Alamar 
Blue assay. *** p<0.001. These p values show the significance difference between PDT and PCI 
treatments.  
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Figure 32: Phalloidin/ Hoechst stained images of HEY cell spheroid constructs upon 
treatment with PDT, saporin only and PCI. The constructs were treated using TPPS2a only 
at concentration 0.5 μg/ml (B, F, J and N), saporin only at concentration 20nM (C, G, K 
and O) and PCI (D, H, L and P) after different periods of illumination. A reduced number 
of spheroids is evident when TPPS2a and saporin are combined compared to using each 
drug alone. The samples were illuminated with blue lamp (420nm). HEY the arrow 
highlights a fragmented pattern of cell aggregates (IV). Alexa Fluor 488 phalloidin (green) 
was used to stain the cytoskeletal structure of the cells and Hoechst 33258 (blue) was 
used to stain the nuclei. The scale bar presented in each image is 400μm.  
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Figure 33: Phalloidin/ Hoechst stained images of SKOV3 cell spheroid constructs upon 
treatment with PDT, saporin only and PCI. The constructs were treated using TPPS2a only 
at concentration 0.7 μg/ml (B, F,J and N), saporin alone at concentration 40nM (C, G, K 
and O) and PCI (D, H, L and P) after different  periods of  illumination. A reduced number 
of spheroids is evident when TPPS2a and saporin are combined compared to using each 
drug alone. The samples were illuminated with blue lamp (420nm).  Alexa Fluor 488 
phalloidin (green) was used to stain the cytoskeletal structure of the cells and Hoechst 
33258 (blue) was used to stain the nuclei. The scale bar presented in each image is 
400μm.  
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Live dead images (Figure 34) acquired after treatment of spheroids using PCI also 
supported the data presented in Figures 32 and 33. 
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Figure 34: Live-dead images of spheroid 3D compressed collagen constructs of HEY (A-D) and 
SKOV3 (E-H) cells after undergoing PDT, saporin only and PCI treatment. The cells were 
treated with TPPS2a only (0.5!g/ml for HEY cells) (B) and (0.7!g/ml for SKOV3 cells) (F), 
saporin only (20nM for HEY cells) (C) and (40nM for SKOV3 cells) (G) and a combination of 
both drugs (D and H) following 3 minutes of exposure to light and a 48 hour post-illumination 
assay time point. The samples were illuminated with blue lamp (420nm). 3D constructs were 
incubated with the Live/dead solution containing Calcein-AM to stain live cells (green) and 
Ethidium homodimer-1 to stain dead cells (red). The scale bar presented in each image is 
400!". 
CNT PDT Saporin only PCI 
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3.8 Role of oxygen in PCI 
 
A good supply of oxygen is required for the photosensitiser TPPS2a to generate ROS 
efficiently upon activation by light. These ROS are the means by which the sub-lethal PDT 
effect is produced that aids the occurrence of the PCI effect. Initial experiments were 
conducted to see if the higher cell density and therefore oxygen consumption had affected 
the oxygen levels within the construct. 3D spheroid constructs of both cell lines were 
imaged on day 7 and compared to the O2 levels in the 3D non-spheroidal constructs one 
day after seeding using the Image-iT hypoxia reagent. The reagent consists of a 
fluorogenic compound which is weakly fluorescent in environments with normal O2 level 
as well as live cells and becomes strongly fluorescent as the O2 concentrations decrease. 
As figure 35 shows the O2 concentrations are far lower on day 7 (B and D) when the 
SKOV3 and HEY spheroids have been formed since the O2 consumption levels are higher 
than in non-spheroidal constructs (day 1) (A and C) and this may therefore reduce the 
PCI effect due to the lack of sufficient O2 in the models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In another experiment, the effect of different oxygenation levels ie normoxia (20% 
oxygenation) and hypoxia (1% oxygenation) on PDT and PCI in monolayer cultures and 
3D non-spheroid SKOV3 cell constructs were studied since as both treatments rely on the 
generation of reactive oxygen species. As shown in Figure 36A although the PDT/PCI 
treatments were carried out in hypoxic conditions in monolayer cultures of SKOV3 cells, 
a significant reduction in percentage viability was still achieved compared to PDT and 
Figure 35: Reduction of oxygenation with spheroid formation. Images of oxygen 
reduction in SKOV3 cells (A-B) and HEY cells (C-D) non-spheroid and spheroid 
constructs were obtained as spheroids formed on day 7 (B and D), compared to 
one day post seeding before the formation of spheroids (A and C), The hypoxia 
levels within the spheroids were measured using the Image-iTTM Red Hypoxia 
reagent. The scale bar presented in each image is 400!". 
Day 1 Day 7 
A B 
C D 
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saporin only treatments. For the 3D non-spheroid constructs (Figure 36B) under normoxic 
conditions significant cell killing was achieved in PDT/PCI treated constructs. Using 40 
nM saporin and 7 minutes exposure, the viability using PDT was reduced to 33.5% and 
7.3 % for PCI. However, under hypoxia, no significant decrease in cell viability was seen. 
Although a PCI elicited a small reduction in mean viability to 82% was observed with PCI, 
this was not found to be statistically significant compared to normoxia. Using saporin 
alone, comparable small reductions in viability were observed for both normoxia and 
hypoxia. The Live-dead assay images shown in Figure 37 obtained after PDT/PCI using 
hypoxic constructs are consistent with the viability data. These data show that both PDT 
and PCI were strongly inhibited at low oxygenation levels. Figures 38 and 39 compare 
PDT/PCI in hypoxic vs. normoxic conditions in spheroid constructs of SKOV3 cells. As 
the Live-dead images (Figure 39) show no PDT/PCI effect occurs in spheroid constructs 
in hypoxic conditions compared to normoxic conditions. 
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Figure 36: Effect of hypoxia on PCI and PDT. A. Percentage viability of SKOV3 cell in 2D monolayer 
experiments after PCI treatment in normoxic condition compared to hypoxic condition using TPPS2a 
only (0.3μg/ml) only for PDT, saporin 40 nM only and a combination of both drugs for PCI as well as a 
light irradiation period of 7 minutes. ***p<0.001, the p values show the significance difference between 
PDT and PCI.  B. Percentage viability of SKOV3 cell 3D non-spheroid constructs after PCI treatment in 
normoxic condition compared to hypoxic condition using TPPS2a only (0.3μg/ml) only for PDT, saporin 
40 nM only and a combination of both drugs for PCI as well as a light irradiation period of 7 minutes. 
The samples were illuminated with blue lamp (420nm).  Alamar Blue assay was carried out 48 hours 
after exposure to light. 
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Figure 37:  Live- dead images showing effect of hypoxia on PCI and PDT in SKOV3 cell non-
spheroid constructs. PCI treatment in normoxic condition (I-IV) was compared to PCI treatment 
in hypoxic condition (V-VIII). The therapies used were TPPS2a  (0.3μg/ml) only for PDT, saporin 
40 nM only and a combination of both drugs for PCI as well as a light irradiation period of 7 
minutes. The samples were illuminated with blue lamp (420nm). The scale bar presented in each 
image is 400!". 
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Figure 38: Percentage viability of SKOV3 cell 3D spheroid constructs after PDT, 
saporin only and PCI treatment in normoxic condition compared to hypoxic condition. 
The constructs were treated using TPPS2a only (0.7μg/ml) only for PDT, saporin 40nM 
only and a combination of both drugs for PCI as well as a light irradiation period of 7 
minutes. The samples were illuminated with blue lamp (420nm).  Alamar Blue assay 
was carried out 48 hours after exposure to light. No significance difference (ns) 
between PDT and PCI can be observed. 
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3.9 Stimulation of apoptotic cell death in PCI treated 3D constructs 
 
To determine the mode of cell death (necrosis or apoptosis) induced after treatment with 
PCI and other conditions, the non-spheroid 3D constructs were stained with Annexin V 
(for detection of apoptosis- shown in green) and Propidium iodide (for detection of 
necrosis – shown in red) either 24 hours or 48 hours after illumination. Without light 
illumination (Figure 40) a much lower level necrosis and apoptosis can be observed 
compared to samples exposed to irradiation with a slightly higher level of both type of cell 
death being detected in constructs treated with both TPPS2a and saporin (D and H) 
compared to monotherapies and control (A, B, C, E, F and G). As shown in Figure 41, for 
both cell lines a stronger apoptotic effect can be seen in constructs treated with PCI (D, 
H, L and P) than those treated with TPPS2a (PDT) (B, F, J and N) or saporin (C, G, K and 
O) only. In contrast, the necrotic effect observed in constructs treated with PDT only is 
noticeably higher than those treated with PCI or saporin only. Furthermore, a greater 
apoptotic effect is observed at 48 hours (H and P) compared to 24 hours (D and L).  
 
 
 
 
 
 
 
 
 
 
 
 
Saporin only PDT PCI CNT 
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Figure 39: Live-dead images of SKOV3 cell spheroid constructs after PDT, saporin only and PCI 
treatment in normoxic condition (I-IV) compared to hypoxic condition (V-VIII). The constructs were 
treated using TPPS2a (0.7μg/ml) only for PDT, saporin 40nM only and a combination of both drugs 
for PCI as well as a light irradiation period of 7 minutes. The samples were illuminated with blue 
lamp (420nm). The scale bar presented in each image is 400µ".  
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In an additional experiment, spheroid constructs of HEY cells were also stained with 
Annexin V FITC and Propidium iodide after treatment with PDT and PCI. As shown in 
Figure 42, higher level of necrosis can be detected in PDT treated samples (B and F) than 
PCI treated samples (D and H) whereas apoptotic cell death is more visible in PCI treated 
constructs. Furthermore, in the PDT treated constructs a greater degree of necrosis can 
be observed 48 hours after illumination (F) compared to 24 hours post illumination (B). In 
the PCI treated constructs on the other hand, the degree of both necrosis and apoptosis 
is greater in constructs incubated for 48 hours post illumination (H) than those incubated 
for 24 hours post illumination (D). 
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Figure 40: Apoptotic and necrotic induced cell death in 3D compressed constructs of 
SKOV3 and HEY cells. Comparison of cell death pathways induced after PCI 
compared to PDT or saporin alone in non-spheroid constructs of SKOV3 (A-D) and 
HEY (E-H) cells without light illumination. In PDT only treated constructs TPPS2a was 
used at concentrations of 0.3	!g/ml in SKOV3 cells (B) and 0.4	!g/ml in HEY cells 
(F). The saporin concentration used in this experiment was 20nM. The assay was 
carried out 24 hours post removal of drugs and chasing. Annexin V- was used to 
indicate apoptosis (green) and propidium iodide was used to indicate necrosis (red). 
The scale bar represents 400!". 
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Figure 41: Apoptotic and necrotic induced cell death in 3D compressed constructs of SKOV3 
and HEY cells. Comparison of cell death pathways induced after PCI compared to PDT or 
saporin alone in non-spheroid constructs of SKOV3 (A-H) and HEY (I-P) cells at 24 hours (A-
D) and (I-L) and 48 hours post illumination (E-H) and (M-P) have been shown. In PDT only 
treated constructs TPPS2a was used at concentrations of 0.3	!g/ml in SKOV3 cells (B and F) 
and 0.4	!g/ml in HEY cells (J and N). The saporin concentration used in this experiment was 
20nM. The constructs were illuminated for 7 minutes using blue lamp (420nm).  Annexin V- 
was used to indicate apoptosis (green) and propidium iodide was used to indicate necrosis 
(red). The scale bar represents 400!".  
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Figure 42:  Apoptotic and necrotic induced cell death in 3D spheroid constructs of 
HEY cells. Constructs were treated with PDT (B and F) and PCI (D and H)  24 hours 
(A- D) and 48 hours (E- H) post illumination. In PDT only treated constructs TPPS2a 
was used at concentrations of 0.5	!g/ml (B and F). The saporin concentration used 
in this experiment was 20nM. The samples were illuminated with blue lamp (420nm) 
for 7 minutes.  Annexin V- was used to indicate apoptosis (green) and propidium 
iodide was used to indicate necrosis (red). The scale bar presented in each image 
is 400!".  
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Chapter 4 
 
4. PCI in 3D non-spheroid constructs of ovarian 
cancer using Dactinomycin as chemotherapeutic 
drug  
 
In this chapter another anti-cancer drug called dactinomycin or actinomycin D, with a 
high molecular weight (approximately 1255 Da) has been used for PCI studies as it is 
likely to be uptaken via endocytosis which makes it suitable candidate for such study. 
Dactinomycin is a clinically approved agent which acts as an anti-tumour antibiotic 
and functions through DNA intercalation as well as inhibition of RNA and protein 
synthesis. This agent has not been tested for PCI before and based on its molecular 
weight, it should be taken up partly via endocytosis like bleomycin which has a 
molecular weight of approximately 1400 Da. Furthermore, Dactinomycin is fluorescent 
unlike bleomycin, therefore fluorescence imaging can be carried out to show 
endolysosomal localisation of this drug.  
 
The experiments carried out for this chapter include investigating lysosomal uptake of 
the drug since PCI is designed to deliver drugs that are prone to endolysosomal 
entrapment and degradation, PCI treatment of 2D and 3D cultures of SKOV3 and HEY 
cells and investigation of dactinomycin uptake at different temperatures to confirm 
occurrence of endocytosis. Preliminary studies were carried out to determine the 
correct parameters for the PCI treatment and treatments on monolayer cultures were 
carried for comparison purposes to the 3D cultures. The molecular structure of 
dactinomycin is shown in figure 43. 
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4.1 Intracellular uptake and localisation of Dactinomycin in HEY and SKOV3 cells 
Dactinomycin uptake studies were carried out monolayer cultures of HEY and SKOV3 
cells as well as 3D non-spheroid cultures of SKOV3 cells by incubating the cells with the 
drug at 50nM concentration for 4 hours before washing and additionally staining them with 
lysotracker red to determine co-localisation.  
As shown in Figure 44, bright fluorescence can be detected from both Dactinomycin (A, 
D, G, J) (green) and Lysotracker red (B, E, H, K) (red) in monolayer cultures of both cell 
lines. Such can also be observed in the 3D cultures (Figure 45) where the cells have also 
begun forming very small aggregates. The exact overlap of the green and fluorescence 
(C, F, I, L) indicated that both the Dactinomycin drug and Lysotracker red are co-localised 
within the lysosomes of the cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Structure of Dactinomycin (Actinomycin D). 
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Figure 44:  Intracellular uptake of dactinomycin in HEY (A-F) and SKOV3 (G-L) 
monolayer cultures. (A and G): intracellular uptake of dactinomycin in HEY and 
SKOV3 monolayer cultures, (B and H): intracellular uptake of lysotracker red in HEY 
and SKOV3 monolayer cultures, (C and I): co-localisation of dactinomycin and 
lysotracker red in HEY and SKOV3 monolayer cultures. The blue arrows show a 
single cell from each cell line magnified and shown in figures D-F (HEY cells) and 
J-L (SKOV3 cells). Images were obtained with fluorescence microscope (60x 
objective, Olympus BX63). The fluorescence of dactinomycin was measured at 
520nm using FITC channel. The scale bar presented in images A-C and G- I is 
10μm. 
HEY cells 
HEY cells 
SKOV3 cells 
SKOV3 cells 
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4.2  In vitro PDT/PCI phototoxicity studies in monolayer and 3D non-spheroid cancer 
cultures using dactinomycin as anti-cancer drug 
 
Using the fluorometric Alamar blue cell viability assay, the cell viabilities in both monolayer 
and 3D cultures post treatment with different conditions were measured. For comparative 
purposes 2D monolayer cultures were initially used in the study. The same TPPS2a 
concentrations used in earlier PDT/PCI studies for monolayer and non-spheroid 
constructs (0.3µg/mL for SKOV3 cells and 0.4µg/mL for HEY cells) were used in this 
study.  
 
Toxicity studies using dactinomycin only indicated that 1nM concentration resulted in low 
cell death (≤10%) in the monolayer cultures and was therefore declared as suitable for 
use in this experiment. Figure 46 shows reductions in cell viability using various 
concentrations of dactinomycin. 
 
 
Dactinomycin only Lysotracker red only Dactinomycin + Lysotracker red 
Figure 45: Intracellular uptake of dactinomycin in 3D constructs of SKOV3 
cells. A: intracellular uptake of dactinomycin in SKOV3 3D constructs, B: 
intracellular uptake of lysotracker red in SKOV3 3D constructs, C: co-
localisation of dactinomycin and lysotracker red in SKOV3 3D constructs. 
Images were obtained with fluorescence microscope (20x objective, 
Olympus BX63). The dimensions of the images are 72µm x42µm. 
A B C 
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The MTT results showed that viabilities after PCI dropped to 48% vs. 55% (3 minutes), 
13% vs. 17% (5 minutes) and 4% vs. 5% (7 minutes) in HEY and SKOV3 monolayer 
cultures respectively. The alpha values for each illumination period were calculated as 
1.4, 2.8 and 6.4 in HEY cells and 1.4, 2.8 and 4.9 in SKOV3 cells. Figure 47 shows the 
percentage viabilities of both cell lines after PCI compared to monotherapies and control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46:  Percentage viability of cells post treatment with various 
concentrations of dactinomycin. MTT assay was carried out 48 hours 
after removal of drug and washing the cells with PBS. 
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The Alamar blue study results also showed that in 2D monolayer cultures a significant 
PCI effect and reduction in percentage viability was achieved particularly compared to 
treatment with Dactinomycin alone. In SKOV3 cells the viabilities were reduced from 94% 
to 38% (3 minutes), 88% to 14% (5 minutes) and 89% to 6% (7 minutes) compared to 
dactinomycin only with the PCI efficacies being 1.9 and 2.5 (3 minutes), 2.1 and 6.3 (5 
minutes) and 2.7 and 14.8 (7 minutes) compared to using PDT and dactinomycin alone 
respectively (Figure 48). The corresponding alpha values for each of the mentioned 
irradiation periods were 1.8, 1.9 and 2.4.  
 
PCI continued to show a significant effect in the HEY cell monolayer cultures as well with 
the viabilities being reduced from 96% to 28% (3 minutes), 97% to 14% (5 minutes) and 
98% to 4% (7 minutes) compared to dactinomycin alone. The PCI efficacies achieved for 
each illumination period were 2.5 and 3.2 (3 minutes), 3.8 and 8.9 (5 minutes) and 9.0 
Figure 47: Percentage viability of HEY (A) and SKOV3 (B) cells in monolayer cultures after 
treatment with PDT, Dactinomycin and PCI (MTT assay). The cells were treated with TPPS2a 
(0.4μg/ml for HEY cells, 0.3μg/ml for SKOV3 cells), Dactinomycin only (1nM) and PCI. The 
samples were illuminated with blue lamp (420nm). The cultures were incubated for 48 hours post 
illumination before terminating the experiment using MTT assay. *p<0.05, **p<0.01, *** p<0.001. 
These p values show the significance difference between PDT and PCI treatments.  
020
4060
80100
120
CNT PDT Dactinomycin
only
PCI
Vi
ab
ili
ty
%
A
** 
*** 
 ** 
020
4060
80100
120140
CNT PDT Dactinomycin only PCI
Vi
ab
ili
ty
%
B
**
*
*
 114 
and 46 (7 minutes) versus PDT and dactinomycin alone respectively with the highest PCI 
efficacy observed after 7 minutes (P<0.001) (Figure 48). Good synergistic alpha values 
of 2.2, 3.3 and 8.3 were calculated after each irradiation period.  The percentage 
viabilities, PCI efficacies and synergistic values are also tabulated in table 8. 
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Figure 48:  Percentage viability of HEY (A) and SKOV3 (B) cells in monolayer cultures after 
treatment with PDT, Dactinomycin and PCI (Alamar blue). The cells were treated with TPPS2a 
(0.4μg/ml for HEY cells, 0.3μg/ml for SKOV3 cells), Dactinomycin only (1nM) and PCI. The 
samples were illuminated with blue lamp (420nm).  The cultures were incubated for 48 hours post 
illumination before terminating the experiment using Alamar blue assay. *** p<0.001. These p 
values show the significance difference between PDT and PCI treatments.  
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Table 8: Summary of percentage viabilities	±	%SD, PCI efficacies and alpha values in 2D 
monolayer cultures of SKOV3 and HEY cells 
 
Although there was a lower reduction in percentage viability of both cell lines in the 3D 
constructs, PCI still caused a significant effect in the cells as shown in Figure 49. For 
example, in SKOV3 the viabilities reduced from 96% to 42% (3 minutes), 93% to 22% (5 
minutes) and 91% to 9% (7 minutes) compared to dactinomycin alone with the PCI 
efficacies being 1.9 and 2.3 (3 minutes), 1.7 and 4.7 (5 minutes) and 2.2 and 10.1 
(7minutes) compared to PDT alone and dactinomycin alone respectively. Similarly, the 
HEY cells showed reduction in viability from 91% to 33% (3 minutes), 88% to 15% (5 
minutes) and 89% to 4% (7 minutes) compared to dactinomycin alone. The PCI efficacies 
for this cell line compared to PDT alone and dactinomycin alone were 2.2 and 2.8 (3 
minutes), 2.9 and 5.9 (5 minutes) and 5.5 and 22.3 (7 minutes). In this experiment the 
alpha values after each illumination period were calculated as 1.8, 1.6 and 2.0 for SKOV3 
cell constructs as well as 2.0, 2.5 and 4.9 for HEY cells. Overall the HEY cells showed 
more sensitivity to PCI treatment using dactinomycin than SKOV3 cells. Table 9 also 
shows a summary of the results discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             2D  Culture    
Cell 
line 
Incubatio
n period 
post light 
exposure 
(hour) 
Light 
Exposur
e period 
(minute) 
PDT only 
(% mean 
viability ±	% SD)    
 
Dactinomy
cin only 
(% mean 
viability ± 
% SD) 
 
PCI (% 
mean 
viability ± 
%SD)	 
PCI 
efficacy 
ratio vs. 
PDT 
PCI efficacy 
ratio vs. 
Dactinomycin 
only  
Alpha 
values 
SKOV3 48 
 
3 
 
70. 7 ±2.
9 
94. 3 ±4.7 37.8±3.5 1.9 2.5 1.8 
HEY 48 3 
 
68.7±8.2 89. 7 ±5.9 28.4±5.7 2.5 3.2 2.2 
SKOV3 48 5 30. 2 ±3.
0 
88. 2 ±7.4 14.4±6.4 2.1 6.3 1.9 
HEY 48 5 37.7±2.9 89.2±4.2 10.0±2.8 3.8 8.9 3.4 
SKOV3 48 7 16.3±3.1 88.5±3.4 6.0±3.4 2.7 14.8 2.4 
HEY 48 7 18.4±3.0 91.6±5.8 2.4±0.54 9.0 46 8.3 
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Table 9: Summary of percentage viabilities	±	%SD, PCI efficacies and alpha values in 3D cultures 
of SKOV3 and HEY cells 
 
Live-dead images at the end of each experiment also confirmed the results displayed in 
Figure 49. As shown in figures 50 and 51, with the increase in illumination periods some 
consistent increase in the level of cell kill can be seen in both cell lines using PDT only. 
             3D  culture    
Cell 
line 
Incubatio
n period 
post light 
exposure 
(hour) 
Light 
Exposur
e period 
(minute) 
PDT only 
(% mean 
viability ±	% SD)    
 
Dactinomy
cin only 
(% mean 
viability ± 
% SD) 
 
PCI (% 
mean 
viability ± 
%SD)	 
PCI 
efficacy 
ratio vs. 
PDT 
PCI efficacy 
ratio vs. 
Dactinomyin 
only  
Alpha 
values 
SKOV3 48 
 
3 
 
78.0±2.7 95.7±6.3 42.2±2.2 1.9 2.3 1.8 
HEY 48 3 
 
74.2±5.0 91. 1 ±4.9 33. 3 ±2.
8 
2.2 2.8 2.0 
SKOV3 48 5 34.4±2.8 93.0±2.1 20.1±2.1 1.7 4.7 1.6 
HEY 48 5 43.1±3.2 88.3±4.6 15.2±2.4 2.9 5.9 2.5 
SKOV3 48 7 20.3±5.0 90.5±2.9 9.2±2.6 2.2 10.1 2.0 
HEY 48 7 21.6±4.4 88.8±1.4 4.1±0.4 5.5 22.3 4.9 
Figure 49: Percentage viability of SKOV3 and HEY cells in non-spheroid 3D compressed 
collagen constructs after treatment with PDT, dactinomycin only and PCI. Constructs were 
treated with TPPS2a (0.3!&/"1)(SKOV3 cells) and (0.4!&/"1)(HEY cells), 1 nM dactinomycin, 
as well as 48 hours incubation post illumination. The samples were illuminated with blue lamp 
(420nm).  ***p<0.001. The p values show the significance difference between PDT and PCI 
treatments. 
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However, such cytotoxic effect is much more significant in PCI treated samples than the 
montherapies. 
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Figure 50: Live dead images of HEY 3D cultures post PDT (B, F, J and N), Dactinomycin 
only (1nM) (C, G, K and O) and PCI (D, H, L and P) treatment using different light 
conditions. The samples were illuminated with blue lamp (420nm). The assay was carried 
out 48 hours post illumination. 3D constructs were incubated with the Live/dead solution 
containing Calcein-AM to stain live cells (green) and Ethidium homodimer-1 to stain dead 
cells. The scale bar presented in each image is 400!". 
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Figure 51: Live dead images of SKOV3 3D cultures post PDT (B, F, J and N), Dactinomycin 
only (1nM) (C, G, K and O) and PCI (D, H, L and P) treatment using different light 
conditions. The samples were illuminated with blue lamp (420nm).  The assay was carried 
out 48 hours post illumination. 3D constructs were incubated with the Live/dead solution 
containing Calcein-AM to stain live cells (green) and Ethidium homodimer-1 to stain dead 
cells. The scale bar presented in each image is 400!". 
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4.3 Temperature dependence of dactinomycin uptake by ovarian cancer cells in 
monolayer cultures 
 
In this experiment SKOV3 monolayer cultures were incubated with dactinomycin (1nM) 
for 2 hours either at 4℃ or 37 ℃ to confirm if the drug is taken up via endocytosis. At the 
end of the 2 hours incubation with dactinomycin the cells were washed with PBS and 
treated with fresh drug-free media and were incubated for a further 2 hours at either 4℃ 
or 37 ℃ before terminating the experiment. 
 
The results showed that the fluorescence detected from cells incubated at 37 ℃ was 5.8 
times higher than that detected from cells incubated at 4℃ indicating that uptake was 
higher at 37 ℃ and confirming that it occurred through endocytosis. The results are 
presented in Figure 52. 
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Figure 52: Fluorescence detected from dactinomycin after incubation of 
SKOV3 cells with the drug at different temperatures (4℃ or 37 ℃). 
**P<0.01 shows the significance difference in the dactinomycin 
fluorescence in the two temperatures. 
** 
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Chapter 5 
5. PCI using saporin in tumouroid constructs of 
ovarian cancer  
 
Since tumours in vivo are more complex than the simple models created in vitro, 
tumouroid constructs of ovarian cancer which consist of stromal cells as well as cancer 
cells have been used for PDT/PCI studies in this chapter. These constructs were also 
incubated for 7 days prior to undergoing treatment. However, embedding the original 
cancer mass in a bigger compressed collagen construct consisting of stromal cells allows 
the growing cancer cells to invade the stromal environment unlike the spheroid constructs 
where the cells could only grow within the simple cancer mass model. The regrowth of 
cancer cells post PDT treatment has also been studied. Figure 5 and 53 demonstrate the 
steps involved in the creation of the 3D compressed collagen cancer constructs. Figure 
5A also shows the original method used for fabricating both 3D simple and tumouroid 
compressed collagen constructs through partial plastic compression (174). A schematic 
diagram of the ovarian tumouroid used in the experiments presented in this chapter has 
been shown in Figure 54. 
 
 
 
 
 
 
 
 
 
 
 
Collagen I 
hydrogel  
(ECM) 
containing 
cancer cells 
Removal of interstitial 
fluid (compression) to 
create dense cancer 
mass 
Cancer mass nested in 
collagen I hydrogel 
populated with stromal 
cells and compressed to 
create tumouroid.  
Figure 53: Steps involved in creating tumouroid construct (212). The diameter of the tumouroid  
construct created is approximately 15mm. 
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5.1 Tumouroid growth and stroma invasion 
 
In this experiment constructs consisting of cancer cells (HEY cells) and stromal cells 
(fibroblasts: HDFs and endothelial cells: HUVECS) were incubated for 7 days prior to 
undergoing treatment. By day 10 (termination point of experiment) the cancer cells had 
managed to proliferate and invade the stroma both in the area surrounding the central 
cancer mass and further into the stroma. The staining for each cell line was carried out as 
described in the methods and materials section. The experiments were repeated 3-5 
times. As shown in Figure 55, the HEY cancer cells are able to invade the stroma with 
stromal cells present (fibroblast and endothelial cells) (B and C) as effectively as they 
could invade the a-cellular stroma (A). Although (bi and bii) show a tumouroid consisting 
of all three cell lines, only the stained HEY and HDF cells have been presented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Stroma
Fibroblast cells
Endothelial cells
Cancer cells invading 
the stroma
Central cancer mass
Stroma
Fibroblast cells
Endothelial cells
Central cancer mass
Cancer cells invading the 
stroma
Control PDT treated
Figure 54: Schematic of ovarian tumouroid. The central cancer mass is manufactured by mixing 
HEY cancer cells and collagen type 1, allowing to set as hydrogel and applying absorbers 
(RAFTTM) to remove liquid and create a more stiff, compressed 3D tissue. The cancer mass is 
placed in a large “stromal” hydrogel populated by fibroblasts (HDF) and endothelial cells 
(HUVECs), with further addition of stroma hydrogel. The whole construct is compressed (RAFTTM) 
to produce tumouroids.  Tumouroids are allowed to mature for 7 days, with cancer invading from 
the cancer mass into the stroma, prior to drug assault.  
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 Figure 55:  Cancer cell invasion into the stroma in ovarian tumouroids 10 days post 
manufacture. Invasion of cancer cells (HEY, arrows) from original cancer mass 
(denoted with dotted line) into acellular stroma (A), and stroma with fibroblast (HDF) 
and endothelial cells (HUVEC) (B and C; I = stroma adjacent to cancer mass; ii = 
deeper stroma). HEY, HDF and HUVECS were stained with Anti-cytokeratin 7 (Alexa 
Fluor 488) 6Ex/Em: 490/525 (green), Anti-Vimentin (Alexa Fluor 405)	6Ex/Em: 401/421 
(blue) and Anti-CD31 (PerCP-eFluor 710)	6Ex/Em: 482/709 (red) conjugated antibodies 
respectively. Scale bar = 100!". 
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5.2 PDT and PCI in tumouroid constructs 
 
In one experiment the tumouroid constructs were exposed to PDT treatment using TPPS2a 
(1µg/mL) and 5 minutes illumination period to study the effect of a stronger PDT treatment 
on the cancer mass and the stroma (Figure 56). Compared to the control construct (Figure 
56A) which shows invasion of cancer cells from the central cancer mass into the stroma 
with normal shaped HDF and HUVECS, the PDT treated constructs (Figure 56B) show 
destruction in the invading cancer mass as well as the HUVEC cells and a reduction in 
the number of cancer cells in the central cancer mass and the HDFs. 
 
PCI treatment using TPPS2a (0.5 µg/mL) and Saporin (20nM) and 3 minutes illumination 
period was carried out on the tumouroid constructs (Figure 57D) basing the 
concentrations and the illumination period on previous PCI experiments on simple 
spheroid constructs (chapter 3.6). Treatment using PDT only (Figure 57B) caused a 
reduction in cancer cells invading the stroma and HDFs in comparison to the control and 
saporin only treated constructs (Figure 57A and 57C). In the PCI treated constructs a 
further destruction of the cancer cells in the central cancer mass and those invading the 
stroma was observed as well as destruction of HUVEC and HDF cells in the stroma 
(Figure 57D). One interesting point noticed in the studies was that the HEY cells showed 
a tendency to migrate and some of the cells populated in the border of the central cancer 
mass which possibly resulted in a higher destruction of cells in the center of the cancer 
mass than those in the edges of the cancer mass (Figure 60). 
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Control PDT (TPPS2a 1µg/mL) 
I B 
Figure 56: PDT treatment in ovarian tumouroids. (A) control 
tumouroid showing invasion of stroma by cancer cells (HEY, green) 
from original cancer mass (denoted by white dotted line). (B) PDT of 
tumouroids using TPPS2a (1	!g/mL) and 5 minutes of illumination, 
showing tissue-wide disruption. The samples were illuminated with 
blue lamp (420nm).  The images were obtained 48 hours post 
illumination. HEY, HDF and HUVECS were stained with Anti-
cytokeratin 7 (Alexa Fluor 488) 6Ex/Em: 490/525 (green), Anti-Vimentin 
(Alexa Fluor 405)	6Ex/Em: 401/421 (blue) and Anti-CD31 (PerCP-
eFluor 710)	6Ex/Em: 482/709 (red) conjugated antibodies respectively. 
Scale bar =100!". 
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The treatment of constructs with TPPS2a (1µg/mL) and PCI (TPPS2a (0.5µg/mL) + Saporin 
(20nM) in the dark showed no evidence of significant toxicity due to lack of reduction in 
the cancer and stromal cells which again proves importance of an appropriate light source 
being available for the treatment to elicit good results (Figure 58). 
 
 
 
 
 
Saporin (20nM) PCI (TPPS2a + Saporin) 
C 
PDT (TPPS2a 0.5µg/mL) Control 
  
B 
Figure 57: PDT and PCI treatment with 3 minutes of light illumination 
in ovarian tumouroids. Original cancer mass denoted by white dotted 
line in all images (A): Control tumouroid construct; cancer cells (HEY, 
green) have invaded into the stroma. (B) PDT of tumouroid using 
TPPS2a (0.5	!g/mL). (C) Tumouroid treated with Saporin (20nM) only. 
(D) PCI of tumouroid using a combination of both drugs. The samples 
were illuminated with blue lamp (420nm). The images were obtained 
48 hours post light illumination. HEY, HDF and HUVECS were stained 
with Anti-cytokeratin 7 (Alexa Fluor 488) 6Ex/Em: 490/525 (green), Anti-
Vimentin (Alexa Fluor 405)	6Ex/Em: 401/421 (blue) and Anti-CD31 
(PerCP-eFluor 710)	6Ex/Em: 482/709 (red) conjugated antibodies 
respectively. Scale bar presented = 100!". 
A 
D 
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In another experiment the effect of PDT/PCI on the stroma (HDFs in particular for this 
experiment) was investigated as cancer associated fibroblasts can play an important role 
in cancer progression (214). Although the fibroblasts used in this experiment are not a 
cancer associated phenotype, they still provide a representation of how PDT/PCI can 
affect such stromal cells. As figure 59 shows both PDT (59B) and PCI (59C) cause 
destruction of fibroblast cells, with PDT showing slightly more effect than PCI. 
 
 
A B C 
CNT PDT (TPPS2a 0.5µg/mL) TPPS2a (0.5µg/mL) + Saporin (20nM) 
 
Figure 59: PDT and PCI treatment of fibroblast cells (HDFs) using 3 minutes light illumination. (A) 
control 3D constructs populated with fibroblasts and undergoing (B) PDT treatment using TPPS2a 
(0.5	!g/mL). (C) PCI treatment using combination of TPPS2a (0.5	!g/mL) and Saporin (20nM). 
The samples were illuminated with blue lamp (420nm). The images were obtained 48 hours post 
light illumination.  The HDFs were stained with Anti-Vimentin (Alexa Fluor 405)	6Ex/Em: 401/421 
(blue). Scale bar = 100!". 
Control PDT (TPPS2a 1µg/mL) 
  
TPPS2a (0.5µg/mL) + 
Saporin (20nM) 
B A C 
Figure 58: (A): Control untreated tumouroids, (B): tumouroids treated with PDT using TPPS2a 
(1	!g/mL), (C): PCI using combination of TPPS2a (0.5	!g/mL) and Saporin (20nM) without light 
illumination. The images were obtained 48 hours after treatment. The HEY, HDF and HUVECS 
were stained with Anti-cytokeratin 7 (Alexa Fluor 488) 6Ex/Em: 490/525 (green), Anti-Vimentin 
(Alexa Fluor 405)	6Ex/Em: 401/421 (blue) and Anti-CD31 (PerCP-eFluor 710)	6Ex/Em: 482/709 (red) 
conjugated antibodies respectively. Scale bar = 100!". 
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Measurements of distance within the stroma invaded by cancer cells were taken from 
constructs treated with PDT (conditions presented in Figure 56) and PCI (Conditions 
presented in Figure 57) to generate graphs in figure 61. An average was taken from 24 
areas (3 repeats, 8 areas each) for each condition. As histogram 61(A) shows the cancer 
cells have invaded far into the stroma in the control samples but such invasion is almost 
non-existent in the PDT treated samples. Histogram 61(B) also shows a similar pattern to 
that observed in Figure 57 with invasion of stroma by cancer cells being major in the 
control and saporin only constructs but lower in the PDT and PCI treated samples with a 
stronger effect being observed in the PCI treated samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Centre of 
cancer 
mass with 
few cancer 
cells 
Cancer 
cells 
Cancer cells 
near the edge 
of the central 
cancer mass 
Figure 60: Distribution of HEY cells in the 
central cancer mass. The cells were stained 
with Anti-cytokeratin 7 (Alexa Fluor 488) 6Ex/Em: 
490/525 (green) conjugated antibody. The 
scale bar presented is 200!". 
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Figure 61: Histograms showing distance (!") of invasion into the stroma of the tumouroid by HEY 
ovarian cancer cells post PDT and PCI treatments, measured from experiments depicted in figures 
57 and 58. A: Distance (!") of invasion into the stroma after PDT treatment using TPPS2a 
(1µg/mL). B: Distance (!") of invasion into the stroma after PCI treatment using TPPS2a 
(0.5µg/mL) and saporin (20nM). The samples were illuminated with blue lamp (420nm). (n=8 
measurements / tumouroid). Each measurement was taken from the border of the original cancer 
mass to the furthest point of invasion in the stroma, taken vertically to the cancer mass. ***P<0.001 
shows the significance difference versus control.   
*** 
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5.3 Tumour regrowth after PDT   
 
In a further experiment rate of cancer cell regrowth post PDT was examined where the 
constructs were incubated for a further 7 days after PDT treatment before the experiment 
was terminated. Figure 62 shows an example of construct that had undergone PDT using 
TPPS2a (0.5µg/mL) in addition to 3 minutes of light illumination and was incubated for 7 
days prior to staining. In comparison to figure 62A where the construct was given the 
same PDT treatment but was stained 2 days after the treatment (5 days earlier than the 
construct in figure 62B), a higher population of cancer cells can be seen in the central 
cancer mass as well as a massive invasion of the stroma by the cancer cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
PDT (TPPS2a 0.5µg/mL)- 48 hours post 
illumination 
PDT (TPPS2a 0.5µg/mL)- 7 days 
post illumination 
Figure 62: Regrowth of HEY cancer cells in PDT treated ovarian tumouroid, 7 days post 
treatment.  The tumouroid was previously treated with TPPS2a (0.5!&/"1), 3 minutes of light 
illumination. A: Tumouroid image obtained 48 hours post light illumination to demonstrate effect 
on treatment. B:  Tumouroid image obtained 7 days post illumination to demonstrated ability to 
recover. The samples were illuminated with blue lamp (420nm). The cells were stained with Anti-
cytokeratin 7 (Alexa Fluor 488) 6Ex/Em: 490/525 (green) conjugated antibody. Scale bar =  200!".  
  
A B 
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Chapter 6 
 
Discussion  
 
The studies presented in the previous chapters have examined the efficacy of 
Photochemical Internalisation in 3D cancer models for enhancing the cytoxicity of agents 
that are susceptible to entrapment within endolysosomes. The key aim of this work was 
to show that administration of sub-lethal PDT and the cytotoxic agent could act 
synergistically to enhance the cytotoxicity over the sum of the two individual therapies. 
This is based on the concept that PCI-induced intracellular release of the agents from the 
endolysosomes into the cytosol can enhance the efficacy of the agents by enabling them 
to reach their optimum intracellular target such as the nucleus where they exert their toxic 
effect. 
 
PDT and PCI share several common features: both are minimally invasive light-activated 
modalities primarily for the treatment of solid tumours. In PDT the treatment is used as 
the sole method for eradicating cancer cells whereas in PCI low dose PDT is used to aid 
the delivery of chemotherapeutic drugs to their intracellular target sites. For clinical 
treatment both rely on light delivery to the target lesion using similar wavelengths and light 
sources. 
 
Despite these similarities, PCI has several potential advantages over using PDT such as 
reduced skin photosensitivity since relatively low photosensitiser doses are required for 
PCI. There is also a decreased likelihood of vascular shut-down in normal healthy tissue 
using PCI as a result of less damage caused to endothelial cells which should reduce 
damage to normal tissue adjacent to the treated tumour. PCI may also be effective at 
counteracting multi-drug resistance in cancer cells (127, 202-208). Whereas PDT 
photosensitisers are often subject to multi-drug resistance mechanisms (e.g ABCG2 efflux 
transporters) the disulfonated photosensitisers used for PCI are not substrates for these 
efflux transporters (127, 205-207). A Study by Lou et al .(2006) showed that PCI treatment 
using doxorubicin of cells resistant to doxorubicin restored the cytotoxicity to levels 
comparable to the doxorubicin-sensitive clones (209). 
 
Most in vitro PCI studies to date have been carried out on 2D (monolayer) cultures. 
However, such simple cultures have several deficiencies that prevent them from 
mimicking the conditions in vivo. Some of these limitations include the lack of hypoxic 
conditions found in vivo and ease of drug penetration (155). The use of 3D models on the 
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other hand has helped to overcome some of the limitations seen in 2D cultures as they 
can encapsulate several physiological properties observed in vivo, such as hypoxia. 
Therefore, more PCI studies in 3D models are required to allow better optimisation of 
treatments prior to moving onto in vivo studies.  
 
Since PCI involves the combination of PDT with a bioactive agent, in this case cytotoxins, 
in order to verify that PCI can induce significantly higher cytotoxicity, control experiments 
with PDT alone and cytotoxin alone had to be performed. Therefore, as part of this work, 
information about PDT efficacy in 3D models was also obtained. 
 
For testing PCI, three subtypes of 3D compressed collagen construct were used in order 
of complexity:  non-spheroid, spheroid and tumouroid constructs. For the simple non-
spheroid constructs, for which experiments began 24 hours after preparation of the 
constructs, the cells still largely exhibited a “single isolated cell” distribution within the 
construct. In the next stage, for comparing how the efficacy and optimum treatment 
parameters change in in multicellular deposits of cells, spheroid constructs were 
employed where the cells had formed spheroidal aggregates after 7 days incubation in 
the constructs. Finally, the treatments were applied to tumouroid constructs to study the 
effectiveness of the treatments in a more complex system which also included other cell 
types that can normally be found in the stroma of a tumour. 
 
The photosensitiser used throughout was meso-tetraphenyl porphine disulfonate 
(TPPS2a) which has been used in several previous studies including those in our 
laboratory (138, 215). Two cytotoxic chemotherapeutic agents, saporin and dactinomycin, 
were investigated for the treatment of various breast and ovarian cancer 3D compressed 
collagen constructs were evaluated. Dactinomycin functions through DNA intercalation as 
well as inhibition of RNA and protein synthesis whilst saporin acts as a Type 1 ribosome-
inactivating protein (RIP). The PCI photosensitiser, TPPS2a, is suitable for PCI since it has 
two sulfonate groups substituted on adjacent phenyl rings of the porphyrin macrocycle 
which can localise at the aqueous-lipid interface of endolysosomes with the hydrophobic 
portion of the porphyrin macrocycle inserted into the lipid bilayer. 
 
Moreover, the TPPS2a porphyrin photosensitser has an analogous structure to the clinical 
disulfonated chlorin photosensitiser (TPCS2a, Fimaporfin) and is therefore a good choice 
as the photosensitiser to test using PCI, particularly since blood absorption is not a factor 
affecting the photosensitiser efficacy in the studies presented here.  
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6.1 Intracellular uptake of TPPS2a 
 
In both 2D and 3D constructs of SKOV3 and HEY cells, intracellular uptake of TPPS2a 
was observed when treated with concentration (1µg/mL). Further experiment involving co-
localisation with Lysotracker green in 3D also confirmed that the photosensitiser is in fact 
taken up and localised in both SKOV3 and HEY cells rather than becoming engulfed in 
collagen (Figures 25, 26 and 27). High resolution imaging was not possible in these 
models but numerous other studies have demonstrated lysosomal uptake of this 
photosensitiser. In one of the first studies by Berg et al.(1991) before PCI was developed, 
TPPS2a was found to localise in endocytic vesicle and relocate to other intracellular 
compartments upon exposure to visible light (216). This relocalisation is consistent with 
the light-induced rupture of the endolysosomal membranes by oxidative damage which 
releases the bound photosensitiser.  
 
6.2 PDT/PCI studies in 2D and non-spheroid 3D constructs 
 
Measurements obtained through different viability assays presented a significant 
reduction in percentage viabilities of SKOV3, HEY and MCF-7 monolayer cultures after 
treatment with PCI (photosensitiser combined with anticancer drug) compared to control 
as well as monotherapies with PDT (TPPS2a only) or anti-cancer drug 
(saporin/dactinomycin) only.  
 
Using both viability assays it was found that the cell viabilities of all 3 cell lines reduced 
steadily with increasing illumination periods after PDT treatment in monolayer cultures. 
However, such reductions were not as significant as the those resulting from PCI 
treatment. The MTT vs. Alamar blue results showed that the viabilities after PDT treatment 
in HEY cells were 71% vs. 77% (3 minutes), 43% vs. 51% (5 minutes) and 33% vs. 35% 
(7 minutes). In SKOV3 cells such results were 71% vs. 65% (3 minutes), 50% vs. 45% (5 
minutes), 38% vs. 32% (7 minutes). Finally, the results for MCF-7 cells showed viabilities 
of 78% vs. 71% (3 minutes), 33% vs. 25% (5 minutes) and 26% vs. 17% (7 minutes) after 
PDT treatment (Figures 16 and 17). 
 
The measurements however varied slightly between the assays at times. For example, 
PCI using saporin (10nM) and 3 minutes illumination in HEY cells showed viability 
reductions from 93% to 44% (MTT assay) (Figure 16) vs. 92% to 38% (Alamar blue assay) 
(Table 2) compared to saporin only.  However, PCI with the same concentration of saporin 
but 7 minutes light illumination in SKOV3 cells resulted in viability reductions from 98% to 
27% (MTT assay) and 93% to 16% (Alamar blue assay) compared to using saporin only. 
From measurements with Alamar blue assay the alpha values were calculated to be 1.6 
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(3 minutes), 1.4 (5 minutes) and 1.4 (7 minutes) in SKOV3 cells and 1.7 (3 minutes), 2.1 
(5 minutes) and 1.5 (7 minutes). 
 
The cytotoxin and photosensitiser were both co-incubated with the cells for 20 hours, 
followed by a 4-hour chasing period where the cells were resuspended in drug-free 
medium prior to light exposure. This is the standard PCI protocol, as originally established 
by Berg et al and renders the cells less sensitive to PDT-induced damage of the 
extracellular membrane that can mask the PCI effect.  
 
The pre-incubation of SKOV3 and MCF-7 cells with TPPS2a and saporin, 24 hours prior 
to seeding in 3D (for PDT/PCI studies in non-spheroid constructs) resulted in a low 
reduction in percentage viability even after the longest irradiation period (7 minutes) 
compared to the non-spheroid constructs that were treated after seeding (Figure 28). This 
could suggest that the drugs may begin to leach out of the cells 24 hours after they have 
been incubated with the drugs. 
 
However, a test without the chasing period was also carried out to confirm that this was 
indeed necessary by pre-incubation of the cells with drugs prior to seeding and then PCI 
without chasing. In this experiment PDT and PCI without chasing led to a much higher 
reduction in percentage viability compared to cultures which underwent chasing in both 
2D and 3D non-spheroid cultures of SKOV3 and MCF-7 cells (Figures 19 and 29). This is 
attributable to the much stronger PDT photocytotoxic effect exerted by photosensitiser 
residing in the extracellular membrane, whereas the chasing will dilute the membrane 
levels of the photosensitiser and lessen this direct PDT effect.  
 
Another important result was that increasing the incubation period post illumination with 
saporin in SKOV3 and HEY monolayer cultures from 48 hours to 96 hours resulted in 
significant further reductions in percentage viability and an increase in PCI efficacies in 
some cases. Although the difference in the viability of PCI treated cultures was higher 
compared to control or anticancer drug monotherapies than compared to PDT 
monotherapies, the PCI efficacies (Table 2) calculated indicated that, the reduction in 
viability obtained after combining the photosensitiser with each anti-cancer drug was 
significant enough to claim that a PCI reaction had taken place. While it was determined 
that the appropriate concentration of saporin for the PCI studies were 10 and 20nM, for 
dactinomycin 1nM concentration was found to be suitable making it the more effective 
and potent drug, as discussed in further detail below. 
 
For treatments using dactinomycin (1nM) the monolayer cultures of SKOV3 cells showed 
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viability reductions from 94% to 38% after 3 minutes irradiation compared to dactinomycin 
only (Figure 48) with the alpha values being 1.8 (3 minutes), 1.9 (5 minutes) and 2.4 (7 
minutes). PCI continued to show a significant effect in the HEY cell monolayer cultures as 
well with the viabilities being reduced from 96% to 28% after 3 minutes irradiation 
compared to dactinomycin alone. The corresponding alpha values for this treated cell line 
were 2.2 (3 minutes), 3.3 (5 minutes) and 8.3 (7 minutes). 
 
 A previous study by Fretz et al. (2009) (217) also showed that PCI treatment using 
saporin, in the human ovarian cancer cell line OVCAR-3 in 2D culture was effective. In 
their study, reduction in cell viability over a range of saporin doses at a fixed light dose 
were investigated, in contrast to this study where we have also varied the light dose. 
Interestingly, Fretz et al found that targeted liposomal delivery of saporin was more 
effective for PCI than free saporin. Successful PCI treatment of SKOV3 cells in 2D using 
a targeted recombinant fusion toxin incorporating another Type 1 ribosome-inactivating 
protein toxin, gelonin has also been demonstrated (3).  
 
As shown in Figures 20 and 49, a similar pattern of results was observed in the 3D non-
spheroid cultures of all 3 cell lines which were respectively found to require the same 
TPPS2a concentrations as their monolayer counterparts for the PCI studies with saporin 
and dactinomycin. However, the viability reductions measured and calculated post 
treatment in the 3D cultures were lower than the monolayer cultures. For example, in PCI 
treated SKOV3 monolayer cultures the viabilities were reduced from 91% to 27% 
compared to saporin only when using 20nM saporin and 3 minutes light illumination. In 
their 3D non-spheroid counterparts however, the viabilities were reduced from 96% to 
40% compared to saporin only.  
 
In 3D cultures treated with PCI-dactinomycin a significant PCI effect was also observed 
with the viability reductions again being mostly lower than those observed in their 
monolayer counterparts. In SKOV3 3D cultures viability reduction from 96% to 42% were 
observed after 3 minutes irradiation compared to dactinomycin only. For the same 
treatment conditions, HEY cultures showed viability reduction from 91% to 33% compared 
to dactinomycin alone (Figure 49). The lower reduction in viability in the 3D cultures could 
be due to the dense collagen matrix acting as a barrier which can limit drug delivery in a 
manner similar witnessed in vivo. Despite the lower viability reductions achieved in 3D, 
the good PCI efficacies and synergistic alpha values indicate (Tables 3, 4 and 9) the 
treatment is also effective in a more restricted environment than the 2D monolayer 
cultures.  
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A key result from this work is the observation of different responses between the cell lines 
when comparing 2D vs. 3D non-spheroid experiments. Even though the HEY cells 
required a higher concentration of TPPS2a (0.4 µg/ml) than SKOV3 and MCF-7 cells (0.3 
µg/ml) in the non-spheroid cultures, they exhibited more sensitivity towards the PCI 
treatment (ie were killed more efficiently) than the other two cell lines.  
 
As with the monolayer cultures, elongating the incubation period post illumination from 48 
hours to 96 hours resulted in further reductions in percentage viability in all 3 cell lines as 
confirmed by Alamar blue and live-dead assays. Apoptosis is a slower process than 
necrosis (218, 219) therefore elongating the incubation time after illumination to 96 hours 
demonstrates a more increased reduction of cell viability compared to models, which were 
incubated for 48 hours prior to termination of the experiment. Selbo et al. (2009) found 
that increasing incubation period post light exposure from 24 hours to 48 hours resulted 
in an increased cytotoxic activity in PCI (137, 220). Therefore, as shown in Table 6 a longer 
incubation period post illumination (96 hours) with saporin (20nM) results in similar cell 
kill to using Saporin (40nM) but shorter incubation period (48 hours) so a lower 
concentration of the drug may be required for treatment thus reducing side effects from 
saporin.  
 
PDT or PCI in Type 1 collagen constructs developed without the plastic compression step 
has been examined by A few other studies. The sensitivity of neurons and glia to PCI 
using either a chlorin (TPCS2a) or the same porphyrin, TPPS2a, and bleomycin 
(chemotherapeutic drug) compared to PCI30 cells (head and neck squamous cell 
carcinoma) was examined by O’Rouke et al. (186) in order to find means of minimising 
nerve toxicity following PCI treatment. In their study, 3D non-spheroid uncompressed 
hydrogel co-cultures were used. The results showed that neural and mixed glial cell death 
was lower than PCI30 cell death following PCI using TPCS2a or TPPS2a suggesting that 
neurons have a higher resistance towards PCI treatment than PCI30 cells and can survive 
conditions that are adequate for destroying tumour cells such as those induced by PCI. A 
similar study by Wright et al. (187) used the same 3D culture system to investigate the 
sensitivity of neurons and glia cells to PDT using meta-tetrahydroxyphenyl chlorin 
(mTHPC) (photosensitiser) compared MCF-7 cells (breast adenocarcinoma). Reduction 
in cell viability of 48% in MCF-7 cells, 39% in gilial cells and 11.9% in neurons was 
observed with mTHPC at 4 μg/mL suggesting that neurons were significantly more 
resistant to mTHPC-PDT than MCF-7 and glial cells. 
 
Martinez et al. (137) also used the 3D non-spheroid uncompressed collagen hydrogel 
culture, to test the effect of PCI using TPCS2a/TPPS2a (photosensitiers) and saporin 
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(chemotherapeutic drug) on PC3 and MatLyLu prostate carcinoma cells. In their study, 
only the images from a Live/dead assay were presented which showed that PCI was 
effective in the 3D model but no quantitative comparisons can be made with the present 
study. They did however note that PCI resulted in changes in cellular morphology with the 
cells assuming a more rounded shape post treatment. 
 
6.3 Intracellular uptake of Dactinomycin in 2D and 3D non-spheroid cultures 
 
Following the positive results using PCI for enhancing the cytotoxicity of dactinomycin, 
which has not been tested before for PCI, it was important to ascertain whether the 
assumptions that this drug would be suitable for PCI could be proven.  Dactinomycin was 
originally partly because it has not been tested for PCI before but also based on its 
molecular weight. This relatively large drug should be taken up at least partly via 
endocytosis like bleomycin which has a molecular weight of approximately 1400 Da. 
Furthermore, since dactinomycin is fluorescent unlike bleomycin, fluorescence imaging 
can therefore be carried out to demonstrate endolysosomal localisation of this drug. 
 
Intracellular uptake studies showed that dactinomycin localises within the lysosomes of 
the SKOV3 and HEY cells in 2D cultures and in SKOV3 3D cultures as confirmed by co-
localisation with lysotracker red (Figures 44 and 45). This type of localisation within the 
lysosomes is important for the successful delivery of the therapeutic agent to its target 
site of action as TPPS2a localises in the membrane of the endolysosomes which causes 
the membrane to rupture upon the activation of the photosensitiser by light thus releasing 
the macromolecular agent into the cytosol. 
 
To provide further confirmation that dactinomycin is taken up via endocytosis (an energy-
dependent active uptake mechanism), the temperature dependence of uptake was 
examined. As shown in Figure 52, the intracellular fluorescence measurements taken 
from cells after incubation with dactinomycin at either 4℃ or 37 ℃, showed that the 
fluorescence values were higher at 37 ℃ than at 4℃. This result is consistent with 
endocytosis being a major route of internalisation. If uptake occurred passively via 
transmembrane diffusion a temperature dependent uptake should not be present. Further 
experiments could be carried out to investigate the particular type of endocytosis that 
applies to dactinomycin, but these were not pursued as part of the present work. 
 
A similar study by Wang et al. (2012) (221) looked at the uptake of cell penetrating peptide 
porphyrin conjugate (Tat-TPP) by human squamous cancer cells (HN5) in monolayer 
cultures at different temperatures (4℃ and 37℃) in order to determine the temperature 
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dependency of the drug uptake as it is believed that endocytosis is inhibited at lower 
temperatures. They discovered that decreasing the incubation temperature of the cells 
from 37℃ to 4℃ significantly reduced cellular uptake of Tat-TPP. Such behaviour was 
also observed with TPPS2a. To illustrate the value of such experiments, Garaiova et al. 
(2012) (222) also studied the effect of the same temperatures on the uptake of 
macromolecular Chitosan polyplexes (LCO and SBTCO) by Human Cervical cancer cells 
(HeLa). By using fluorescence intensity to measure polyplex binding to the cell surface, 
they found that incubation at 4℃ led to a substantial reduction in fluorescence levels and 
therefore cellular uptake of both polyplexes compared to incubation at 37℃. The results 
acquired by both of these groups implied that the compounds used in these studies are 
taken up by endocytosis indicating that this mechanism of drug uptake is temperature 
dependent in contrast to passive transport. In relation to our study, as both SKOV3 and 
HEY cells were incubated with dactinomycin at 37℃ and a high fluorescence from the 
drug was detected during fluorescence microscopy imaging, it is concluded that this agent 
was uptaken via endocytosis by the cell lines, which confirms the original hypothesis and 
motivation for the study. Furthermore, as the studies found that the drugs are taken up by 
endocytosis at 37℃ (body temperature), it gives an indication that if applied clinically, the 
mechanism by which the cancer cells will take up the drugs is likely to be endocytosis.  
 
6.4 PDT/PCI in 3D spheroid cultures 
 
For the experiments on the 3D spheroid constructs of SKOV3 and HEY cells, it was found 
that sizable spheroids formed 7 days post seeding and that higher concentrations of 
TPPS2a were required for the PCI studies compared to the non-spheroid constructs (0.7 
µg/ml for SKOV3 cells and 0.5 µg/ml for HEY cells) (Figure 31).  
 
Interestingly unlike the non-spheroid constructs of HEY cells which required a higher 
concentration of the photosensitiser compared to the SKOV3 constructs, the spheroid 
constructs of the HEY cells behaved oppositely requiring a lower dose of TPPS2a than 
SKOV3 spheroid constructs. In terms of saporin concentration, the SKOV3 spheroid 
constructs required a higher concentration of 40nM to produce a significant PCI effect 
compared to their non-spheroid counterparts.  However, the HEY cells as spheroid 
constructs again showed more sensitivity to PCI treatments than the SKOV3 cells. 
Although a relatively long incubation period of 20 hours was used, higher photosensitiser 
concentrations had to be employed in the spheroids to achieve the sub-lethal PDT effect 
for initiating PCI. However, this does not explain the lower sensitivity of SKOV3 spheroid 
constructs to PCI than the HEY cells which formed generally larger spheroids and required 
a slightly lower photosensitiser dose. This could possibly be due to the porous sub-
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structure of the HEY spheroids which enables the compounds to penetrate more 
efficiently albeit this was not apparent from the imaging studies. Furthermore, growth of 
cells in the 3D microenvironment will result in phenotype changes such as gene 
expression which could account for the difference in response to PCI (223). So far no 
systematic studies have been reported for these cell lines on phenotypic changes in 3D 
models, however a comparative study on changes in fibronectin expression in SKOV3 
and HEY spheroids vs. 2D reported similar results for both cell lines (224).  
 
According to Lee et al. (2013) (225) in terms of spheroid formation HEY and SKOV3 cells 
tend to form large dense aggregates and perhaps this suggests that the drug uptake is 
reduced in such constructs compared to the non-spheroid 3D constructs used. 
Furthermore, as cells grow and form spheroids, their oxygen consumption increases 
creating a more hypoxic condition, and this may influence the efficacy of PCI since this 
method requires good oxygen abundance to function effectively. The better PCI effect 
exhibited in the HEY cell spheroid models compared to the SKOV3 cell spheroid models 
throughout all illumination periods offers a promise for using PCI to treat papillary 
cystadenocarcinomas in ovarian cancer patients. 
 
These results can be compared with previous studies in 3D models using 
photosensitisers. Although very few of these studies investigated the use of 
chemotherapeutics some parallels can be drawn. The results of these studies are now 
discussed in more detail. 
 
In this project a significant difference was observed between the non-spheroid and 
spheroid cultures in terms of viability reduction after PDT. In SKOV3 and HEY cell non-
spheroid constructs the viabilities were reduced to 49% and 37% respectively after 7 
minutes light irradiation. However, in the spheroid constructs the viabilities were reduced 
to 19% and 31% respectively after 7 minutes light irradiation but required higher 
concentrations of TPPS2a to achieve this. 
 
In a study by Chen et al. (2015) (182) the micro-fluid platform was used to develop a 
breast cancer sphere culture environment with T47D cells on a chip. The spheres were 
formed through the aggregation of cells in each microwell. The 3D cultures underwent 
incubation with photosensitiser methylene blue at 10 μM concentration for 1 hour prior to 
undergoing illumination for different periods of 14 seconds, 10 minutes 30 minutes and 1 
hour with numerous light exposure doses of (0.1 J/cm2) (minimum) to (total 43.8 J/cm2) 
(maximum). 2D cultures of the T47D cell line were also seeded and treated with the same 
PDT conditions for comparison purposes.  The results found that after 10 minutes 
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exposure to a light dose of 7.3 J/cm2 approximately 50% cell kill was achieved in the 2D 
cultures while in the 3D spheres a majority of the cells remained viable. After an 
illumination period of 30 minutes under an exposure dose of 21.9 J/cm2 nearly all of the 
cells in the 2D culture were destroyed whereas many cells within the 3D sphere still 
showed to be viable. Even after the longest illumination period (1 hour) and exposure to 
the highest light dose (43.8 J/cm2) a portion of the T47D cells located within the centre of 
the sphere were still viable.  The larger spheres exhibited a higher level of resistance 
towards PDT under the same therapeutic conditions compared to the small spheres which 
implied that sphere size has an effect on PDT efficacy. The lower levels of oxygen within 
the interior of the spheroids and the more difficult penetration of the photosensitiser are 
both factors that contribute towards limiting the efficacy of PDT in larger spheroids. These 
results match those observed in the PDT studies of this project. 
 
Another study by Rizvi et al. (2010) (183) concentrated on using BPD-PDT to enhance 
the efficacy of chemotherapy drug (carboplatin) in 3D tumour models of ovarian cancer, 
which comprised of micronodules of OVCAR5 human cancer cells developed on growth 
factor reduced (GFR) Matrigel. The models were incubated with 1.25 μmol/L BPD prior to 
undergoing irradiation using a 690nm fiber-coupled diode laser either before or after 
treatment with low dose Carboplatin 40mg/m2. According to the results a great synergistic 
reduction in viability was when BPD-PDT was carried out prior to carboplatin treatment 
compared to monotherapies. The mean fraction viability with PDT+ carboplatin treatment 
was 0.45 compared to 0.80 and 0.92 observed with PDT alone and carboplatin alone 
respectively. However, no synergistic effect was observed between the reverse treatment 
order which included carboplatin followed by BPD-PDT and the monotherapies. This 
shows that with the application of BPD-PDT prior to carboplatin treatment a lower dose of 
this drug can be used thus resulting in the occurrence of few side effects. Moreover, the 
mono-therapies carried out in 2D indicated that the sensitivity of the OVCAR5 cells in the 
2D monolayer is more than twice of that seen in the same cells in the 3D cultures; this 
shows the benefit of using 3D models to get a more accurate representation of therapeutic 
behaviours in vivo as seen with the other studies mentioned. The same 3D model was 
used by Anbil et al. (2013) (188) to study the effect of BPD-PDT using various 
concentrations of BPD. The models underwent incubation with 0.25 μM, 1 μM and 10 μM 
BPD for duration of 90 minutes before undergoing irradiation with a 690 nm fibre-coupled 
diode laser. Significant reduction in cell viability was observed in nodules which were 
treated with 0.25 μM BPD-PDT mostly after 72 hours and 96 hours after the treatment in 
comparison to nodules that were treated with 1 μM and 10 μM BPD-PDT. Interestingly 
the nodules that were treated with a higher concentration (10 μM) BPD-PDT produced 
the poorest response. 
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Significant reduction in cell viability was observed in nodules which were treated with 0.25 
μM BPD-PDT mostly after 72 hours and 96 hours after the treatment in comparison to 
nodules that were treated with 1 μM and 10 μM BPD-PDT. Interestingly the nodules that 
were treated with a higher concentration (10 μM) BPD-PDT produced the poorest 
response. 
 
Ovarian cancer spheroid growth on GFR containing Matrigel was adopted in another 
similar study by Evans et al. (2011) (180), the again using the OVCAR5 cells to examine 
the effect of PDT using photosensitiser 5-ethylamino-9-diethylaminobenzo[a] 
phenothiazinium chloride (EtNBS) on hypoxic cell populations within 3D tumour models 
of ovarian cancer. The spheroids underwent incubation with 500nM EtNBS for 4.5 hours 
to allow the photosensitiser to concentrate into the cells within the core of the spheroid. 
Using a light dose of 5J/cm2, EtNBS showed to selectively destruct the cells in the core 
of the spheroid. This indicates that EtNBS can both concentrate into as well as destroy 
the hypoxic cell populations that are normally hard to treat. Higher light doses resulted in 
cell killing across the entire model by EtNBS-PDT which showed that such therapy is 
effective against both hypoxic and normoxic regions of a tumour. Interestingly it was found 
that the uptake and cytotoxicity of EtNBS increased with expansion of spheroid size 
mostly due to the rise in the hypoxic populations found in the larger spheroids. 
 
Hung et al. (2016) (226) however, encapsulated EtNBS in PLGA NPs in order to minimise 
dark toxicity of EtNBS and investigate its potential as a PDT photosensitiser in 2D and 
spheroid cultures of ovarian cancer developed from OVCAR5 cells. Reduced dark toxicity 
was observed in monolayer cultures treated with EtNBS loaded nanoparticles compared 
to cultures treated with free EtNBS. The uptake studies in spheroid cultures found that the 
PLGA-EtNBS diffused throughout the spheroids similar to the free EtNBS and the 
photosensitiser was released from PLGA upon exposure to laser light of 635 nm. 
Furthermore, PDT using PLGA- EtNBS also proved to be effective in the hypoxic cellular 
microenvironment within the spheroids, showing comparable efficacy to free EtNBS.  
 
Gaio et al. (2016) (227) on the other hands studied the photoinduced damage by two 
liposomal formulations of m-THPC, Foslip® and Fospeg® compared to Foscan® in 
cervical cancer spheroid cultures developed from HeLa cells. Using confocal microscopy, 
it was revealed that m-THPC penetration was limited and mainly occurred in the external 
cell layers of the spheroids with Foslip® and Fospeg® showing a slightly higher 
accumulation compared to Foscan®. Incubation of spheroids with Foscan (8 μM) in the 
dark resulted in significant reduction in cell viability while the liposomal formulations did 
not cause dark toxicity in the spheroids. Upon treating the spheroids with PDT, the cell 
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viabilities were considerably reduced with all three different formulations with Foslip® 
causing the highest reduction in viability at each particular time point. 
 
The results of the present study had several features in common with the studies 
mentioned above: the higher concentration of photosensitisers required for treating the 
spheroid constructs compared to the 2D and non-spheroid constructs may be a result of 
drug penetration problems caused by the formation of dense spheroids. However, a 
further factor specific to this work to consider is that the hydrogel constructs used herein 
contained much denser compressed collagen surrounding the cellular aggregates which 
could further limit penetration and drug and oxygen diffusion.  
 
This will be an interesting area for further studies. López-Dávila et al. (2016) found that 
the efficacy of free AZD6244 (MEK1/2 inhibitor) was higher in compressed collagen 
hydrogels containing a colorectal cancer mass than when the drug was encapsulated into 
liposome formulations. The results were the opposite in the monolayer cultures of this 
cancer. The therapeutic effect of the nano-formulations was therefore hindered by poor 
diffusion through the cancer mass in 3D cultures (173). 
 
An increase in hypoxic conditions formed with the growth of spheroids and particularly in 
the core of spheroids should restrict the effect of PDT and the results obtained using 
different oxygenation levels are now discussed. Such studies have not previously been 
carried out for PCI. 
 
6.5 Oxygen consumption studies in 3D non-spheroid and spheroid and post PDT/PCI in 
non-spheroid 3D constructs  
 
Imaging with a hypoxia reagent showed that oxygen consumption increases significantly 
with growth of cancer cells and as they form spheroids since the fluorescence observed 
in the day 1 constructs is considerably lower than day 7 constructs (Figure 35). This could 
imply that hypoxic conditions are indeed created as spheroids form thus affecting the 
efficiency of PDT/PCI. Lower oxygen levels were detected by Cheema et al. (2012) (228) 
in the core of a fibroblast-seeded 3D compressed collagen construct at higher seeding 
densities using a thin embedded probe. A localised rise in vascular endothelial growth 
factor (VEGF) expression was also observed in their study. Another study by Virumbrales-
Munoz et al. (2017) (229) also reported development of hypoxic conditions in a 
microfluidic 3D model using the same imaging probe as Cheema et al. (228). The 
photodynamic photosensitiser TPPS2a requires a sufficient supply of oxygen in order to 
be able to produce ROS upon becoming activated and cause rupturing of endolysosomal 
membranes which are also necessary for PCI to be effective. The lower oxygen levels 
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within the spheroid constructs may limit the PDT effect, which leads to initiation of the 
ROS-induced intracellular drug redistribution and therefore PCI treatment efficacy (180, 
230). Molecular oxygen is also consumed by the photo-oxidation reactions which occur 
during PDT. Seeding the cells in compressed high density collagen matrix is also another 
factor that contributes towards the reduction in oxygen diffusion into the construct (231), 
which may limit the amount of oxygen available for PCI thus leading to a poorer 
therapeutic response. Compressed collagen gels were found to reduce oxygen transport 
by ten times compared to uncompressed gels in the study by Cheema et al. (228).  
 
Since oxygen can diffuse more freely from the surrounding medium in 2D cultures PDT 
can therefore still be effective even in hypoxic conditions (1% oxygenation) as shown in 
our results where as such is not the case in 3D cultures (non-spheroid and spheroid) due 
to limited diffusion (Figures 36-39). Price et al. (2013) and Moan and Sommer (1985) have 
explored the effect of oxygen levels on PDT in monolayer cultures using various 
photosensitisers (232, 233). The requirement of lower PDT dose for PCI also limits 
photochemical consumption of oxygen. In PDT/PCI experiments it was found that oxygen 
consumption increased exposure of drug treated constructs to light compared to control 
constructs of both ovarian cancer cell lines since the fluorescence from the hypoxia 
reagent became significantly more intense post treatment. This is because such 
treatments also consume oxygen since the singlet oxygen reacts with the tissue 
components so free oxygen is reduced as a result. Furthermore, it was observed that the 
fluorescence levels were higher 24 hours post light exposure compared to 4 hours post 
irradiation. All of these results stress critical importance of sufficient oxygen availability in 
achieving good PDT/PCI effects. As solid tumours often contain hypoxic cores, these 
results may be relevant to clinical studies. In an interesting study Ferguson et al. (2018) 
(234) investigated the effect of culturing cells under hyperoxia (air) over a long period on 
PDT. The PDT treatment results showed that cells which had been grown under hyperoxic 
conditions generated higher levels of mitochondrial ROS than cells which had been 
cultured under physioxic (2% O2) conditions. However, no significant difference between 
the viabilities of cells cultured under the two conditions was observed. 
 
6.6 Apoptosis/necrosis studies 3D non-spheroid constructs 
 
Through staining with Annexin V-FITC and Propidium iodide it was observed that PCI 
treated non-spheroid constructs experienced more apoptotic cell death than PDT treated 
non-spheroid constructs (Figure 41) whereas a higher level of necrosis was detected in 
PDT treated constructs than the PCI treated constructs. A minimal level of necrosis and 
apoptosis was observed in the control, saporin only treated constructs as well as the 
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constructs which were incubated with the drug but were not exposed to light (Figure 40). 
Furthermore, the levels of necrosis/ apoptosis detected in the PDT/PCI treated constructs 
were higher 48 hours post illumination than 24 hours post illumination. Also, greater levels 
of necrosis/ apoptosis were detected in spheroid constructs (Figure 42) than non-spheroid 
constructs. 
 
Intracellular localisation of the photosensitiser is a key factor in determining the nature of 
cell death as being necrotic or apoptotic (235, 236). Photosensitisers that localise in 
mitochondria or ER mainly stimulate apoptosis whereas localisation within the plasma 
membrane or lysosomes tend to promote necrosis of cells (237) (238).  
 
Sub-lethal damage caused by PDT generally induces apoptosis (239) in comparison with 
cells that are treated with high dose PDT using photosensitisers that localise in the plasma 
membrane or lysosomes such as TPPS2a. Saporin also functions by inducing apoptosis 
via mitochondrial cascade (240). PCI using saporin is therefore known to cause cell death 
mainly through apoptosis due to the sublethal effects of PDT as well as the use of saporin 
in the treatment. The increase in level of apoptosis after 48 hours post illumination 
compared to 24 hours could be due to apoptosis being a slower process than necrosis 
thus leading to more apoptosis over a longer period of time. These results are in 
agreement with that obtained in the study by Mathews et al. (2012) where AlPcS2a was 
used as a photosensitiser and cisplatin, cisplatin analog [D prostanoid, DP], doxorubicin, 
and bleomycin were used as chemotherapeutic agents for treating monolayer cultures of 
three breast cancer cell lines (MCF-7, MDA-MB-435, and MDA-MB-231) it was found that 
PCI treatment lead to a reduction in the percentage of viable cells, mainly through 
enhancing apoptotic cell death. Coupienne et al. (2011) (241) on the other hand showed 
that PDT using 5-aminolevulinic acid (5-ALA) in glioblastoma cells mainly resulted in necrotic 
cell death.  
 
6.7 Cancer cell growth in tumouroid constructs 
 
The final part of the thesis results concerned the preparation of tumouroid constructs of 
the HEY human ovarian cancer cell line and their treatment by both PDT and PCI. By 
using tumouroids it is possible to observe the effect of treatment on the morphology and 
spatial behaviour of cancer cells and stromal cells. PCI (photochemical internalisation of 
chemotherapy) was chosen as the test treatment, as PCI is known to target cancer cells 
but also has wider effects within the cancer tissue. Here it has been demonstrated that 
PCI reduces cancer invasion into the stroma and also appears to perturb cells within the 
stroma, with less fibroblasts, less endothelial cells and less organisation by both. 
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In these studies the same photosensitiser was used, TPPS2a, and saporin was the 
chemotherapeutic agent. According to Figure 55, which shows images of the tumouroid 
constructs, the HEY cancer cells were able to proliferate and successfully invade the 
stroma in the area closely surrounding the central cancer mass and further into both the 
a-cellular and cellular stroma. This invasive behavior correlates well with another study 
from our laboratory using human colorectal carcinoma cells. 
 
Magdeldin et al. (2017) (212) employed the same 3D culture system to develop a 
colorectal tumouroid construct using HT29 and HCT116 (colorectal cancer cells), HDFs 
(fibroblast cells) and HUVECS (endothelial cells) in order to study the mechanisms 
involved in cancer progression. Their results found two different mechanisms of migration 
whereby the HT29 cells invaded the stroma as cellular aggregates and the HCT116 cells 
invaded as epithelial cell sheets.  
 
The HEY cells also appeared to invade the stroma initially as epithelial cell sheets but the 
cancer cells which migrated further into the stroma then coalesced and invaded as 
aggregates. The tumouroids created in this project consist of fully compressed cancer 
mass and stroma compared to the original tumouroid construct that was presented by 
Nyga et al. (2013) where only the cancer mass in the centre was compressed (174). 
 
Other groups have used different methods to develop in vitro complex 3D models. For 
example Jaganathan et al. (2014) (242) created a co-culture breast cancer model 
consisting of breast cancer cells SUM159 and MDA-MB-231as well as fibroblast cells 
Hs785bst, 293T and patient derived cancer associated fibroblast cells. In their study 
various combinations of the breast cancer and fibroblast cells were co-cultured at 
different ratios in ultra-low attachment well plates prior to being exposed to magnetic 
levitation. 
 
Amann et al. (2017) (243) on the other hand  made use of the hanging drop technology 
to develop a tri-culture model consisting of non-small cell lung cancer (NSCLC) cell lines 
(A549 and Colo699) as well as a fibroblast cell line (SV 80) and two different endothelial 
cell lines (CC-2527 and CC-2935) with the purpose of studying the effects of anti-
angiogenic drugs. According to their results endothelial cells formed small colonies in 
microtissues containing Colo699 cells and tube-like structures mostly in the stromal 
compartment of A549 containing microtissues. Also, the inhibition of proangiogenic 
factors using antiangiogenic drugs such as bevacizumab and nindetanib led to a 
significant decrease in the migration of endothelial cells into the microtissues.  
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6.8 PDT/PCI in tumouroid constructs 
 
This section of the study showed that the PDT only treatment using TPPS2a 
(0.5µg/mL)	and 3 minutes of light irradiation caused a reduction in cancer cells in the 
central cancer mass and those invading the stroma as well as HDFs compared to the 
control and saporin only treated constructs (Figure 57B). In the PCI treated constructs a 
further destruction of the cancer cells in the central cancer mass and those invading the 
stroma was observed in addition to the destruction of HUVEC and HDF cells in the stroma 
(Figure 57D). However, PDT with TPPS2a (1µg/mL) and 5 minutes of light exposure 
caused a significant destruction in the invading cancer mass and the HUVEC cells as well 
as a reduction in the number of cancer cells in the central cancer mass and the HDFs 
(Figure 56). 
 
An interesting observation was that PDT and PCI application on the stroma (focusing on 
the fibroblast only) resulted in significant reduction in fibroblasts compared to the control 
construct however the effect was more severe with PDT than with PCI (Figure 59). 
 
Since there are no previous PDT/PCI studies using tumouroid models no direct 
comparisons can be drawn with previous work. However, some general observations can 
be made since there are several studies on breast and ovarian cancer cell lines in 
uncompressed hydrogel models. In a PDT study by Wright et al. (2009) (187) 
uncompressed collagen 3D cultures were employed for investigating the sensitivity of 
neurons and glia to PDT using photosensitiser meta-tetrahydroxyphenyl chlorin (mTHPC) 
compared to breast carcinoma (MCF-7 cells) since some tumours can be located within 
or adjacent to the nervous system. In this study they observed that the cell viabilities were 
reduced by 48% in MCF-7 cells, 39% in glial cells and 11.9% in neurons when mTHPC 
was used at concentration 4 μg/mL which suggested that the neurons showed 
significantly more resistance towards mTHPC-PDT than MCF-7 and glial cells.  
 
Rizvi et al. (2013) (244) however developed a 3D co-culture model consisting of ovarian 
cancer (OVAR-5 cells) and Human umbilical vascular endothelial cells (HUVECs) using 
the low adherence plate system to produce OVCAR-5 spheroids prior to transferring the 
OVCAR-5/HUVEC co-culture into GFR matrigel coated plate to examine the potential of 
this model for testing PDT mediated combination treatment. Interestingly this study 
discovered that the size of the OvCa spheroids declined as the cell density of HUVECs 
increased suggesting that the ratio of each cell type in such model has an influence on 
the interaction between the two cell types. Our study on the other hand, found that the 
HEY cells could effectively invade far into the stroma regardless of the presence or 
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absence of stromal cells and also without the size of cancer masses invading the stroma 
being influenced majorly. 
 
In another interesting study Chen et al. (2015) (182) developed breast cancer spheres of 
T47D, SUM-159 and MCF-7 cells using microfluidic device to study the effect of PDT on 
the cancer cells. The results showed that even when using 10µM methylene blue 
(photosensitiser) and a light exposure dose of 43.8 J/cm2, the cells in the centre of 
spheres still remained viable and the larger spheres showed more resistance to PDT 
treatment than the small sphere. Furthermore, this group also investigated the effect of 
cancer associated fibroblasts (CAFs) from primary samples on the response of the cancer 
cells to the treatment. For this experiment the cells were treated with media conditioned 
by the secretions from CAFs to mimic the effect of fibroblasts on that particular breast 
cancer type. It was discovered that using culture media from CAFs resulted in no 
significant increase in PDT resistance which suggested that fibroblast mediated 
resistance may not increase resistance to PDT.  
 
The tumouroid studies in this thesis demonstrated that cancer cells invading the stroma 
showed more sensitivity towards PDT/PCI treatment than cancer cells in the central 
cancer mass. Nyga et al. (2013) measured the oxygen levels in various parts of a partially 
compressed tumouroid model and found that the oxygen levels were significantly lower in 
the core of the central cancer mass than in the border of the central cancer mass with the 
surrounding stromal environment (174). Such difference in oxygen availability within the 
tumouroid construct could limit the effect of PDT and PCI in the central cancer mass. 
 
6.9 Regrowth of cancer cells in tumouroid constructs post PDT treatment 
 
In terms of regrowth after PDT it was found that the HEY cells are able to regrow and 
invade the stroma 7 days post PDT treatment using TPPS2a (0.5µg/mL)	and 3 minutes of 
light exposure (Figure 62). According to the study  carried out by Schumann et al. (2015) 
(245) in mice a single dose of combination therapy with photosensitiser phthalocyanine 
(Pc) and siRNA as a DJ-1 gene suppressor resulted in full eradication of ovarian tumours 
(grown from A2780/AD cancer cells) without any evidence of recurrence whereas PDT 
only treated tumours began to regrow 16 days post treatment. Their study also explained 
that the ROS and heat generated after a single those of PDT could at first produce a 
strong response in the tumours. The further combination of the treatment with DJ-1 
suppression causes a more significant therapeutic effect therefore preventing tumour 
regrowth. 
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In relation to the study presented herein, when the PDT experiment (using the same 
concentrations of drug and illumination period as that in the regrowth study) in tumouroids 
is terminated 48 hours after light illumination, it is apparent that cells within the central 
cancer mass are reduced in number and that the number of cells invading the stroma is 
also significantly reduced. However, incubating the constructs for a further 5 days led to 
extensive regrowth of the cancer cells, as shown in Figure 62. This suggests that a single 
dose of PDT can provide a strong response initially, but the cancer cells are eventually 
able to overcome the conditions created by PDT as the treatment loses effect if the 
constructs are not exposed to additional cycles of the treatment. It is possible that some 
cancer cells remain dormant owing to the hypoxia  that develops within the tumouroids 
(174) that could protect the cells from PDT damage so that they can eventually invade 
further. The tumouroid preparation techniques employed here was slightly different as 
discussed in the introduction but it is likely that the tumouroids used here were also 
hypoxic at the centre since the surrounding stroma was also a compressed collagen 
hydrogel. It would be interesting in future to test how the rate of cancer cell invasion is 
affected by treatment of the tumouroids with multiple illumination cycles or low power 
densities which could counteract the effect of the pre-existing hypoxia and treatment-
induced hypoxia on PDT and PCI efficacy (246). 
Conclusions 
 
PCI as a non-invasive treatment method has a potential for treating female cancers. The 
photosensitiser TPPS2a and chemotherapeutic drug dactinomycin have proven to be 
uptaken by cancer cells in 2D and 3D cultures. PCI using saporin and dactinomycin as 
chemotherapeutic drugs has proved effective in both 2D and non-spheroid 3D cultures 
with cultures incubated for 96 hours post illumination experiencing more cell killing than 
those incubated for 48 hours.  
 
Dactinomycin is a relatively old drug in terms of its use for cancer but is still being used 
clinically. The new results presented here show that this agent could be ‘re-purposed’ 
using PCI for future clinical treatment of a wider range of tumours. 
 
Achieving a similar cell kill in 3D non- spheroid cultures which were treated with 40nM 
saporin and incubated for 48 hours post illumination and cultures which were treated with 
half of that concentration and twice as long incubation period post illumination provides a 
promise for treating cancers effectively while needing a low concentration of saporin and 
therefore reducing the likelihood of side effects associated with saporin such as fever, 
myalgias, hepatotoxicity, thrombocytopenia and vascular leak syndrome from occurring. 
Although PCI showed effectiveness in both monolayer and 3D cultures, higher 
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concentrations of the photosensitiser and saporin were required for treating the spheroid 
constructs which may have been due to formation of dense aggregates as well as the 
development of hypoxic conditions within the constructs. The pre-incubation of cells with 
drugs prior to imbedding in 3D collagen constructs resulted in most cells remaining viable 
at the end of the treatment possibly due to the leaching out 24 hours after they are initially 
applied to the cells. PDT/PCI treatments carried out without chasing however a much 
higher level of cell kill in both 2D and 3D constructs compared to cultures which did 
undergo chasing. 
 
Whilst PDT/PCI using the strongest parameters of the experiment (40nM saporin and 7 
minutes light exposure) in monolayer cultures of ovarian cancer in hypoxic conditions (1% 
oxygenation) was still able to lead to a reasonable level of cell killing, in 3D non-spheroid 
cultures such effect was much weaker and in spheroid cultures the reductions in 
percentage viability were minimal. Furthermore, the ovarian cancer cells showed to 
consume excessive oxygen as they grew into spheroids compared to non-spheroid 
constructs thereby creating a more hypoxic environment. This is particularly important as 
tumour environment is hypoxic and oxygen abundancy is crucial for PDT/PCI to function 
effectively. The imaging of oxygen level consumption after PDT/PCI in non-spheroid 
constructs of ovarian cancer showed that oxygen consumption was higher in PDT and 
PCI treated constructs after exposure to light with the consumption levels steadily 
increasing for up to 24 hours after light irradiation. However, the level of oxygen 
consumption in control constructs and those treated with drugs but no light irradiation as 
well as constructs treated with saporin only in the presence or absence of light was very 
minimal. 
 
In both 3D non-spheroid and spheroid constructs of the two ovarian cancer cell lines, PCI 
leads to more apoptosis than necrosis whereas PDT showed the opposite effect. The 
fluorescence levels corresponding to necrosis and apoptosis were more intense in 
spheroid cultures than non-spheroid cultures probably due to more cells being present 
and consequent higher integrated intensities. The level of necrosis and apoptosis was 
higher 48 hours post illumination than 24 hours post illumination in the PDT/PCI treated 
cultures particularly in the case of apoptosis. This is since apoptosis is a slower process 
than necrosis and occurs over a longer period and is important as saporin causes cell 
death via apoptosis which also explains why a bigger cytotoxic effect was observed 96 
hours post illumination compared to 48 hours post illumination. 
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Importantly, the application of each drug without light exposure as well as the application 
of saporin only with or without exposure to light resulted in negligible level of necrosis and 
apoptosis. 
 
Regarding the tumouroid constructs, which were more complicated to prepare, just the 
HEY ovarian cancer cell line was investigated. Tumouroids were prepared successfully 
and compared well in structure to previous published studies from our laboratory using 
colorectal HCT116 cells. 
 
The cells were able to grow and invade the surrounding stromal environment successfully 
regardless of the presence of the stromal cells. PDT using TPPS2a (0.5µg/mL) and 3 
minutes illumination period caused a reduction in cancer cells invading the stroma and 
HDFs in comparison to the control whereas PCI using the same parameters and saporin 
(20nM) resulted in a further destruction of the cancer cells in the central cancer mass and 
those invading the stroma was observed as well as destruction of HUVEC and HDF cells 
in the stroma. However, doubling the concentration of TPPS2a to (1µg/mL) and increasing 
the illumination period to 5 minutes for PDT treatment showed destruction in the invading 
cancer mass as well as the HUVEC cells and a reduction in the number of cancer cells in 
the central cancer mass and the HDFs therefore exerting a much stronger effect than the 
PDT treatment with TPPS2a (0.5µg/mL) and 3 minutes illumination period. 
 
Furthermore, treatment of the constructs with TPPS2a (1µg/mL) and PCI with TPPS2a 
(0.5µg/mL) + Saporin (20nM) without exposure to light showed negligible toxicity as a lack 
of reduction in cancer or stromal cells was observed and the cells maintained their normal 
shapes looked comparable to the controls. 
 
Regarding the regrowth of cancer cells post treatment with PDT, it was shown that in PDT 
treated constructs where TPPS2a (0.5µg/mL) in addition to 3 minutes of light illumination 
were applied, the cancer cells were able to regrow and invade the stroma 7 days after the 
treatment.  
 
Using the complex tumouroid constructs has the benefit of allowing other components 
and cells found in the stroma of the tumour to be included in the model and for their 
response to the treatment as well as the effect of their presence on the response of the 
cancer cells on the treatment to be examined. Other approaches can also be used for 
testing PDT treatment in tumour models as has been demonstrated by Zhang et al. (2015) 
(247) who used the relatively in-expensive Zebrafish tumour models to test nanoparticle-
mediated PDT.  
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As HEY cells are derived from papillary cystadenocarcinoma which is known as one of 
the most common types of ovarian cancer, it will be interesting to examine how this cell 
line and other cell lines respond to the PCI treatment in vivo. 
Future work  
 
To expand on the current research as part of future work, confocal microscopy could be 
used to study more accurately the intracellular uptake of the photosensitiser in non-
spheroid 3D constructs as well as the growth of cancer cells in different dimensions of the 
tumouroid.  Furthermore, conjugates of photosensitiser and drug can be used to allow 
them both to be delivered into the cell at the same time.  
 
The penetration and distribution of anti-cancer drugs in the constructs is also crucial to 
study as a higher concentration of the drug may be required for various constructs (ie non-
spheroid vs. spheroid). The cytotoxin can be fluorescently labelled for such study, 
however such conjugation may affect the diffusion properties of the drug. 
 
To increase the complexity of the tumouroid constructs and better replicate the in vivo 
environment extracellular matrix proteins such as laminin and fibrillin can be incorporated 
into the collagen matrix. Moreover, cancer associated fibroblasts can be used in the 
stroma as they aid cancer progression and again mimic in vivo cancer microenvironment 
better than the currently used HDFs. 
 
As Dactinomycin has shown to be an efficacious drug requiring a low concentration for 
PCI studies, it would be important to see how effective this cytotoxin behaves in more 
complex constructs such as the spheroid and tumouroid constructs. Furthermore, as this 
is the first time such drug is being used for PCI studies, it would be interesting to examine 
its effect in in vivo models. 
 
Correlation of the 3D results with in vivo experimental tumour models using the same 
tumour lines would be very useful and it would then be possible to ascertain whether the 
different cellular sensitivities to PCI elicited in 3D models are replicated in vivo. 
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